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Abstract  
The hereditary spastic paraplegias (HSP), are a very heterogeneous group of 
neurological diseases, both clinically and genetically. Until now, 48 loci and 29 genes 
have been identified, as well as their encoded products. 
The present work was based on a systematic epidemiological survey of hereditary 
ataxias and spastic paraplegia in Portugal. It has three components, an 
epidemiological, a clinical and a genetic one. 
We reviewed the characteristics of 448 patients, belonging to 212 families (239 patients 
from 89 families with an autosomal dominant mode of transmission, and 175 patients 
from 103 families with autosomal recessive inheritance). 
The most representative subgroups were studied, both those already known to be the 
most prevalent, as was the case of dominant paraplegia, and the easiest to identify and 
characterize, as was the case of recessive paraplegia, that focus on forms with thin 
corpus callosum. 
In Portugal, the overall prevalence of HSP was 4.1/100,000 inhabitants; 2.4/100,000 for 
the dominant forms and 1.5/100,000 for the recessive ones. 
Autosomal dominant spastic paraplegia. The frequency of major genotypes (SPG3 and 
SPG4) was similar to other studies, with the exception of a low frequency of gene 
deletions in SPG4 and the rarity of SPG31 gene in our population. We found that, 
despite age-of-onset being usually earlier in SPG3, the probability of finding a mutation 
in SPG4 was always greater than in SPG3, for all age groups. We found that there was 
no significant relationship between genotypes and the degree of disease progression, 
which was more associated with age-at-onset, being (unusually) worse in patients with 
later onset. 
We identified 17 novel mutations, 16 in SPG4 and one in SPG3. For the first time, we 
show that an association exists between the type of mutation and age-at-onset in 
SPG4, which is rather interesting, given that rarely a genotype-phenotype correlation 
has been shown in this disease, probably because usually were not found statistical 
significant phenotypic differences. 
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Autosomal recessive spastic paraplegia. The clinical and genetic research allowed a 
certain rearrangement of the recessive forms, quantifying the population frequency of 
each subgroup. In summary, the complex forms represent 73% of families, while 27% 
are pure. Among the complex forms, 73% have cognitive impairment and half of these 
correspond to the syndrome of thin corpus callosum (TCC). 
Autosomal spastic recessive paraplegia with TCC. This syndrome represents 30% of 
Portuguese families with recessive spastic paraplegia. In these patients, the spastic 
paraplegia was associated with cognitive deterioration and affection of the second 
motor neuron. We studied 31 families with this phenotype. 
Together, mutations in SPG11 and SPG15 were present in 23% of recessive families 
and in 77.5% of those with TCC. Given the phenotypic similarities, we searched also 
for mutations in SPG21, but none was found. 
We showed that these patients have no mental retardation, but an early-onset cognitive 
deterioration, the mode-of-onset in almost all patients. We proved that the corpus 
callosum is not hypoplasic, but progressively atrophic. It was also shown that brain 
impairment, both of the white matter and of the cerebral cortex, is much more extensive 
than previously thought. 
All patients with a complete atrophic corpus callosum syndrome have mutations in 
SPG11 or SPG15, what makes this subgroup a relatively well-defined entity. This 
phenotype can be seen as a good guide for the genetic study. On the other hand, 
whenever this clinical syndrome is not complete, patients are clinically and genetically 
more heterogeneous; in this study, none had mutations in these two genes.  
We found a novel SPG11 mutation. Due to the high frequency of one of the 20 SPG11 
mutations and one of the four SPG15 mutations found, there is a high probability of a 
founder effect existing in Portugal. 
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Resumo 
As paraparesias espásticas hereditárias (HSP) são um grupo de doenças neurológicas 
muito heterogéneo, clinicamente e geneticamente. Já foram identificados 48 loci e 29 
genes, assim como os produtos que estes codificam.  
O presente trabalho baseou-se no rastreio nacional de ataxias e paraparesias 
espásticas hereditárias em Portugal e encerra três vertentes: uma epidemiológica, 
outra clínica e outra genética. 
Foram revistas as características de 448 doentes, pertencentes as 212 famílias (239 
doentes de 89 famílias com modo de transmissão autossómica dominante e 175 
doentes a 103 famílias com hereditariedade autossómica recessiva). 
Foram estudados prioritariamente os subgrupos mais representativos, quer os que se 
já se sabia serem os mais prevalentes, como foi o caso das paraparesias espásticas 
dominantes, quer os mais fáceis de identificar e caracterizar, como foi o caso das 
paraparesias recessivas com corpo caloso fino. 
Em Portugal, a prevalência global das HSP foi de 4,1/100 000 habitantes; sendo de 
2,4/100 000 nas formas dominantes e de 1,5/100 000 nas recessivas. 
Paraparesias espásticas autossómicas dominantes. A frequência dos principais 
genótipos (SPG3 e SPG4) foi semelhante à de estudos noutros países, com excepção 
de uma frequência relativamente baixa de deleções no gene SPG4 e de apenas 
termos encontrado uma mutação no gene SPG31, num doente. Verificámos que, 
apesar da idade de início da doença ser quase sempre precoce no SPG3, a 
probabilidade de se encontrar uma mutação no SPG4 é maior do que no SPG3, em 
todas as faixas etárias. Constatámos que não existe relação significativa entre os 
genótipos e o grau de progressão da doença, a qual se associa mais com a idade de 
início, sendo (invulgarmente) pior nos doentes com idade de início mais tardia. 
Identificámos 17 novas mutações, 16 no SPG4 e uma no SPG3 e, pela primeira vez, 
mostrámos que existe uma relação entre o tipo de mutação SPG4 e a idade de início, 
o que é interessante, dado que poucas descrições de correlação genótipo-fenótipo 
foram até agora estabelecidas. 
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Paraparesias espásticas autossómicas recessivas. O estudo clínico e genético 
permitiu um certo rearranjo das formas recessivas, quantificando a frequência de cada 
subgrupo, alicerçada numa base populacional. Resumidamente, as formas complexas 
representaram 73% e as puras 27% destas famílias. Entre as formas complexas, 73% 
tinham alterações cognitivas e metade destas (56%) correspondiam ao síndrome do 
corpo caloso fino. 
Paraparesias espásticas recessivas com corpo caloso fino. O síndrome do corpo 
caloso fino representou 30% de todas as famílias portuguesas com HSP recessivas. 
Nestes doentes, à paraparesia espástica associa-se um défice cognitivo e um 
atingimento do segundo neurónio motor. Estudámos 31 famílias com este fenótipo. 
Mutações nos genes SPG11 e SPG15, em conjunto, explicam 23% das famílias 
autossómicas recessivas e 77.5% das que tinham corpo caloso fino. Dadas as 
semelhanças fenotípicas, foram pesquisadas mutações no gene SPG21, mas 
nenhuma foi encontrada. No conjunto de todas as paraparesias espásticas 
hereditárias (dominantes e recessivas) o SPG11 é o segundo gene mutado em 
frequência. 
Demonstrámos que os doentes não têm um atraso mental, mas que as dificuldades 
cognitivas são o começo de uma deterioração cognitiva progressiva, de início precoce, 
e que é este verdadeiramente o modo de início em quase todos os doentes. Provámos 
que o corpo caloso não é hipoplásico, mas progressivamente atrófico e que o 
atingimento encefálico, quer da substância branca, quer do córtex cerebral, é muito 
mais extenso que o que se julgava. Todos os doentes com um síndrome completo de 
atrofia do corpo caloso tinham mutações no gene SPG11 ou no SPG15. Isso faz deste 
subgrupo uma entidade relativamente bem definida, podendo o seu fenótipo ser um 
bom guia para o estudo genético. Pelo contrário, sempre que este síndrome clínico 
não era completo, os doentes eram clínica e geneticamente mais heterogéneos e 
nenhum tinha mutações no SPG11 ou no SPG15. 
Encontrámos uma mutação nova no gene SPG11; mas, mais interessante que isso, 
verificámos uma elevada frequência de uma das 20 mutações no SPG11 e de uma 
das quatro mutações no SPG15, pelo que é provável que em Portugal existam dois 
efeitos fundador nas HSP.  
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Introduction 
1. A review on hereditary spastic paraplegia 
Definition 
Between 1876 and 1898, Seeligmüller1, Strümpell2 and Lorrain3 described patients with a 
dominant hereditary disease, characterised by progressive spasticity and weakness of the 
lower limbs, with moderate vibratory sense and bladder dysfunction. They also presented 
necropsy descriptions that remain the neuropathological hallmark of the disease: the 
degeneration of the longest spinal pathways, corticospinal tracts and medial dorsal 
columns. 
In the course of time, the so called Strümpell-Lorrain disease turned into a puzzling of 
neurogenetic group of disorders, the hereditary spastic paraplegias (HSP). Data on 
clinical heterogeneity and the rapid identification of dozen of loci and genes, still in 
expansion, may cause perplexity in practical clinical minds. The corticospinal 
impairment remains the strongest link among these diseases, agglutinating that 
diversity. 
 
 
Figure 1. Adolf Strümpell. Ueber die hereditare spastiche Spinalparalyse. 
Deutsche zeitschrift für Nervenfeilkunde, 1893. 
 
Classification 
The HSP are classified by their phenotype, mode of inheritance and mutated gene. All 
modes of hereditary transmission are included: autosomal dominant (AD), autosomal 
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recessive (AR) and X-linked HSP. Clinically, they are subdivided in pure and complex 
forms, according to the absence or presence of other neurological and 
extraneurological features, besides the corticospinal signs. 
There is a conspicuous lack of correlation between the molecular and the clinical 
findings. The current classification is the result of that difficulty. Clinical features, 
although essential, are not enough discriminative; thus, HSP are classified mainly by 
their genetic loci. According to this, the SPG (spastic paraplegia) initials and a number 
are used to designate each locus, according to their chronological order of 
identification. 
At the moment, 48 loci have been identified: 19 AD, 24 AR, and 5 X-linked (Table 1); 
29 of these genes and their encoded products are known: 12 in AD-HSP, 24 in AR-
HSP and 3 in X-linked HSP. (In reality 27 AR-HSP genes exist, because in four genes 
encode for the AP4 complex in SPG47)4.  
Table1. Genetic classification of hereditary spastic paraplegia (HSP) 
Type Locus Gene Product Age at onset Additional features 
Autosomal dominant 
Pure forms 
SPG3 14q11–q21 ATL1 atlastin Early Pure rarely complex (Silver syndrome) 
SPG4 2p22 SPAST spastin Predominantly late 
Pure; rarely complex (dementia, 
epilepsy, PNP, tremor, ataxia) 
SPG6  15q11.1 11  NIPA1 NIPA1 Predominantly late 
Pure or sometimes complex (PNP, 
epilepsy, dystonia, spasticity in upper 
limbs) 
SPG8 8q23–q24 8  KIAA0196 strumpellin Predominantly late  
SPG10 12q13.3  KIF5A 
kinesin heavy 
chain 5A 
Predominantly early 
Pure or sometimes complex (mental 
retardation, Parkinsonism, deafness, 
retinitis). Allelic to CMT2, Silver 
syndrome 
SPG12 19q13 3  RTN2 reticulon2 Predominantly early  
SPG13 2q24-q34. 2  SPGD1 Mt HSP60 Predominantly late Pure or complex (dystonia) 
SPG19 9q33–q34    Predominantly late  
SPG31 9p21 1 >30  REEP1 REEP1 Predominantly early 
Pure or complex (axonal neuropathy, 
Silver-like-syndrome, cerebellar ataxia, 
tremor, dementia 
SPG33 
10q24.2 1  
 
ZFYVE27 SBP Late (foot deformities) 
SPG37 
8p21.1–q13.3 
 
unknown unknown Predominantly late  
SPG42 3q24–q26 1  SLC33A1 ACoA carrier Early  
Complex forms 
SPG9 10q23.3–24.1 unknown unknown Predominantly early 
Cataracts, gastro-esophageal reflux, 
PNP, muscle wasting 
SPG17 11q12–q14 12  BSCL2 seipin Predominantly early Silver syndrome. Allelic to CMT2 
SPG29 
1p31.1–21.1  
 
unknown unknown Predominantly late 
Hearing impairment, persistent vomiting 
from hiatal hernia 
SPG36 
12q23–24 
 
unknown unknown Predominantly early PNP 
SPG38 4p16–p15  unknown unknown Predominantly early Silver syndrome 
SPG40 unknown unknown unknown  Memory deficits; or pure 
SPG41 11p14.1–p11  unknown unknown Predominantly early 
Mild weakness of small hand muscles; 
or pure 
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Table1. Genetic classification of Hereditary Spastic Paraplegias (cont.) 
Type Locus Gene Product Age at onset Additional features 
Autosomal recessive 
Pure forms 
SPG24 13q14   unknown unknown Early Pseudobulbar signs 
SPG27 10q22.1–q24  unknown unknown Late Pure, rarely complex 
SPG28 
14q21.3–
q22.3 
unknown unknown Early  
Complex forms 
SPG11 15q13–q15  KIAA1840 spatacsin Early 
Cognitive impairment, TCC, WML PNP-
neuronopathy, ataxia, parkinsonism, 
Kjellin syndrome. Allelic to ALS-5 
SPG15 14q22–q24  ZFYVE26 spastizin Early 
Cognitive impairment, TCC, WML, 
PNP, Kjellin syndrome 
SPG18 
8p12–8q11.22  
 
ERLIN2 SPFH2  Early 
Intellectual decline, epilepsy, congenital 
hip dislocation) 
SPG20 13q12.3 >25  SPG20 spartin Early 
Complex (Troyer syndrome, dysarthria, 
distal wasting) 
SPG21 15q22 ACP33 maspardin Predominantly late 
Pure or complex (dementia, cerebellar 
syndrome, extrapyramidal signs, TCC, 
WML) 
SPG23 1q24–q32  unknown unknown Early Pigmented skin lesions 
SPG25 6q23–q24 unknown unknown Predominantly late Disc herniation) 
SPG26 12p11.1–q14  unknown unknown Predominantly late Intellectual impairment, amyotrophy  
SPG32 
14q12–q21 
 
unknown unknown Early 
Mental retardation, TCC, brainstem 
dysraphia, cerebellar atrophy 
SPG35 
16q21–q23 1  
 
FA2H FA2H Early 
Pure or complex (cognitive decline, 
seizures, WML). Allelic to NBIA 
SPG39 19p13.2 1  NTE esterase Early Axonal neuropathy 
SPG43 19p13.11–q12 unknown unknown  
Wasting of distal hand muscles (Silver-
syndrome). Allelic to NBIA 
SPG44 1q42.13 
GJA12/GJ
C2 
connexin47 Predominantly early WML, hypomyelination.  
SPG45 10q24.3–q25 unknown unknown Early Mental retardation, ocular lesions  
SPG46 
9p21.2–
q21.12  
unknown unknown Early 
Mental retardation, cataract, cerebellar 
dysfunction, TCC 
SPG47 
1p13.2 – 1p12  
 
AP4B1, 
E1, M1, S1 
AP4B1, E1, 
M1, S1  
Early 
Mental retardation, seizures, TCC, 
periventricular WML 
Pure or complex forms 
SPG5 
8q12–q13  
 
CYP7B1 OAH1 Late 
Most pure (posterior cordonal 
syndrome, WML) 
SPG7 16q24.3  SPG7 paraplegin Predominantly early Optic or cerebellar atrophy, TCC, PNP 
SPG14 3q27–q28  unknown unknown Predominantly late Mental retardation, mPNP 
SPG30 
2q37 2  
 
KIF1A kinesin3 Predominantly early Cerebellar signs, sPNP. Allelic to HSAN 
SPG48 7p22.2  KIAA0415 AP5 protein Late Spinal cord hyperintensities 
X-linked 
SPG1 Xq28 L1CAM NCAM Early 
Complex, mental retardation, 
hydrocephalus, aphasia, adducted 
thumbs (MASA syndrome), TCC 
SPG2 Xq21 PLP1 MPLP Early 
Pure or complex, optic atrophy, ataxia, 
WML, PNP, dementia 
SPG16 
Xq11.2  
 
unknown unknown Early 
Pure or complex (aphasia, impaired 
vision, mental retardation) 
SPG22 Xq21  SLC16A2 MCT8 Congenital 
Pure or complex (Allan Herndon Dudley 
syndrome) 
SPG34 Xq25–27  unknown unknown  Pure 
Modified from: Finsterer J et al.
4
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Prevalence 
The prevalence of HSP varies from 0.5 to 7.4/100,000, according to different series, 
different epidemiological approaches, and a tendency for regional clustering. In the last 
years two population-based studies have been published5, 6 but there is still some 
uncertainty about their global prevalence and geographic distribution. 
Three forms (SPG3, SPG4 and SPG31) may be responsible for about 50% of AD-HSP 
families. In AR-HSP, SPG11 represent about 20% of families4. 
It has been assumed that there are more AD-HSP families and patients than in AR-
HSP. The difference is probably not as marked as established before. In fact, there are 
more patients in each dominant family, as a rule, but there may not be more dominant 
families7. 
 
Clinical manifestations 
Motor difficulties 
Most patients begin by noting inability to walk quickly, a feeling of stiffness, frequent 
falls, cramps or abnormal wear of the outside of the shoes. Given the slow progression, 
sometimes the family members are the ones who notice the first changes. When early, 
symptoms may be expressed as a delayed acquisition of gait. 
Age-at-onset, particularly in pure forms, is very variable, ranging from the first year of 
life to the eighth decade. Mean age-at-onset tends to be later in dominant forms and 
earlier in recessive forms. 
In the early years, spasticity is frequently noticeable only when walking, not at rest. 
Over time, especially in complex forms, pyramidal signs may ascend to the upper 
limbs, but the majority of patients have only tendon hyperreflexia that may include a 
brisk jaw reflex. The presence of weakness or spasticity in the upper limbs is not 
frequent, especially in pure forms. In some patients with complex forms, dysarthria and 
dysphagia may reach a pseudobulbar state. 
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Other manifestations 
Far more frequently than in the dominant ones, recessive forms may have additional 
neurological manifestations, such as cognitive impairment (mental retardation or 
deterioration), epilepsy, optic atrophy, muscular atrophies (neuronopathy), neuropathy 
(usually axonal), ataxia (usually mild), bradykinesia and dystonia. 
Cognitive impairment 
Three profiles of cognitive impairment were described in HSP: (1) mental retardation of 
any degree, generally antedating the spastic paraplegia8; (2) dementia, varying from 
subtle frontal type personality changes to a much more severe dementia, as seen in 
some AR-HSP forms; and (3) progressive mental deterioration, developing over a 
previous mental retardation, as reported in AR-HSP with thin corpus callosum (AR-
HSP-TCC)9. Mild cognitive difficulties may not be a direct genotype expression, and 
may be due just to lack of stimulation.  
Amyotrophies 
Muscle wasting is frequent and may be related to immobility, when restricted to the 
lower limbs and reflexes are maintained. Otherwise, it corresponds to either anterior 
horn cell involvement or peripheral neuropathy, most of which of axonal type. Distal 
amyotrophies characterize some forms. In AD-HSP, they were described in SPG3 
(very rarely)4; SPG610, SPG1011, SPG17 (Silver syndrome)12, SPG3113, SPG3614, 
SPG3815 and SPG4116. In AR-HSP, they characterize and worsen the phenotype of 
several AR-HSP-TCC particularly in SPG119, SPG1517,SPG2018, 19 and SPG2720. 
Sensory disturbances 
With time, moderate changes often arise in vibration sensitivity and in vesico-sphincter 
function, either in complex or in pure forms. More extensive sensory disturbances are 
seldom found, except in complex forms with peripheral neuropathy. 
Extra-neurological manifestations 
Although rarely, extra-neurological manifestations, such as, pigmentary retinopathy, 
cataracts and skin changes may also occur. In addition to the characteristic phenotype, 
the usual complications of chronic motor difficulties are frequent, such as pains and 
joint deformities. 
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Table 2. Basic differences within dominant, recessive and X-linked HSP 
 Dominant Recessive X-linked 
Phenotypic 
variety 
Less heterogeneous  More heterogeneous More heterogeneous 
Clinical 
forms 
Predominantly pure Predominantly complex Predominantly complex 
Age at 
onset 
Predominantly late onset Predominantly early onset Predominantly early onset 
Weakness Later Earlier Earlier 
Severity 
Moderate, less complex 
forms 
More severe, more 
complex forms 
Frequently severe 
Loci  19 24 5 
Genes 
identified 
12 24 3 
More 
frequent 
forms 
SPG4, SPG3, SPG31 SPG11, SPG15 SPG1, SPG2 
 
Genotypes and phenotypes 
Autosomal dominant  
SPG3 
The gene (ATL1) encodes atlastin21, a GTPase related to a transmembrane Golgi 
complex. It is involved in vesicle trafficking, and is probably a spastin partner22. It 
represents about 10% of AD-HSP families23, 24. Disease onset is usually in childhood25. 
SPG4 
It is the most frequent form; the gene (SPAST) encodes spastin26, which belongs to a 
large family of proteins called AAA (ATPases associated with various cellular 
activities). Spastin is involved in the remodelling of protein complexes and interactions 
between axonal microtubules and endoplasmic reticulum27. Regarding detrimental 
effects, both the hypotheses of haploinsufficiency and of a toxic gain-of-function have 
been discussed. SPG4 represents about 40% of AD-HSP families, and age of onset 
varies widely28, 29. 
SPG31 
It is probably the third most frequent gene mutated in AD-HSP30, 31. SPG31 encodes 
REEP1 (receptor-expression enhancing protein 1), a mitochondrial protein of unknown 
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function. The phenotype is almost always pure, but recently a mutation has been 
reported in which paraplegia was associated with a marked distal motor neuropathy; it 
was proven that the protein expression had a large expression in the second motor 
neuron.  
More 16 loci have been identified in dominant forms. Nine other loci are related to pure 
forms: SPG632, 33, SPG834, SPG1035, 36, SPG1237, SPG1338, 39, SPG1940, SPG3341, 
SPG3742, and SPG4243. The other seven loci are linked to complex forms: SPG944, 
SPG1712, SPG2945, SPG3646, SPG3847, SPG4148 and SPG4449. 
These 16 loci are all rare, having been described in a few or even in just one family.. 
One study extrapolated for the European population an SPG10 mutations frequency of 
3%50. Another study found no mutations in SPG6, SPG10, and SPG1351. In another 
study, 223 European index patients were screened for SPG42 mutations, and not one 
was found, concluding that these must be extremely rare, at least in Europe52. 
The dominant paraplegias are similar in their presentation and clinical evolution, not 
allowing the inference of the underlying genotype. There are a few exceptions, in the 
case of complex phenotypes: congenital cataracts, peripheral neuropathy and gastro-
oesophageal reflux in SPG9; slight mental retardation and distal motor neuropathy in 
SPG14; lower motor neuron affection and distal amyotrophies (Silver syndrome) mainly 
in SPG17, SPG38 and SPG41; sensory deficits and muscle atrophy in SPG36; 
deafness and hernia of the hiatus in SPG29; and hypomielination on MR-spectroscopy 
in SPG44. These exceptions, however, are of little help in the diagnosis, because these 
forms are rare. 
Autosomal recessive  
Pure forms 
Three loci are linked to pure forms: SPG24, SPG27 and SPG28; while four may relate 
both to pure and complex forms: SPG5, SPG7, SPG14 and SPG30. 
Exclusively pure forms 
SPG24 
Identified in one Saudi family; age at onset was very early53. 
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SPG27 
This locus was mapped in a Canadian family; it had adulthood onset54. 
SPG28 
Described in a Moroccan family, the disease began in childhood, and had a slow 
progression55. 
Predominantly pure forms 
SPG5 
This was the first recessive locus to be mapped. Mutations in the gene (CYP7B1)56 
cause loss of function of the cytochrome P-450 7b1, which is a 7α-hydroxylase 
responsible for synthesis of bile acids from cholesterol metabolism, in the brain. 
Patients may have an increased serum 17-hydroxycholesterol and a much larger 
increase in cerebrospinal fluid57. The age of onset is late. The brain MRI showed focal 
hyperintensities in the white matter. In a minority, patients show a complex phenotype, 
including mild optic atrophy and cerebellar ataxia. The frequency of this genotype is 
unknown, but may be more frequent than the other seven loci referred above58. 
SPG7 
This was the first recessive gene to be identified59. The corresponding protein is 
paraplegin, a mitochondrial protein with proteolytic activity. It is a nuclear encoding 
metalloproteinase, belonging to the AAA ATPases that have been implicated in the 
regulation of cell cycle, degradation of proteins, genesis of organelles and vesicular 
traffic. The lack of paraplegin, located in the inner mitochondrial membrane, cause 
reduced activity of complex I, and lower resistance to oxidative stress. Muscle biopsies 
from severe patients may have ragged-red fibres, and structural mitochondrial 
changes. In transgenic mice, changes in axonal transport lead to a spinal and 
peripheral distal axonopathy60. It is an interesting form, from a pathophysiological point 
of view, but a very rare one. The age of onset is variable, but tends to be early. The 
complex forms include: moderate optic atrophy, axonal neuropathy, cerebral atrophy 
and cerebellar and a few vascular lesions on T2 MRI. There may be an increase in CK 
(creatine kinase). Basically, everything is according to the findings of a mitochondrial 
disease. 
SPG14 
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This locus was identified in an inbreed Italian family; some patients have moderate 
mental retardation and distal motor neuropathy61.  
SPG30 
Two families, one Palestinian and one Algerian, were linked to this locus. The 
phenotype may include ataxia and moderate sensory neuropathy, and is caused by a 
mutation in a motor protein, KIF1A62. 
Complex forms 
Complex forms with thin corpus callosum 
SPG11 
In 1994, the association of spastic paraplegia with mental retardation and hypoplasia of 
the corpus callosum63 was described in two Japanese families. In 2007, in a group of 
families of different nationalities, including some Portuguese, the gene (KIAA1840) and 
the corresponding protein (spatacsin) were identified9. Patients in school had learning 
difficulties. A progressive spastic paraparesis began in adolescence, and they 
developed a mental deterioration of the frontal type. Moreover, the motor limitations 
were accentuated by a neuronopathy (impairment of the second motor neurone), 
manifested by progressive weakness and distal muscular atrophies. Patients often also 
have a neuropathy, predominantly axonal. The corpus callosum is thin; there are areas 
of hyperintensity in the white matter, and a certain degree of cerebral atrophy. 
SPG15 
Not all patients with thin corpus callosum have mutations in SPG11. A similar 
phenotype, initially called Kjellin syndrome, is related to the SPG15 locus (gene: 
ZFYVE26; protein: spastizin)17. 
Other genotypes, described below, may also have similar phenotypes, but no 
mutations in SPG11 nor in SPG15. Their frequency is probably very low. 
SPG20 
This gene encodes a protein designated spartin. The disease, also known as Troyer 
syndrome64, begins in childhood, includes mental retardation, speech delay with 
manifest dysarthria, short stature and distal muscle atrophy, particularly of muscles of 
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the hands. Patients are emotionally very unstable and may have cerebellar signs. MRI 
shows a thin corpus callosum, a poorly developed cingulum and foci of mild 
hyperintensity lesions in the periventricular white matter65, 66. 
SPG21 
The product of this gene is a protein designated by maspardin. The spastic paraplegia 
manifests itself in early adulthood. It has a slow evolution, is accompanied by 
dementia, pseudobulbar signs; later, cerebellar ataxia and dystonia may appear. 
Patients also have a thin corpus callosum and white matter changes on MRI64, 67, 68. 
SPG32 
This locus, without known gene, was identified in one Portuguese family. The disease 
has early onset, slow progression, and is accompanied by moderate cognitive and 
emotional disorders. The corpus callosum is thin and the brainstem has a dysraphic 
aspect69. 
SPG46 
Identified recently in Tunisia, this locus is associated with congenital cataracts, 
cerebellar signs in the upper limbs, and a thin corpus callosum70. 
SPG47 
This locus and gene (AP4B1) were described in a family of Arabic origin. Patients had 
some similarities with cerebral palsy; they also showed cognitive delay, epilepsy, and 
had a thin corpus callosum71. 
Other complex forms 
SPG18 
Patients presented, between age 6 months to 2 years, a regression of motor function, 
and developed severe contractures of all joints. All had a severe intellectual disability. 
Electron microscopy of white blood cells showed large membrane-bound vacuoles in 
some cells. The gene (ERLIN2) is involved in the endoplasmic reticulum degradation72. 
SPG23 
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This form of paraplegia, described in an Israeli Arab family, was associated with 
cutaneous hyperpigmentation73. 
SPG25 
This locus described was in one Italian family. Their disease was associated with 
herniated discs in all patients74. 
SPG26 
Patients from two families had distal muscular atrophies, and some had a moderate 
cognitive delay75. 
SPG35 
Mutations of a fatty acid hydroxylase (FA2H gene) do not cause exactly a complex 
form of paraplegia, but above all a leukodystrophy with spastic paraplegia, cognitive 
impairment and dystonia76. 
SPG39 
Although rare, this form, described in two Jewish families, is nevertheless important 
because the paraplegia is associated to a second motor neuron syndrome, with 
muscular atrophies in the four limbs. The cause is a mutation in the gene PNPLA6, 
which encodes an esterase (NTE, neuropathy target esterase)77. 
SPG44 
This was described in one Italian family (gene GJA12/GJC2). The patients had a 
relatively early onset, mild cognitive impairment, dismetria, and intention tremor. Brain 
MRI showed a hypomyelinating leukodystrophy and thin corpus callosum. Peripheral 
nerve conduction was normal49. 
SPG45 
It was described in a Turkish family, causing an early-onset spastic paraplegia with 
cognitive delay and ocular abnormalities78. 
SPG48 
This locus corresponds to a recently identified gene (KIAA0415), which may be related 
to DNA repair. The only two patients known have paraplegia, beginning by age 50, 
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accompanied by urinary incontinence and areas of cervical medullary hyperintensity. 
The brain MRI was normal79. 
 
 
X-linked HSP 
SPG1 
This locus is responsible for complex and variable phenotypes, which may include 
spastic paraplegia, mental retardation, aphasia, agenesis of the corpus callosum and 
hydrocephalus due to stenosis of the aqueduct of Sylvius. They are caused by different 
mutations in the gene (L1CAM) of a glycoprotein with functions of adhesion and 
intercellular signaling. This protein has three portions: extracellular, transmembrane 
and cytoplasmic. The phenotype is affected by the site and type of the mutation. When 
they affect the extracellular portion, truncating the protein, phenotype is, as expected, 
more severe. When they only cause amino acid exchanges, or affect the cytoplasmic 
domain, the phenotype is less severe80, 81. 
SPG2 
Two different phenotypes are related to this locus: a leukodystrophy (Pelizaeus-
Merzbacher disease) and a spastic paraplegia. These two different phenotypes are 
allelic disorders, caused by mutations in the proteolipin 1 (PLP1), which enters into the 
composition of myelin. Age of onset and clinical severity are related to the nature of 
each mutation. Onset of leukodystrophy is early. It includes developmental impairment, 
mental retardation, optic atrophy, nystagmus, stridor, ataxia, hypotonia, progressive 
corticospinal signals and, sometimes, epilepsy. Anatomo-pathologically (or on MRI) 
there is a very scarce, occasionally almost absent myelination. The spastic paraplegia 
may include pure and complex forms, the "pure" forms later evolving into complex, with 
dementia, optic atrophy, nystagmus and sensory neuropathy82. 
Other forms linked to chromosome X 
These are very rare. SPG16 is related to a severe complex form, with maxillary 
hypoplasia and mental retardation83; SPG22 causes mental retardation and thyroid 
changes84, while SPG34 causes a pure phenotype85.  
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Neuropathology 
There are few pathology studies. HSP involves various axonal pathways and different 
neuronal groups, within and outside the central nervous system. Judging by their 
genetic, pathogenic and clinical variety, different pathological profiles that have not yet 
been identified may exist. New neuropathology studies must be based not only on 
defined phenotypes, but also on genotypes, includin the precise mutation. 
A review on the neuropathology in HSP (including classical features and the variation 
in dominant and recessive forms) was made by us six years ago86; since then, only a 
few further pathology reports have been published87-89. 
In the only quantitative study90, the pattern of a length-dependent dying back 
axonopathy was undoubtedly confirmed. Nerve fibers loss was not size-selective, both 
large and small diameter fibers being affected. 
Control                                           HSP 
    
 
Figure 2. Reduction in the density of both the small and large fibres in HSP Palmgren-stained 
transverse section of corticospinal tract in the spinal cord (x400). DeLuca G C, et al.
90
 
(permission rights-link license: 2992090963917) 
In a recent paper89 the authors presented the neuropathological description of a patient 
with a NIPA1 (SPG6) mutation and a phenotype including motor neuron disease and 
cognitive decline. Examination revealed degeneration of corticospinal tracts and dorsal 
columns. TDP-43 immunostaining showed widespread spinal and cerebral neuronal 
cytoplasmic inclusions. An interesting link has been established with other pathologies, 
in which there is also corticospinal degeneration and motor neuron disease, since TDP-
43 (TAR DNA binding protein) is a major component of neuronal cytoplasmic inclusions 
in amyotrophic lateral sclerosis and frontotemporal degeneration with motor neuron 
disease.  
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Pathogenesis 
The pathogenesis of HSP remains uncertain, and important questions have not yet 
been answered. How can such a wide genetic variety correspond to a similar 
phenotype? Is there a common final pathway, through which axons degenerate? Is 
there any link among functions of the different HSP genes? Why does axonal 
degeneration involve the distal ends of long axons?  
Identified pathogenic defects  
We are far from a good understanding of the pathogenesis of hereditary spastic 
paraplegia; however, with so much genetic diversity and despite many uncertainties, 
the pathogenic mechanisms begin to show some organization, and some common 
aspects are already being established. 
Defects in embryonic development 
The first genetic form to be described, SPG1, corresponds to mutations in a neuronal 
cell adhesion molecule (L1CAM), which is important for the migration and 
differentiation of neurons, as well as for axonal growth. In transgenic mice, in the 
absence of L1CAM, the corticospinal fibers are misguided, not managing to cross the 
midline in the medullar pyramids.  
Defects in oligodendroglial function 
The second form to be described, SPG2, corresponds to mutations in the proteolipid 
protein (PLP1) that, although with poorly understood functions, is a major component of 
myelin; its absence causes defects of varying severity in the myelination process. 
In SPG44 there is also hypomyelination, due to a recently identified gene 
(GJA12/GJC2) encoding a gap-junction protein (connexin-47)49. 
Defects in mitochondria 
Three HSP loci, one recessive (for SPG7) and two dominant (for SPG13 and SPG31), 
correspond to proteins of mitochondrial localization. 
The gene for SPG7 (SPG7) encodes paraplegina, which is implicated in numerous 
activities such as protein degradation, traffic vesicles and origin of organelles within the 
cytoplasm60. 
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The gene for SPG13 (SPGD1), encoding a heat-shock protein (Hsp60), has monitoring 
functions in mitochondrial enzymatic processes. Its defect leads to axonal 
degeneration91. 
The gene for SPG31 (REEP1) encodes for a protein that enhances expression of the 
receptor protein 1 (REEP1). It is a mitochondrial protein that has to do with cell-surface 
odoriferous receptors. In addition, homologous proteins were found in plants, with 
better functions studied, abnormal mitochondrial network organization in fibroblasts, 
and defective mitochondrial energy production in fibroblasts and muscle31. The 
alteration of mitochondrial morphogenesis seems to correlate with the type of mutation.  
Defects in lipid metabolism 
Mutations in recessive SPG5 cause loss of function of the cytochrome P-450 7b1 
(CYP7B1), which is a 7α-hydroxylase responsible for a specific step in the synthesis of 
bile acids of cholesterol metabolism in the brain. Patients may have an increased 
serum 17-hydroxycholesterol and a much larger increase in cerebrospinal fluid92.  
SPG35 is a recessive leukodystrophy, due to mutations in the acid 2-hydroxylase gene 
(FA2H), leading to abnormal hydroxylation of myelin galactocerebroside lipid 
components and a severe, progressive phenotype93. This is a gene with multiple 
expression, because it can cause neurodegeneration with brain iron accumulation94, a 
familial leucodystrophy or a complex spastic paraplegia.  
In two other recessive forms, SPG2855 and SPG4879, fatty-acids metabolizing enzymes 
have been involved (CYP2V1 and DOHD1 respectively).  
Defects in axonal transport and vesicular trafficking 
The common denominator to hereditary spastic paraplegia is a slow degeneration of 
long axons, going from the most distal to the most proximal parts. So, if something fails 
at the end of axons, it is logical to presume that defects in axonal transport, related to 
various proteins and different mutated genes, may be major pathogenic mechanisms. 
The following are just the main examples that support this hypothesis, already very 
consistent. 
a) Atlastin, the protein mutated in the autosomal dominant SPG3, has GTPase activity 
and strong similarities with the dynamins. The dynamins are a family of motor proteins, 
associated with the cytoskeleton (actin and microtubules). They are involved in vesicle 
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trafficking (recycling of synaptic vesicles), and maintenance and distribution of 
mitochondria11. 
b) Spastin, the protein involved in the autosomal dominant SPG4, belongs to the AAA 
protein family (ATPase associated with various cellular activities). It is implicated in the 
remodeling of protein complexes and in axonal microtubule interactions with 
endoplasmic reticulum (ER)27. Spastin interacts with other proteins involved in HSP, as 
atlastin (SPG3), and stabilizes microtubules, giving them consistency. It interacts also 
with a tubular protein ZFYVE27, mutated in SPG33, and also with reticulon 2, the gene 
product in SPG12.  
c) The phenotype of another dominant form, SPG10, is due to a mutation in a kinesin 
heavy chain (KIF5A). Kinesins are tetrameters of two heavy-chains and two light-
chains, which carry substances along microtubules towards the periphery of cells. They 
are present especially in motor neurons (both in the first and the second ones). 
Pathogenically, this distribution is consistent with the existence of a type of Charcot-
Marie-Tooth (CMT2A) caused by a mutation in another kinesin (KIF1Bβ). 
d) SPG30 is a predominantly early-onset AR-HSP, caused by mutations that affect the 
motor domain of still another kinesin (KIF1A). Interestingly, different mutations in this 
gene were reported also in hereditary sensory and autonomic neuropathies, and the 
type of the KIF1A mutations seems to be a predictor of the phenotype and vice versa62.  
e) Spartin, the protein mutated in the recessive form SPG20, has an AAA domain (MIT 
domain, also present in spastin), which is involved in the interaction between 
microtubules and in endosomal trafficking. It also seems to be associated with 
mitochondria.  
f) In another recessive form, SPG21, its gene encodes for maspardin, a protein that is 
located in vesicular structures involved in endosomal recycling, and hence is very likely 
associated with the intracellular transport of vesicles and proteins. 
Other genes and proteins are related, still in an uncertain way, to vesicular trafficking or 
to proteins complexes closely associated with cytoplasmic vesicles (as in SPG11, 
SPG15, SPG47 and SPG48). 
In short, different mutated proteins, by different pathways, damage axonal transport 
and other intracellular movements essential for the good functioning and maintenance 
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of axons. Some of these molecules are themselves proteins involved in motor function 
or impair the intracellular dynamics by interactions with cytoskeletal or vesicular 
proteins.  
Table 3. Genes products known to be implicated in the pathogenesis of HSP 
Locus Gene Protein  Function 
SPG1  L1CAM NCAM 
Axonal glycoprotein involved in neuronal migration and 
differentiation 
SPG2 PLP1 
proteolipid 
protein 
CNS myelin protein with structural role in maintaining 
intraperiod line of compact myelin 
SPG3 ATL1 atlastin 
Interacts with ER membrane in corticospinal neurons to 
coordinate ER shaping and microtubule dynamics 
SPG4 SPAST spastin 
Promotes formation of microtubule networks, essential for 
axon growth and branching 
SPG5 CYP7B1 OAH1 
ER membrane protein catalyzing the first reaction in 
cholesterol catabolic pathway of extrahepatic tissues 
SPG6 NIPA1 NIPA1 Inhibits BMP signaling, important for distal axonal function 
SPG7 SPG7 paraplegin Unknown, located at inner mitochondrial membrane 
SPG8 KIAA0196 strumpellin 
Unknown, valosin-containing protein binding partner, 
expressed in cytosol and ER 
SPG10 KIF5A 
kinesin 
heavy-chain 
Implicated in the anterograde axonal transport 
SPG11 KIAA1840 spatacsin Accessory protein of the AP5 complex of sorting of vesicles 
SPG12 RTN2 reticulon2 Interacts with spastin (SPG4) and involved in ER shaping 
SPG13 HSPD1 Hsp60  Mitochondrial Hsp60 chaperone 
SPG15 ZFYVE26 spastizin 
Accessory protein of the AP5 complex of sorting of vesicles, 
putatively involved in endosomal trafficking 
SPG17 BSCL2 seipin 
Unknown, ER protein; mutations disrupt an N-glycosylation 
motif, enhance ubiquitination, and result in ER stress 
SPG18 ERLIN2 SPFH2 
Component of the ER associated degradation system for 
proteins 
SPG20 SPTG20 spartin 
Involved in degradation of epidermal growth factor receptor, 
associated with mitochondria 
SPG21 ACP33 maspardin 
Suspected to function in protein transport and sorting in 
trans-Golgi transportation vesicles 
SPG22 SLC16A2 MCT8 Unknown, monocarboxilate tyroide hormone transporter 8 
SPG30 KIF1A kinesin3 Involved in axonal transport and trafficking 
SPG31 REEP1 REEP1 Unknown, interacts with tubular ER membrane 
SPG33 ZFYVE27 protrudin 
Member of the FYVE-finger family, interacts with spastin, 
involved in the intracellular trafficking 
SPG35 FA2H FA2H Involved in lipid hydroxylation 
SPG39 NTE NTE Unknown, phospholipase/lysophospholipase 
SPG42 SLC33A1 ACoA-carrier Unknown, Acetyl-CoA transporter 
SPG44 GJA12 connexin 47 Cell junction protein 
SPG47 AP4B1 AP4B1 Involved in forming and sorting of vesicules 
SPG48 KIAA0415 KIAA0415 
Member of the AP5 complex involved in vesicules sorting 
and putatively in DNA-repair by homologous recombination 
DNA double-strand break repair 
 
Adapted from: Finsterer J et al.
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Diagnosis 
The diagnosis of HSP is based on the findings and on the investigation steps 
discussed below. 
(1) Presence of a progressive spastic paraparesis 
Since the beginning, and even after many years of disease, spasticity frequently 
predominates over paraparesis. This is the norm, particularly in pure forms. In complex 
forms, the weakness may occur earlier and be preceded by a delay in cognitive 
acquisitions, sometimes marked or evidenced only by poor school results. The onset of 
spasticity is often asymmetrical; usually, one side persists more affected than the other. 
(2) Presence of the same disease in the family 
In spite of HSP being a group of hereditary diseases, its familial nature is not always 
evident. The existence of apparently isolated patients is due to several factors: parents 
with asymptomatic or mild clinical manifestations, misdiagnosis with other clinical 
entities, late onset of the disease in the transmitting parents, and geographic dispersion 
of people from the same family. Persons sometimes ignore the whereabouts or the 
clinical status of their relatives. The growing number of couples with only one or two 
children may also make more difficult the determination of its inheritance. If only one 
child is affected, in the absence of siblings, this can give the appearance of recessive 
inheritance, which might not always be the case.  
(3) Exclusion of other diseases 
All diseases for which there is any treatment should be first methodically excluded in 
the differential diagnosis of HSP, such as compressive myelopathies, vitamin B12 
deficit, tropical spastic paraparesis (HTLV 1), L-dopa sensitive dystonia or a primary 
progressive form of multiple sclerosis. 
Especially with a recessive mode of transmission and a complex phenotype, the 
exclusion of other degenerative, metabolic and hereditary diseases must first be 
meticulously carried out by biochemical analyzes: serum lactate and pyruvate, serum 
and urine amino acid chromatography, organic acids in urine, arylsulphatases, 
galactocerebrosidases, and very-long chain fatty acids. 
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(4) Phenotypic characterization 
Brain MRI, in addition to the exclusion of other diseases, allows a more complete 
characterization of the phenotype and provides a better guidance for genetic studies. 
Particularly relevant will be the presence of a thin corpus callosum, white matter 
changes or cerebellar atrophy.  
Except for the exclusion of other myelopathies, a spinal MRI has no interest in the 
diagnosis of HSP; at the most, it may reveal a nonspecific moderate spinal atrophy, in 
advanced cases. Electromyographic studies are important, not for diagnosis, but for the 
characterization of a neuropathy or neuronopathy sometimes associated. Brain MRI is 
recommended at least in one patient per family in all complex forms, whatever the 
mode of inheritance, and in all recessive and X-linked forms. An ophthalmological 
examination should be done in recessive forms, especially the complex ones. In pure 
forms, with family history of autosomal dominant transmission, a careful neurological 
examination should be able make the clinical diagnosis, without any other exams.  
 (5) Genetic diagnosis 
Nevertheless, a precise genetic diagnosis will always be important to confirm or 
exclude a clinical suspicion, in addition to being essential to have it in a proband for 
adequate genetic counseling of at-risk relatives (resolution of the genetic 
heterogeneity, by identification of the locus and mutation involved in each family). 
Autosomal dominant forms 
The search for mutations in SPAST (SPG4) must be made in AD-HSP forms, as well 
as in apparently isolated patients, particularly with pure forms. If the search is negative 
and age-at-onset is early (<20 years), mutations in ATL1 (SPG3) should always be 
sought. 
Autosomal recessive forms 
In AR-HSP with thin corpus callosum, mutations of KIAA1840 (spatacsin, SPG11) 
should first be investigated. If no present, the next gene to study is ZFYVE26 
(spastizin, SPG15). Apart from these, presently it is difficult to define more general 
guidelines for the genetic study of AR-HSP, though this may depend on the population 
under study.  
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In spite of that, some particularities of a few phenotypes may provide some guidance. 
Although many are nonspecific, they are present in several forms, many of which are 
too rare. Just to cite one example, not including the TCC, distal muscular atrophies or 
neuropathies were described in SPG3 (rarely), SPG6, SPG17, SPG20, SPG27, 
SPG31, SPG36, SPG38 and SPG41. Another example, also excluding TCC related 
genotypes, is the presence of white matter lesions in SPG2, SPG5, SPG10, SPG44, 
SPG47 and SPG48.  
 
Management 
Learning to live with spasticity 
There is undisputable advantage in achieving an early diagnosis, so that patients and 
families may be well informed. They can better plan their lives, and acquire early 
measures to promote general health, combating spasticity, as well as preventing some 
of its complications. We should always highlight the advantages of regular exercise, 
preferably in hot water, including exercises for relaxation and muscle stretching. 
Anti-spastic drugs 
Drugs mainly used are baclofen and tizanidine and, sometimes, dantrolene sodium. 
Baclofen improves spasticity and spasms in about 80% of patients. The main side 
effect, in addition to drowsiness, is the increase of muscle weakness, which often 
precludes their use, at least in moderately elevated doses. Tizanidine has an 
equivalent efficacy, being perhaps better tolerated. It is common practice to use both 
drugs, though there is little evidence of the benefit of this combination. Intrathecal 
administration of baclofen is indicated in patients who do not respond to maximal oral 
doses. The benefits of continuous infusion of baclofen were demonstrated in over 80% 
of patients, regarding spasticity, and in over 60% for spasms. The main risks are 
related to their sudden withdrawal (hyperthermia and convulsions)95. The use of 
botulinum toxin, although effective and safe, is applicable to a limited number of 
patients only, given the extent of muscle involved and the possibility of aggravation of 
weakness. It must also be bared in mind that it is sometimes spasticity that is still 
holding the patients standing and not confined to a wheel chair. 
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Genetic counseling 
A genetic diagnosis if crucial for genetic counseling, to determine risks for relatives, to 
perform presymptomatic or carrier testing (as indicated) and to communicate 
information about the mode of inheritance, penetrance, natural history of the disease, 
complication symptoms, and expected range of age-of-onset and rate of progression. 
Nevertheless, most classes of mutations do not provide evidence for establishing a 
genotype-phenotype correlation96. 
Prenatal diagnosis in dominant forms is controversial, and will not usually be 
demanded by the families when forms are pure and less severe. Most patients have a 
long survival, with a quality of life that is often mainly conditioned by social and 
economic factors. Moreover, age-at-onset can be very late or exceptionally late97. 
Some relatives will remain only as asymptomatic carriers; penetrance has never been 
accurately estimated28, even in the most prevalent forms. In more severe forms, 
especially in the recessive ones, prenatal diagnosis is both acceptable and indicated, 
and should be offered and discussed as an alternative to the families at risk who may 
wish to take advantage of it. 
2. Some issues yet unanswered 
Many gaps still exist in the knowledge of HSP. Some of these are: 
(1) more population-based studies are needed to estimate overall prevalence in 
different countries as well as the accurate frequency of the main clinical and genetic 
forms; 
(2) clinical characterization is somewhat incomplete and, as a consequence, a detailed 
clinical classification is not easy to establish; 
(3) although important advances occurred in genetic characterization, many families 
still persist without a molecular diagnosis; 
(4) genotype-phenotype correlation is still an unfinished puzzle; and 
(5) the pathogenesis of HSP still raises as many questions as answers, in spite of 
almost thirty mutated proteins having been identified. 
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3. Objectives of this research 
The aim of the present work is to give some contribution to the knowledge of HSP, 
based on the epidemiological, clinical and molecular genetics studies of the 
Portuguese families identified mainly through the survey of hereditary ataxia and 
spastic paraplegia.  
Epidemiological study: 
(1) to estimate the overall prevalence of HSP in Portugal; 
(2) to determine the relative frequency and the geographical distribution (including 
finding evidence for clusters) of specific clinical forms and genotypes. 
Clinical study:  
(1) to review clinical features in the different families with HSP and try to define 
homogeneous clinical subgroups, to guide further molecular genetics studies; 
(2) to look for phenotype-genotype correlations. 
Molecular genetics: 
(1) to perform the genetics study of the main clinical subgroups; 
(2) to try to identify new loci, genes, and characterize their mutations; 
(3) to analyze the mutations spectrum and try to study mutational mechanisms. 
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Material and Methods 
 
Epidemiological methods and ascertainment of patients  
From 1994 to 2004, a population-based survey of hereditary ataxias and spastic 
paraplegias was conducted in Portugal, by initiative and under the direction of Paula 
Coutinho (Silva, 1997; Coutinho et al., 2012)98. This survey (1994-2004), which used a 
defined and controlled methodology, formed the major source of ascertainment of the 
patients and families included in the current work. 
In a second phase (2004-2012), after the survey had been completed, the clinical study 
of families has improved, more blood samples were collected for genetic studies, and 
several new families and new forms of HSP were identified. Interestingly, these were 
identified, to a very large extent, through the own dynamics created by the survey itself. 
That is, on the one hand, patients and their families continued to strive to approach the 
neurologists involved in the survey; on the other hand, there was an intensified 
research by the neurologists looking for new families and new forms of HSP, and new 
data on the patients previously identified became available. 
The survey was a multidisciplinary project, using multiple sources of information. Its 
population basis resided mainly upon the structures of the National Health Service, 
which covers about 95% of the Portuguese population. The Health Centers are its 
basic units. 
The methodology of the survey comprised different phases: (1) information to the 
population, through the media, in all districts of the country; (2) information and training 
of general practitioners; (3) collaboration of local neurologists; (4) selection of 
probands; (5) neurological observation of the patients referred and of many of their 
family members, by a team of neurologists, at the Health Centers or at home; (6) 
collection of blood samples from patients and available relatives, after written informed 
consent was obtained; (7) registration of personal, clinical and genealogical data; (8) 
statistical analysis of the various data for determination of prevalence and geographical 
distributions, (9) for clinical studies, and (10) for molecular genetics analyzes. 
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Patients and clinical methods 
Thus, data obtained from 448 patients, belonging to 212 families, were analysed: 239 
patients (from 89 families) with AD-HSP; 175 patients (103 families) with AR-HSP; and 
34 patients (20 families) with recessive spastic ataxias. 
Diagnosis of HSP was based on published criteria99, 100. Diseases possibly mimicking 
HSP were excluded by radiological and biochemical investigations. 
The methodology employed did not differ greatly from one study to another, among 
those presented here, although some specific methodological aspects of each study 
are mentioned in the respective articles. Those will not be presented again here, 
separately. 
Family data collected included genealogical information to design family trees; 
geographic origin of the most remote ancestors known (if affected, either from medical 
records, personally examined or only suspected by history); classification as pure or 
complex, and as early or late-onset forms; assigning a code to each family (S, from 
Strümpel, for autosomal dominant and SR, from "Strümpel recessive", for autosomal 
recessive families). 
To update family information, telephone interviews to the families themselves and/or 
their physicians were recently performed, to know how many patients were currently 
alive and where they lived. 
Patients data, recorded and saved in a hospital setting, included: address and district 
of residence; name; birth date; age at the last observation; age of death; mode of 
onset; age at onset of motor or other difficulty; age of need for unilateral or bilateral 
walking aids, wheelchair and bedding; educational level; neurological examination – 
cognitive status, behavioral and psychiatric profile; cranial nerve functions (ocular 
fundus, ocular movements, nistagmus, jaw reflex, disartria, dysphasia); gait pattern, 
grade of motor disability; muscular strength and tone, tendon and plantar reflexes; 
muscle atrophies, axial and limbs cerebellar signs; movement disorder (tremor, 
dystonia, bradikinesis); pain sensitivity; ankle vibration sensitivity, hallux postural 
sensibility, equino-cavum feet, and sphincters function. Other neurological or extra-
neurological features were also recorded, namely: epilepsy report, dysmorphism, 
cataracts, cutaneous and endocrine alterations. 
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Other interventions and complementary exams of diagnosis included: blood sampling 
for DNA extraction and genetic studies (and sometimes for cell cultures); 
neuropsychological examination; ophthalmological examination; encephalic MRI; EMG; 
blood routine analyzes; T3, T4 and TSH; very-long chain fatty acids; chromatography 
of amino acids; lactate and pyruvate; arylsulfatases; galactocerebrosidase; 
chromatography of urinary amino acids; muscle and nerve biopsy (to exclude a 
mitochondrial cytopathy); and exclusion, in isolate patients, of a compressive 
myelopathy, vitamin B12 deficiency, myelopathy caused by human T-lymphotropic 
virus type I ( HTLV1), dystonia sensitive to L-Dopa or a primary progressive form of 
multiple sclerosis. 
Complementary studies were performed in at least one patient per family, in the case 
of AR-HSP. In AD-HSP families, very few patients had biochemical studies, and only a 
few performed brain or spinal IRM or EMG.  
Definition and grade of the parameters employed 
Age-of-onset in pure forms was defined as the start of any change in gait pattern, 
walking difficulties, unexplained falls, or cramps noticed by the patients or relatives. In 
complex forms, onset was defined by the first pathological symptom or sign emerging, 
if part of the respective clinical picture. Early-onset was considered as that before 20 
years of age (other patients were classified as late-onset). 
Complex forms were defined, in AD-HSP families, when they had two or more patients 
with other symptoms, in addition to the corticospinal syndrome. In AR-HSP, complex 
forms were considered those with one patient with other symptoms or signs, in the 
absence of any other explanation for the changes found, besides the HSP syndrome. 
Mental retardation was graded 0 to 3 (0 = absent; 1 = mild, literate; 1 = moderate, 
literacy inability, and 3 = severe, rudimentary speech or no language). 
Cognitive and behavioural deterioration were graded 0 through 3 (0 = absent; 1 = 
slight, reasonable activities of daily life (ADL), behaviour changed; 2 = moderate, 
compromised ADL, apathetic or hardly supportable behaviour; 3 = severe, total 
dependence, mutism, lodging). 
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Disartria was graded from 0 to 3 (0 = absent; 1 = slight, can cause doubt if it exists; 2 = 
moderate, perceptible speech; 3 = severe, almost imperceptible speech, and 4 = 
anarthria). 
Disphagia was graded from 0 to 4 (0 = absent; 1 = slight, occasional for liquids; 2 = 
moderate, frequent for liquids; 3 = frequent for liquids and solids, and 4 = nasogastric 
tube or PEG).  
The motor severity of disease was classified according to the SPATAX disability scale, 
from 0 to 7 (0 = normal; 1 = no functional handicap, but signs at examination; 2 = mild, 
able to run, walking unlimited; 3 = moderate, unable to run, limited walking without aid; 
4 = severe, walking with one stick; 5 = walking with two sticks; 6 = unable to walk, 
requiring wheelchair, and 7 = confined to bed)101 . 
Rate of disease progression was calculated dividing the motor severity by the disease 
duration.  
Muscle strength was graded 0 to 5, using the Medical Research Council Scale for 
Muscle Strength (0 = no contraction; 1 = contraction no movement; 2 = movement but 
unable to overcome the gravity force; 3 = movement possible against gravity force but 
not against resistance; 4 = moderate weakness, possibly against some resistance, and 
5 = normal strength)102. 
Spasticity was quantified from 0 to 4, according to the Modified Ashword Scale (0 = no 
increase in tone; 1= slight increase in muscle tone, manifested by a catch and release 
or minimal resistance at the end of the range of movement (ROM) when the affected 
parts are moved in flexion or extension; 1+ = slight increase in muscle tone, manifested 
by a catch, followed by minimal resistance throughout the remainder - less than half - 
of the ROM; 2 = more marked increase in muscle tone through most of the ROM, but 
affected parts easily moved; 3 = considerable increase in muscle tone, passive 
movement difficult, and 4 = affected parts rigid in flexion or extension)103. 
Tendon reflexes were graded from 0 to 3 (0 = abolished; 1 = decreased; 2 = normal; 3 
= brisk, and 4 = very brisk or polykinetic). 
Muscular atrophies, not caused by lack of use, were assessed on a scale from 0 to 3 (0 
= absent; 1 = mild; 2 = moderate; and 3 = severe). 
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Bladder function was graded from 0 to 3 (0 = no symptoms, occasional urinary tract 
infections; 1 = difficulty in beginning urination; 2 = incontinence by over-flow, and 3 = 
indwelling catheters). 
Molecular genetics analysis 
With very few exceptions, peripheral blood was collected from almost all probands and 
their relatives available, either if affected or healthy. Genomic DNA was extracted from 
peripheral blood leukocytes through salting-out. Results were not disclosed on the 
context of research, but only after validation in a laboratory diagnostic setting, and its 
results delivered always through a physician. In the case of unaffected relatives, results 
were only delivered in the context of genetic counseling, by a clinical geneticist, if the 
consultands showed any wish to receive them, and after validation in a routine 
laboratory diagnostic setting. 
Mutation screening in the vast majority of the patients was performed at the Centro de 
Genética Preventiva e Preditiva (CGPP), and by researchers of the Unidade de 
Investigação Genética e Epidemiológica em Doenças Neurológicas (UnIGENe), both at 
IBMC - the Institute for Molecular and Cell Biology, Porto, Portugal. 
Several genetic studies were also performed by the Neurogenetics team of Giovanni 
Stevanin (EPHE, Paris) based at the Brain and Spine Institute, Paris (Director: Alexis 
Brice), a member of the SPATAX International network (Coordinator: Alexandra Dürr). 
and a few by the U.O. di Medicina Molecolare IRCCS, Ospedale Pediatrico Bambino 
Gesù, Roma (Director: Filippo Santorelli). 
Mutation screening in AD-HSP 
The genetic study of the AD-HSPs was performed in successive phases. It began by 
looking for SPG3 mutations in earlier-onset patients, for SPG4 mutations in later-onset 
patients and all SPG3 ‘negative’ cases. All patients excluded for mutations in both 
genes were finally tested for SPG31. 
Mutation screening was performed, in a first stage, by PCR amplification of all coding 
regions, followed by denaturant high-performance liquid chromatography (DHPLC) and 
then bidirectional direct sequencing of altered profiles for SPG3 and SPG4. 
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More recently, mutation detection was performed by direct sequencing of SPG3, SPG4 
and SPG31 coding sequences and exon-intron boundaries. In patients in whom no 
mutation was found, we performed Multiplex Ligation-dependent Probe Amplification 
(MLPA) to exclude large deletions or duplications. 
Mutation screening in AR-HSP 
Unlike most AD-HSP, where the clinical variation is, in general, not sufficiently accurate 
to define homogeneous phenotype subgroups, the same does not happen with AR-
HSP. After having identified diverse and more or less homogeneous groups, by their 
special nature, research focused on families with a thin corpus callosum. Families were 
selected to look for SPG11 mutations. Those that were ‘negative’ were screened for 
SPG15 mutations; those without mutations in these two genes were also tested for 
SPG21. 
Mutation detection was performed by direct sequencing of coding sequences and 
exon-intron boundaries of the genes for SPG11, SPG15 and SPG21. In patients in 
whom only one or no mutations in SPG11 were found, we performed MLPA to detect 
possible large deletions or duplications.  
Statistical analysis 
In autosomal dominant families, the Student t-test was used to compare the distribution 
of diverse scores, like severity and progression rate of disease, by genotype. 
Univariate analysis of variance (ANOVA) was performed for association between age-
at-onset and genotype. Multivariate ANOVA was performed for the distribution of age-
at-onset, adjusting to the effect of all other possible variables (genotype, specific family, 
gender) and for disease progression, and also for the distribution of disease 
progression and age-of-onset in diverse genotypes, adjusting for mutation type.  
In the autosomal recessive families, univariate analysis of variance (“one-way 
ANOVA”) was used to assess the effect of different clinical parameters, namely motor 
severity, degree of cognitive delay and cognitive deterioration on onset of motor 
symptoms, the duration of the disease and patients' age at the last clinical observation. 
The significance level used was P≤0.05. Analyzes were performed using the SPSS 
software package (PASW Statistics® 18 software for Windows).
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Results 
 
1. Hereditary spastic paraplegia in Portugal 
The story of the survey is interesting both in the phase that preceded it, as during and 
after it. It all started with a purely clinical research, in 1976, for the study of Machado-
Joseph disease (MJD, also known as SCA3).  
The need for clinical studies, as well as the attempt to discover the gene, led to the 
search for more affected families in all corners of the Azorean islands. Paula Coutinho 
had the idea of making a national survey for that disease, which was extended to all 
other hereditary ataxias, but also to spastic paraplegias, given the phenotypic 
overlapping existing. 
The survey is a good example of the use of epidemiological methodologies in the study 
of rare diseases. It was performed still before informatization of medical records in the 
health services, where there were no centralized and organized clinical files. The 
inevitable limitations were not easy to overcome for achieving the good results 
obtained. 
The overall national prevalence of HSP (previously unknown) found after the survey 
was of 4.1/100,000 inhabitants. 
The geographical distribution of families with HSP was not homogeneous in the 
Portuguese territory (Figure 3, Chapter IV). 
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ABSTRACT 
Objective: To present the prevalence and distribution of hereditary cerebellar ataxias 
(HCA) and spastic paraplegias (HSP) in Portugal. 
Design and Setting: Population-based nationwide systematic survey, 1994-2004, in 
Portugal.  
Methods and patients: Multiple sources of information used (review of clinical files, 
active collaboration of neurologists and geneticists, investigation of affected families), 
but mainly active collaboration of general practitioners. Patients examined by the same 
team of neurologists, using homogenous inclusion criteria. Clinical data registered, all 
families genetically tested. 
Results: Overall, 1,336 patients were diagnosed with HCA/HSP, in a population of 
10,322 millions, a prevalence of 12.9:100,000. HCA were more prevalent, 8.9 (5.6 for 
dominant, 3.3 for recessive ataxias) than HSP, 4.1 (2.4 for dominant, 1.6 for recessive). 
Machado-Joseph disease (SCA3) (3.1:100,000), Friedreich ataxia (1.0) and ataxia with 
oculomotor apraxia (0.4) were the most frequent HCA. SPG4 (0.91), SPG3 (0.14) and 
SPG11 (0.26) were the most prevalent HSP. 
Conclusions: This population-based survey covered all the territory and mobilized the 
majority of general practitioners and health centres. It was probably the largest ever 
performed for HCA and HSP. Prevalence of autosomal dominant ataxias was high, 
particularly for MJD/SCA3. The genetic cause has not been identified in 39.7% of the 
patients studied.
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INTRODUCTION 
Hereditary cerebellar ataxias (HCA) and hereditary spastic paraplegias (HSP) are 
neurodegenerative disorders that present with progressive gait impairment. HCA 
involve mainly the cerebellar system and its connections, HSP affect predominantly the 
corticospinal tract. Other systems are often affected, leading to complex forms. These 
are heterogeneous groups, with considerable overlap with each other. Often, they lead 
to incapacity and premature death.  
Epidemiological data on HCA and HSP were still scarce. When this survey began, few 
studies (none population-based) including both diseases had been performed 1-5. Two 
studies were now published6, 7, though there is still much uncertainty about their 
epidemiology. 
In the Azores, a cluster of Machado-Joseph disease (MJD) was identified and studied, 
from 1976 to 19918-10. The existence of other foci of MJD and other HCA/HSP, and 
their prevalence in Portugal was unknown. That was the main objective of this survey. 
Others were to identify groups of families with similar phenotypes, identification of new 
loci and mutations, and set the basis for programs of prevention and assistance, 
especially in the major clusters. 
The survey began in 1994, with a pilot for validation of methods11, and was 
successively extended to all regions, throughout 2004. Systematic follow-up and 
genetic analysis lasted until 2010, and pursued since. This paper presents the 
prevalence estimates and distribution of HCA and HSP in Portugal.  
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SUBJECTS AND METHODS 
1. Study design and setting 
Portugal has 18 districts in the mainland and two autonomous regions (the 
archipelagos of the Azores and Madeira). This study results from a sequence of 20 
cross-sectional population-based surveys, undertaken at regional level, from 1994 to 
2004. The surveyed population was estimated in 10.322 millions (eTable 1). The 
country had a heterogeneous distribution of neurologists, with excess along the coast 
and extreme lack inland. In many hospitals, centralized files did not exist by then. The 
National Health Service covered 95% of the population, the health centre (HC) being its 
basic unit. Each general practitioner (GP) working in a HC covered about 1,200 
persons. Multiple sources were used to identify patients, relying mainly on information 
provided by the GPs. 
2. Case ascertainment 
Clinical research series and hospital records 
(1) Field trips to the Azores. From 1976 to 1991, Coutinho and Andrade performed 
several research visits to all the Azorean islands to identify and study local MJD 
clusters: 343 persons (from 47 families) were examined, with 144 patients identified in 
that period.  
(2) Hospital records. Patient series from hospital practice and clinical research of the 
team members were also used. A systematic inpatient-file search was possible in a few 
hospitals.  
Active survey 
The methodology adopted in the active survey was described elsewhere in detail11, and 
is shown in Fig. 1. Several sources of information were sought:  
(3) Neurologists and clinical geneticists. The project was presented in meetings of the 
Portuguese Neurology and Neuropaediatrics Societies. Letters introducing the study 
were sent to every neurologist and every Neurology Department. Colleagues were 
asked to refer their patients, even if without a definite diagnosis. Genetic centres were 
asked to report patients with HCA and HSP mutations. 
(4) General practitioners. In cooperation with the regional health administrations, a GP 
was selected in every HC to be a representative of the project. They attended 
workshops in genetics, cerebellar dysfunction and typical signs and symptoms of HCA 
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and HSP. At their HC, they replicated these sessions to the other GPs, using a 
publication on these topics and a video showing patients with these diseases. Every 
GP was asked to fill a form for each patient suspected to be affected (presenting with 
progressive gait difficulty, with or without family history), or stating they had none. If a 
GP failed to return the form, reminders were sent and the GP in charge was warned. 
Simultaneously, each local population received information on these diseases and the 
survey, through the local media, and was invited to contact their GP if they had any 
suspected family member. 
Fieldwork. The research team visited every region to observe the patients referred by 
the previous sources, either at the HC or at home.  
Post-survey 
(5) Study of affected families and posterior referrals. Possibly affected family members 
of the patients identified through the previous sources were contacted and evaluated. 
Some families not identified in the active survey sought the neurologist team for 
diagnosis and advice.  
3. Clinical and genetic studies 
Inclusion/exclusion criteria 
Regardless of the source and year of identification, patients were only included if alive 
and affected at prevalence day, according to the following criteria: HCA – presence of 
progressive cerebellar ataxia and family history or molecular diagnosis; isolated 
patients were included when they presented a phenotype consistent with a described 
form of recessive ataxia, had consanguineous parents and non-hereditary causes were 
excluded through clinical, radiological and laboratorial investigation; (b) HSP – 
presence of progressive gait disturbances with corticospinal signs in lower limbs and 
family history of spastic paraplegia or molecular diagnosis; isolated patients were not 
included. 
Data collection and classification of patients and families 
A detailed clinical history, neurological examination and family pedigree were recorded. 
Whenever possible, one patient from each family was admitted for complete clinical, 
serological and radiological workup. Written consent for genetic study was requested 
and DNA stored in all those families.  
All consenting families with autosomal dominant (AD) HCA were tested at least for 
SCA1, DRPLA, SCA2, MJD/SCA3, SCA6, SCA7, SCA10, SCA12, SCA14 and SCA17. 
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All AD-HSP consenting families were screened for SPG3A, SPG4 and SPG31. In the 
autosomal recessive (AR) groups, due to their heterogeneity, clinical presentation 
drove genetic testing. Exhaustive testing was conducted in some groups: patients with 
ataxia and oculomotor apraxia (AOA) were tested for AOA1 and AOA2; patients with 
ataxia and neuropathy were tested for FRDA; patients with ataxia and low vitamin E 
were tested for alfa-TTP gene; patients with HSP and cognitive impairment were tested 
for SPG11 and SPG15. 
Families were classified according to the mutation found; subsequently, there was a 
systematic effort to group families with a similar clinical phenotype. Families without 
molecular diagnosis were pure (only progressive cerebellar ataxia or spasticity) or 
complex (associated to other neurological syndromes). Onset before age 20 years was 
defined as “early-onset”. The AR-HCA families were also classified on a metabolic 
basis, using an adapted version of Palau and Espinós’ criteria12. Patients presenting 
with both cerebellar and corticospinal syndromes (spastic ataxias) were included in this 
group.  
4. Data analysis  
The prevalence day for each region was defined independently, as the middle point of 
the period the active survey took place in that region (usually one week to one month). 
Regional population estimates were based on national censuses and forecasts from 
the National Statistics Institute (INE). To avoid duplicates, all referrals were indexed by 
name, surname and birth date and any similarities scrutinized. Family trees from 
patients with the same mutation were investigated for possible links. The overall 
prevalence for each disease/disease group included all patients throughout the survey 
period and the population estimated for the country. The age at onset limits and 
median were calculated for each disease/disease group. 
 
RESULTS 
The full methodology was accomplished in 19 of the 20 regions. Due to lack of 
cooperation from health authorities, the survey could not be completed in the Azores. 
In spite of this, the results of previous fieldtrips 8 were updated in 1994, families with 
HCA were re-examined and new patients identified. Unfortunately, there was no active 
survey for HSP in this region. 
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During the study, 368 health centres were contacted; 86.1% cooperated. Amongst the 
6,561 GPs contacted, 58.5% participated (eTable 1). A total of 35 neurologists from 
outside the team referred patients to the survey. From all sources of information, 2,724 
patients were ascertained (Fig. 2). Patients not clinically assessed (142) were 
predominantly those extracted from clinical files; most of them had died or resided 
abroad (121). The remainder (21) proved not possible to contact.  
The team observed 1,319 patients referred by the GPs, and 168 referred by 
neurologists and geneticists. Diagnosis of HCA and HSP was confirmed in 34.3% of 
the GPs’ referrals and in 80.4% of the subjects referred by neurologists and geneticists. 
We identified 63 patients with isolated idiopathic ataxia that did not meet criteria for 
inclusion. Most of them had a late disease onset. The cerebellar form of MSA was 
diagnoses in 21 of them. The most common misdiagnoses were cerebral palsy 
(10.4%), muscular disorders (8.0%) and neuropathies (7.3%).  
In the post-survey period, 251 additional suspected patients were observed. From this 
group we excluded 24 patients (9.6%) who became symptomatic only after prevalence 
day and 57 (22.7%) who did not meet the diagnostic criteria. 
From all sources of information, 1,336 patients (52%) with HCA/HSP were included: 
367 (27.5%) were exclusively and directly referred by a GP; 128 (9.6%) were sent by a 
neurologist or clinical geneticist; 586 (43.9%) were ascertained through MJD research 
in Azores, other research series and hospital files (eTable 2). Since the 169 post-
survey patients (12.6%) were almost all identified in families previously referred by the 
GP, the estimated impact of GP information was around 40%. 
Prevalence estimates 
The overall prevalence of HCA and HSP was 12.9 (95% CI, 12.3-13.7) per 100,000 
inhabitants. The prevalence of HCA was 8.9 (8.3-9.5); 5.6 (5.1-6.0) for dominant and 
3.3 (3.0-3.7) for recessive ataxia. The HSP showed to be less prevalent, 4.1 (95% CI, 
3.8-4.8) per 100,000; 2.4 (2.2-2.8) for dominant and 1.6 (1.4-1.9) for recessive spastic 
paraplegia. Excluding the Azorean Islands there is a decrease in the overall prevalence 
to 12.1 (11.5-12.8) per 100,000 inhabitants, as well as the AD-HCA prevalence, 4.6 
(4.2-5.1). The AR-HCA prevalence stays roughly the same 3.3 (3.00-3.7). The HSP 
prevalence estimates does not include the Azores, since the case finding for these 
diseases was not performed there.  
The pathologic mutation was identified in 127 (63.8%) of the AD-HCA families. Of the 
71 families without molecular diagnosis, 87% performed the proposed genetic testing. 
63 
 
MJD had a prevalence of 3.1 per 100,000 persons; followed by dentatorubro-
pallidoluysian atrophy (DRPLA) in 8 families and SCA2 in 5 families (Table 1). No 
families with SCA1, SCA10 and SCA12 were identified in Portugal. In the AR-HCA 
group, Friedreich ataxia had a prevalence of 1.0 per 100,000; followed by AOA with 
0.4.  L-2 hydroxyglutaric aciduria (L-2-HGA gene) had a prevalence of 0.19:100,000 
(Table 2). Figure 3 shows the regional distribution of MJD and Friedreich ataxia, the 
first clustering in the central region and the later with a homogeneous pattern. 
The pathogenic mutation was identified in 29 (33.3%) of the 87 AD-HSP families, 
though 7 families did not consent genetic testing. Just 10% of them had a complex 
phenotype. The SPG4 (27.6%) and SPG3 (4.6%) genes accounted for most of them, 
while mutations in SPG31 (1.1%) were rare (Table 3). In the AR-HSP most families 
(82.3%) remained without genetic diagnosis (Table 4). Pure forms accounted for 35.4% 
of families, while complex forms were 73%, almost all of them with early onset. Within 
the complex forms, 38 families (74.5%) had mental retardation or progressive cognitive 
deterioration of early onset. Among them, 22 families had a thin corpus callosum, 60% 
with SPG11 mutations, 10% SPG15; and 30% still remain without molecular diagnosis.  
 
DISCUSSION 
This study may represent the largest population-based systematic survey ever 
performed for HCA or HSP. The overall prevalence for both was high (12.9:100,000), 
though still slightly underestimated, since Azorean HSP patients could not be included. 
HCA had an overall prevalence of 8.9:100,000, with a major contribution of MJD (3.1). 
HSP were less prevalent (4.1). Most population-based studies yielded similar overall 
prevalence values6, 7, 13-15, with the exception of the surprisingly high prevalence of AD-
HSP in Norway 7. Lower figures are often found in hospital-based or genetic centres 
studies1, 2, 16-18, suggesting the importance of population–based surveys and the use of 
all possible sources of information. MJD was the most frequent ataxia in Portugal, with 
clusters in the Azores and mainland Portugal. Interestingly, the two main haplotypes 
did not mix significantly. MJD is regarded as the most frequent type of dominant ataxia 
worldwide 19, but the prevalence in certain clusters in Portugal (as in Flores) is the 
highest reported. The second most frequent dominant ataxia is DRPLA, with a higher 
frequency than generally described for the rest of Europe or the Mediterranean 19, and 
only comparable to Japan 20 and Singapore 17 ; these Portuguese families share the 
same haplotype as in Asia 21. SCA2 is the third most common dominant ataxia, though 
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not as frequent as in most reported series 19. Friedreich ataxia is, as expected, the 
most prevalent recessive ataxia, although with a lower relative frequency and 
prevalence than in most European countries3, 6, 22, 23. The second most frequent 
recessive ataxia is AOA, while in other European countries ataxia-telangiectasia 
follows19, 24. Ataxia-telangiectasia has clearly a lower prevalence than found in other 
studies12. We didn’t find any families with a clear inheritance pattern suggestive of a X-
linked ataxia, but we cannot discard that some families classified as recessive 
inheritance have X-linked inheritance.  The most frequent AD-HSP is SPG4, followed 
by SPG3, as generally described7, 13. Although almost all other families were tested for 
SPG31, its prevalence seams very low in Portugal. As to AR-HSP, the most frequent 
were SPG11, followed by SPG15, as in other studies25; for most families the affected 
gene has not yet been discovered.  
Since most AD-HCA and AD-HSP families undergone genetic testing, the gene 
prevalence described in these groups (SCA1, DRPLA, SCA2, MJD/SCA3, SCA6, 
SCA7, SCA10, SCA12, SCA14, SCA17, SPG3A, SPG4 and SPG31) should represent 
accurate estimates. In the recessive groups which underwent exhaustive testing, the 
prevalence of the tested genes (AOA1 and AOA2; FRDA gene; AVED; HSP11 and 
HSP15) should also present a close estimation. However, the reported prevalence for 
most of the recessive genes is probably an underestimation, due to non-systematic 
genetic testing. 
Prevalence is quite variable geographically (eTable 3). While some diseases, such as 
MJD and DRPLA, are distributed in clusters, Friedreich ataxia has a clearly uniform 
distribution (Fig. 3).  
Due to the effort of covering all national territory by the same team and in a consistent 
way, this study spanned several years. To reduce uncertainty about disease-onset 
reported by patients, an independent prevalence day was assigned to each region. 
Most patients were examined and confirmed as having the disease close to their region 
prevalence day. Therefore, national prevalence results do not express a point 
prevalence at any given time, but are in fact the average of specific point regional 
prevalence days for those diseases, throughout the study period (1994-2004), of a 
series of cross-sectional population-based surveys. These estimates should be close to 
the real prevalence considering that: (a) the affected status does not change through 
time after disease onset; (b) during the study period there were no medical advances 
that prolonged the survival or prevented disease onset, so that mortality and incidence 
probably stayed constant; (c) these are slowly progressive diseases with a long 
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evolution time in most patients; (d) the Portuguese population was relatively stable 
during this study period (9,997,800 inhabitants, in 1994; and 10,501,970, in 2004), and 
no significant migration movements occurred in that period.  
The response rate of GPs was near 60%; 86.1% of HCs cooperated. These rates are 
higher than in previous studies5, 26, 27. As additional sources were used to cover all the 
districts (eTable 1) and many GPs did not reply to the survey because of a lack of 
patients, adjusting the prevalence to the response rate of GPs or HC would probably 
result in an overestimation. 
Even though the response rate slightly decreased over the years, prevalence estimated 
from GP referrals showed relatively constant. Without their collaboration, around 40% 
of the patients would have been missed. This was especially relevant for the recessive 
forms. The cooperation from neurologists resulted in less referrals. Since there is no 
adequate estimate for the number of neurologists practicing in the country throughout 
the survey period, we could not advance a reliable estimate for their response rate. 
Genetic centres began to offer community services by the end of the nineties; thus, 
their importance was not critical for this study.  
In the post-survey period, 169 (12.6%) patients missed in the active survey were then 
included, either by studying their families or through late referrals to neurologists of the 
research team.  
In spite of all efforts and the use of multiple sources of information, we have most 
certainly missed some patients, especially from families with milder phenotypes who 
did not seek health care, or whenever their GP did not fully cooperate. 
Neurologists from the research team observed almost every referred individual (98%), 
using homogenous pre-established clinical criteria. Those few cases that could not be 
personally examined were excluded. Accordingly, the probability of misdiagnosis 
seems low. Registration of patients in a computer-based file, including family details, 
was essential to eliminate duplicate referrals (Table 1). Applying defined criteria, we 
included 50 isolated AR-HCA patients without identified gene. Most of them (43) 
presented with early-onset ataxia. The relatively low number of isolated cases in our 
population when compared to other studies could probably be due to larger families, 
especially in the more rural areas where the recessive cases were more frequently 
found. Furthermore, the relatively long post-survey period (2005-2010) allowed the 
conclusion of follow-up clinical, familiar and genetic studies. Doubtful cases were 
scrutinized and the observation of possibly affected family members was 
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accomplished. Molecular testing was completed and further genetic research pursued. 
We did not include the isolated HSP patients. Contrary to recessive HCA, very few 
distinct phenotypes for recessive HSP are well documented in a way that we could felt 
confident in including them. Nevertheless, this may result on an underestimation of its 
prevalence. 
The objectives of the survey extended beyond a prevalence study. There was a 
systematic effort to classify families and patients in clinical groups for further genetic 
and clinical research. Families from this pool opened many fields of research on 
Machado-Joseph disease, including molecular biology 28; population genetics and 
epidemiology 29-31 and anthropology and social psychology 32-36. The first known genes 
reported for ataxia with oculomotor apraxia (AOA1 and AOA2) were mapped and 
identified in families ascertained in this survey37, 38. Others contributed to the 
identification of SPG3225. New mutations were found in genes known to cause 
hemiplegic migraine 39, 40, SCA2 41, SCA14 42, L2-HGA 43, Joubert syndrome 44, AD-
HSP (SPG4, SPG3) 45 and AR-HSP (SPG11, SPG15) 46-48. A considerable high 
number of patients in this population-based study have no genetic diagnosis. In the AD 
groups, 36% of AD-HCA (mostly pure forms) and 67% of the AD-HSP families remain 
without a defined genetic diagnosis. In the AR groups, where genetic testing has not 
yet been exhaustive, 40% of the AR-HCA and 82% of the AR-HSP families have no 
molecular diagnosis. There is still much to discover on the molecular basis of these 
diseases with high genetic heterogeneity. Some quite uniform groups of patients are 
being studied.  In some, like ataxia with initial dysarthria, ataxia with initial spasmodic 
cough and dominant congenital ataxia no genes were identified so far; while in others 
like AOA and HSP with thin corpus callosum additional molecular research is needed 
for the identification of further responsible genes.  
Furthermore, the impact of this survey goes beyond the scientific research field with the 
improvement of the molecular 49 and prenatal diagnosis for MJD 50 and other HCA, and 
the launching of a national program for genetic counselling and presymptomatic 
testing.  
In conclusion, approximately 60% of the patients included in this survey obtained a 
molecular diagnosis. This allowed actions for prevention and assistance in areas with a 
high prevalence; two patients’ associations were created, the MJD patients of the 
Azores, and the Portuguese Association of Hereditary Ataxias (www.apahe.pt.vu). 
Finally, the fieldwork in which the survey was based allowed us, mostly hospital 
neurologists, to have a closer look at how affected families cope with disabling 
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diseases, usually rural families coping better than city families. This was a unique 
experience for all of us. 
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Figures 
Figure 1. Active survey methodology 
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Figure 2. Flow chart describing the case ascertainment process according to 
the sources of information. Numbers in brackets represent suspected patients 
referred by more than one source (duplicates) 
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Post - Survey (n = 251)
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Alive and examined at the prevalence period (n = 2532)
1. & 2. 3. 4.
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Asymptomatic carrier 399 (4) 9 57 (4)
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Other disease 33 24 806
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Figure 3. Regional prevalence of Machado Joseph disease (A) and Fridereich 
ataxia (B) in mainland Portugal (/105) 
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TABLES 
 
Table 1. Prevalence of autosomal dominant hereditary ataxias in Portugal 
1994-2004 and families affected 
 
 
Disease group 
No. of 
patients 
No. of 
families 
Age at onset 
median 
(limits) 
Prevalence /100 000 
(95% CI) 
Identified genetic mutation 400 127  3.88 (3.50-4.27) 
SCA3 / MJD 322 102 41  (12-70) 3.12 (2.80-3.48) 
DRPLA 34 8 28  (1-54) 0.33 (0.24-0.46) 
CACNA1A 22 3 18  (1-40) 0.22 (0.13-0.32) 
SCA2 10 5 40  (11-61) 0.10 (0.05-0.18) 
SCA7 5 3 38  (19-40) 0.05 (0.02-0.11) 
SCA8 4 3 21  (20-26) 0.04 (0.02-0.10) 
SCA6 1 1 76 0.01 (0.00-0.06) 
SCA14 1 1 30 0.01 (0.00-0.06) 
SCA17 1 1 31 0.01 (0.00-0.06) 
Unidentified gene 174 72  1.69 (1.44-1.96) 
Pure 108 42  1.05 (0.86-1.26) 
Initial ataxia 63 28 47  (21-75) 0.61 (0.48-0.78) 
Initial dysarthria 21 6 37  (18-63) 0.20 (0.13-0.31) 
Initial spasmodic cough 16 6 37  (25-65) 0.16 (0.09-0.25) 
Initial migraine 5 1 5  (3-37) 0.05 (0.02-0.11) 
Initial nystagmus 3 1 45  (35-58) 0.03 (0.01-0.09) 
Complex 66 30  0.64 (0.49-0.81) 
+ PEO** 16 9 42  (27-64) 0.16 (0.09-0.25) 
+ Dementia 15 7 36  (30-56) 0.15 (0.09-0.24) 
+ Pyramidal signs 12 5 33  (13-70) 0.12 (0.06-0.20) 
+ Parkinson 5 2 45  (35-55) 0.05 (0.02-0.11) 
+ Others 14 5 1  (1-60) 0.14 (0.08-0.23) 
Congenital 4 2 (a) 0.04 (0.02-0.10) 
All 574 199  5.56 (5.12-6.04) 
 CI: confidence interval; ** PEO: progressive external ophthalmoplegia; (a) onset during 
first year of life 
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Table 2. Prevalence of autosomal recessive hereditary ataxias in Portugal 1994-
2004 and families affected 
 
 
Disease group 
No. of 
patiens 
No. of 
familie
s 
Age at onset 
median 
(limits) 
Prevalence /100 
000 (95% CI) 
Congenital ataxias 40 34  0.39 (0.28-0.53) 
Joubert syndrome 15 12 (a) 0.15 (0.09-0.24) 
Others 25 22 (a) 0.24 (0.16-0.36) 
Metabolic ataxias 150 111    1.45 (1.24-1.71) 
Friedreich ataxia  103 72 10  (1-25) 1.00 (0.82-1.21) 
L-2 hydroxyglutaric aciduria 20 16 1  (1-1) 0.19 (0.12-0.30) 
Niemann-Pick type C  11 8   6  (2-16) 0.11 (0.06-0.19) 
Ataxia with isolated hereditary vitamin E 
deficiency 
8 7 20  (7-62) 0.08 
(0.04-0.15) 
Carbohydrate deficient glycoprotein syndrome 4 4 2  (1-6) 0.04 (0.02-0.10) 
Cerebrotendinous xanthomatosis 2 2   23  (22-24) 0.02 (0.01-0.07) 
Hyperargininemia 2 2 1  (1-1) 0.02 (0.01-0.07) 
DNA repair defects 56 35    0.54 (0.42-0.70) 
Ataxia telangiectasia 15 14 2  (1-8) 0.15 (0.09-0.24) 
Ataxia with oculomotor apraxia 41 21   6  (1-19) 0.40 (0.29-0.54) 
Type 1 13 6   4  (2-15) 0.13 (0.07-0.22) 
Type 2 11 3 14  (9-17) 0.11 (0.06-0.19) 
Others** 17 12   5  (1-23) 0.17 (0.10-0.26) 
Other degenerative ataxias 15 9  0.15 (0.09-0.24) 
Charlevoix-Saguenay ataxia 7 3 2  (2-8) 0.07 (0.03-0.14) 
Vanishing white matter 5 4 4  (3-5) 0.05 (0.02-0.11) 
Boucher syndrome 2 1      22 0.02 (0.01-0.07) 
Marinesco-Sjögren syndrome 1 1        (a) 0.01 (0.00-0.06) 
Unidentified gene/ without diagnosis 83 61  0.80 (0.65-1.00) 
Pure  5 4 37  (1-57) 0.05 (0.02-0.11) 
Complex 78 57  0.76 (0.61-0.94) 
+ Pyramidal signs 33 25 12  (1-47) 0.32 (0.23-0.45) 
+ Neuropathy 24 14 12  (1-42) 0.23 (0.16-0.35) 
Others 21 18  8  (1-58) 0.20 (0.13-0.31) 
All 344 250   3.33 (3.00-3.70) 
CI: confidence interval; (a) Onset during first year of life. 
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Table 3. Prevalence of hereditary dominant spastic paraplegias in Portugal 
mainland and Madeira 1994-2004 and families affected 
 
 
Disease group 
No. of 
patients 
No. of 
families 
Age at onset 
median 
(limits) 
Prevalence /100 000 
(95% CI) 
Identified genetic mutations 108 29  1.07 (0.89-1.29) 
SPG4 92 24 33  (2-68) 0.91 (0.74-1.12) 
SPG3 14 4 2  (1-40) 0.14 (0.08-0.23) 
SPG31 2 1 20 0.02 (0.01-0.07) 
Unidentified gene 141 58  1.40 (1.19-1.65) 
Pure  122 49  1.21 (1.01-1.45) 
Early onset 47 19 10  (1-39) 0.47 (0.35-0.62) 
Late onset 75 30 40  (18-70) 0.74 (0.59-0.93) 
Complex 19 9  0.19 (0.12-0.29) 
Early onset 8 3 11  (2-19) 0.08 (0.04-0.16) 
Late onset 11 6 41  (12-60) 0.11 (0.06-0.20) 
All 249 87  2.47 (2.18-2.80) 
CI: confidence interval 
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Table 4. Prevalence of hereditary recessive spastic paraplegias in Portugal 
mainland and Madeira 1994-2004 and families affected 
 
 
Disease group 
No. of 
patients 
No. of 
families 
Age at onset 
median 
(limits) 
Prevalence /100 
000 (95% CI) 
Identified genetic mutations 34 17  0.34 (0.24-0.47) 
SPG11 26 13 14  (2-29) 0.26 (0.17-0.38) 
SPG15 3 2 14  (3-15) 0.03 (0.01-0.09) 
SPG32 3 1 6  (6-7) 0.03 (0.01-0.09) 
SPG5 2 1 5 0.02 (0.01-0.07) 
Unidentified gene 135 79  1.34 (1.13-1.59) 
Pure  45 28  0.45 (0.33-0.60) 
Early onset 33 20 7  (2-25) 0.33 (0.23-0.46) 
Late onset 
 
12 8 40  (23-72) 0.12 
(0.07-0.21) 
Complex 90 51  0.89 (0.73-1.10) 
With cognitive impairment 71 38  0.70 (0.56-0.89) 
Mental retardation 37 17 8  (1-42) 0.37 (0.27-0.51) 
Mental retardation and 
neuropathy 
18 10 14  (1-30) 0.18 
(0.11-0.28) 
Thin corpus callosum 10 7 6  (2-25) 0.10 (0.05-0.18) 
Sjögren-Larsson syndrome 5 3 6  (6-28) 0.05 (0.02-0.12) 
Behr syndrome 1 1 2 0.01 (0.00-0.06) 
With neuropathy 11 8 28  (1-69) 0.11 (0.06-0.20) 
Others 8 5 4  (1-55) 0.08 (0.04-0.16) 
All 169 96  1.68 (1.44-1.95) 
CI: confidence interval 
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2. Autosomal dominant hereditary spastic paraplegia 
The clinical expression of AD-HSP has been known for a long time and is relatively 
monotonous, despite the variability of some of its features. These have been described 
in various articles, but in a sparse manner.  
As a result of the survey in Portugal, an extraordinary opportunity arose to study a 
large number of families, according to homogeneous clinical criteria. For years, the 
same team of neurologists observed personally almost all these families, and followed 
several of them for many years; and this allowed a meticulous review of their clinical 
features.  
This approach had some consequences, among which we highlight the following: first, 
some of our results confirm only what was already known, but the interest of such 
confirmatory data, whether clinical, genetic or epidemiological, was reinforced by it 
being population-based; secondly, the accuracy of the clinical analyses allowed us to 
go further in the correlation between genotype and phenotype, being able to establish a 
correlation between the type of mutation and age-of-onset.  
We carried out the genetic characterization of the Portuguese families clinically 
diagnosed as AD-HSP. At the beginning of this study, this had been done only for six 
families; however, 63% of families remained without molecular diagnosis yet, therefore 
presenting an open field for further investigation. 
It was not possible to include in the articles published some data we analyzed and that 
are still controversial. A very interesting (though small) group of two autosomal 
dominant families (summarily referred in Article 2) showed an unusual association of 
paraplegia and dementia, what deserves a special mention for future studies.. 
We found also that there was anticipation in AD-HSP, a tendency for a decrease in 
age-at-onset in successive affected generations. Analyzing family by family, looking at 
families in which more than one generation was available, anticipation of age-at-onset 
was observed in 79% of the families. If this is a real biological phenomenon in AD-HSP, 
or a statistical artifact, still remains to be studied (Chapter IV, Discussion).  
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Article 2. 
 
 
Autosomal dominant spastic paraplegias: a review of 89 families resulting 
from a Portuguese survey 
Loureiro JL, Brandão E, Ruano L, Brandão AF, Lopes AM, Thieleke-Matos C, Miller-
Fleming L, Cruz VT, Barbosa M, Silveira I, Stevanin G, Pinto-Basto J, Sequeiros J, 
Alonso I, Coutinho P 
Archives of Neurology (in press) 
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Running title: Clinical and genetic aspects of AD spastic paraplegia 
 
ABSTRACT  
 
Background: Hereditary spastic paraplegias (HSP) are a group of diseases 
caused by corticospinal tract degeneration. Mutations in 3 genes (SPG4, SPG3 
and SPG31) are said to be the cause in half of the autosomal dominant HSP 
(AD-HSP).  
Objective: To describe the clinical, genetic and epidemiological features of 
Portuguese AD-HSP families. 
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Methods: Review of records of the families identified through a population-
based survey of hereditary ataxias and spastic paraplegias, and genetic study 
for mutation detection in the most prevalent genes. 
Results: We identified 239 patients belonging to 89 AD-HSP families. The 
prevalence was 2.4/100,000. Thirty-one distinct mutations (26 in SPG4, four in 
SPG3 and one in SPG31) segregated in 41% of the families (33.7%, 6.2% and 
1.2% were SPG4, SPG3 and SPG31, respectively). Seven of the SPG4 
mutations were novel, and 7% of all SPG4 were deletions. When the onset was 
before the first decade, 31% had SPG4 and 27% SPG3 mutations. In SPG4, 
large deletions had the earliest onset, followed by missense, frameshift, 
nonsense, and alternative-splicing mutations. Rate of disease progression was 
not significantly different among SPG3 and SPG4 patients in a multivariate 
analysis. For SPG4 it was worst in later-onset patients.  
Conclusions: AD-HSP prevalence, SPG3 and SPG4 frequency are similar to 
what has been described except that the frequency of SPG4 deletions is lower . 
In contrast, SPG31 is rare compared to other studies. The most interesting 
aspects of this study are: even in early-onset patients the probability of finding a 
SPG4 mutation is higher than for SPG3; there is no difference in disease 
progression with genotype, but an association with the age-at-onset; seven new 
SPG4 mutations were identified, and for the first time the nature of the SPG4 
mutations was found to predict the age-at-onset. 
 
Keywords: Genetic neurological diseases, SPG3, SPG4, SPG31. 
 
INTRODUCTION 
 
Hereditary spastic paraplegias (HSP) are heterogeneous diseases 
characterized by progressive spasticity, and lower limbs weakness due to 
corticospinal tract degeneration. They are divided into pure and complex forms, 
according to the absence or presence of features besides the corticospinal 
signs. HSP are inherited in an autosomal dominant, recessive or X-linked 
manner. Nearly 50 loci were mapped. In autosomal dominant HSP (AD-HSP) 
19 loci and 11 genes were identified. Three of them are reported as 
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representing about 50% of all AD-HSP families: SPG4 being the cause in 40%; 
SPG3 in 10%, and SPG31 in 4.5 to 6% of all families studied1-15. 
SPG4 maps to chromosome 2p22-p21 1 and encodes spastin, which belongs to 
the AAA protein family (ATPase associated with various cellular activities). It is 
implicated in the remodeling of protein complexes and in axonal microtubule 
interactions with endoplasmic reticulum 16. Approximately 250 mutations have 
been reported14. 
SPG3 links to chromosome 14q12-q21 17 and encodes atlastin-1, a Golgi 
GTPase 18 involved in vesicle trafficking, and is probably a spastin partner 19. 
About 25 mutations were described14. 
SPG31 maps to chromosome 2p11.2 and encodes a receptor expression 
enhancing protein 1 (REEP1) of mitochondrial localization and unknown 
function20. 
This study aims to estimate AD-HSP prevalence in the country, the frequency of 
the most prevalent genes, describe the main clinical features, and analyze the 
genotype-phenotype correlations. 
 
PATIENTS AND METHODS 
 
Patients’ ascertainment  
From 1993 to 2004, a population-based systematic survey of hereditary ataxias 
and spastic paraplegias was conducted in Portugal. We included all families 
ascertained during that survey, as well as those identified after. Their methods 
were discussed elsewhere 21. 
 
Clinical studies 
Patients were examined by the same team of neurologists. Blood samples were 
collected after written consent. Diagnosis of HSP was based on published 
criteria22, 23; accordingly 3 patients without family history, and without identified 
mutation, were excluded. Diseases mimicking HSP were excluded by 
radiological and biochemical investigations. 
Onset was systematically defined as the start of any change of gait pattern, 
walking difficulties, unexplained falls or cramps noticed by the patients or 
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relatives. Early-onset was considered when before 20 years (other patients 
were classified as late-onset). We considered complex family those with two or 
more patients with symptoms besides the corticospinal syndrome, in the 
absence of any other explanation for the changes found. 
The motor severity of disease was classified on a scale from 0 to 7 24 and 
transformed into a percentage scale (dividing by the maximum value of 7). 
Annual rate of disease progression was calculated dividing the percentage 
scale of severity by disease duration, and was expressed as a percentage per 
year. Patients with duration shorter than five years were excluded from this 
analysis.  
Spasticity was quantified from 0 to 4, according to the Modified Ashword Scale 
25. 
Muscle strength was graded from 0 to 5, using the Medical Research Council 
Scale for Muscle Strength. Asymptomatic individuals (n=19), though with an 
abnormal neurological examination were excluded 26. 
 
Mutation screening 
Genomic DNA was extracted from blood, according to standard procedures 27. 
Mutation screening was performed by PCR amplification of all coding regions, 
followed by denaturant high-performance liquid chromatography and 
bidirectional direct sequencing of altered profiles for SPG3 and SPG4. More 
recently, mutation detection was performed by direct sequencing of SPG3, 
SPG4 and SPG31 coding sequences and exon-intron boundaries. Each 
fragment was amplified by PCR with HotStarTaq Master Mix (Qiagen, Hilden, 
Germany), directly sequenced with the Big Dye Terminator Kit v1.1 (Applied 
Biosystems, Carlsbad, CA, USA) and loaded on an ABI 3130xl Genetic 
Analyzer (Applied Biosystems, Carlsbad, CA, USA).  In patients in whom no 
mutation was found, we performed Multiplex Ligation-dependent Probe 
Amplification to detect large deletions or duplications28. Patients in whom the 
three loci where tested and excluded are referred as patients without identified 
mutation.  
 
Statistical analysis 
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Student’s t-test was used to compare the distributions of severity score and 
progression rate by genotype. Univariate analysis of variance (ANOVA) was 
performed for the association between age-at-onset and genotype. Multivariate 
ANOVA was performed for the distribution of age-at-onset adjusting to the effect 
of all other possible variables (genotype, family within each genotype, gender) 
and for disease progression, and also for the distributions of disease 
progression and age-at-onset in SPG4 patients, adjusting for mutation type. The 
significance level used for statistical analysis was P≤0.05. To assist with the 
analysis, we used the IBM-SPSS-Statistic 19. 
 
RESULTS 
 
Subjects and families 
We identified 89 families with AD-HSP. Clinical data from 239 patients, 109 
women (45.6%) and 130 men (54.4%), were available. The average age of 
patients was 50.7 years (SD=17.9).  
 
Epidemiology 
The estimated prevalence of AD-HSP in Portugal, based on preliminary 
unpublished results from the survey was 2.4/100.000 inhabitants, distributed all 
over the country though not proportional to the density of various regions. 
 
Clinical results 
 
Age and mode of onset  
The average age-at-onset for all patients was 30 years (SD=18.6) and its 
distribution had a bimodal shape (figure 1). Onset was late (>20y) in 62% of 
patients, and early in 38%.  The initial symptoms were almost always a feeling 
of trapped leg or shuffling gait. The others first symptoms, besides spasticity, 
were mental retardation, dementia, epilepsy, ataxia and tremor and were 
present in 10% of patients.  
 
Neurologic examination 
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Mental examination was normal in 94% of patients. Brisk jaw reflex was present 
in 19%, and its rate of progression was not different from those with a normal 
reflex. Dysarthria was present in 6% of patients, half of whom also had 
dysphagia. Weakness and spasticity of the upper limbs were only present in 
patients with dysarthria (6%). 
Upper limbs hyperreflexia occurred in 54% of patients, who showed no 
difference in disease progression comparing to those with normal reflexes. 
In lower limbs the average weakness was 4; quantification of spasticity, often 
asymmetrical, was possible in 60% of patients, and its average was 2.2. 
Approximately 10% of patients did not have spasticity at rest but only visible 
when walking. Vibration sense was abolished at the ankles in 12%, sphincter 
changes were present in 25%, and pes cavus was seen in 30% of patients. 
 
Severity score and annual rate of disease progression 
The average motor severity score was 3.5 for all patients. Patients that could 
walk were 88% (53.7% walked with no aid, 18.3% required a unilateral aid and 
16% required bilateral assistance). The remaining 12% could not walk (9.1% 
wheelchair-bound, 2.9% bedridden). The average rate of disease progression 
was 4.1%/year (min. 0.43%/year, max.28%/year).  
 
Clinical forms 
Pure forms corresponded to 88% of patients, 58% of which had late-onset. 
Complex forms corresponded to 12% of patients; the majority (54%) also had 
late-onset. Nine patients from four families had a moderate mental retardation. 
Dementia was present in six patients from two families; in most patients it 
started years after the onset of motor difficulties; the prognosis is bad leading to 
a severe pseudobulbar tetraplegic stage. Eight patients from five families had 
moderate lower limb ataxia. An generalized epilepsy and tremor were found in 
four patients in two families. Except for families with dementia, the others had 
patients with complex and also with pure forms. 
 
Genetic results 
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Mutations were searched in 80/89 families (table 1). There were mutations in 33 
families (41%). SPG4 was the most frequent form and concerned 27 families 
(33.7%), followed by SPG3 mutations, found in 5 families (6.2%), and SPG31 in 
one family (1.2% of index patients). Among the 31 distinct mutations identified, 
26 were in the SPG4 gene (8 missense, 6 nonsense, 6 frameshift, one splicing 
mutation and 2 large deletions [7.7%]) including 7 novel mutations. Four 
previously reported mutations (3 missense and one frameshift) were found in 
SPG3 and one nonsense in SPG31.  
 
Genotype-phenotype correlations 
The average duration of the illness (23.3 years) and the average lower limbs 
weakness were similar in all genotypes (table 1). The average lower limbs 
spasticity was 1.9 in SPG4 and 2.4 in SPG3 patients. Two of the four families 
with mental retardation (S39 and S48) had SPG3 missense mutations. These 
mutations were different from those described in complex SPG3 forms, and 
were related to a pure phenotype when published. 
Another family with mental retardation (S36) had the largest SPG4 deletion we 
found, suggesting that major exonic defects may cause major pathological 
effects, although the opposite has been described.  
No SPG mutation, or in dementia related genes (presenilin1, presinilin2; 
amyloid precursor protein; microtubule associated protein TAU; progranuline) 
has been identified in families with dementia. Also, no SPG mutations were 
found in HSP patients with ataxia, epilepsy and tremor, or in patients with 
cranial nerve dysfunction, weakness and spasticity of the upper limbs, except 
for one with an SPG4 mutation. 
 
Age-at-onset and genotypes 
Patients with SPG3 had a lower mean age-at-onset (5.6 years, SD=16.7), than 
patients with SPG4 (31.7 years, SD=10) and patients with no identified mutation 
(30.4 years, SD=18.9) (p<0.001). Only one patient with SPG3 had a late onset 
(in the fourth decade). A great number of SPG4 patients had early-onset as 
well. When the onset was before the age of 15 years, 34% had SPG4 mutations 
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and 20% SPG3. When the onset was before the first decade, 31% had SPG4 
and 27% SPG3 mutations. 
We found a homogeneity of ages-at-onset in related patients (p<0.0001).There 
was no association with gender and affected parent age-at-onset. 
 
Age-at-onset and SPG4 mutation type 
The mean age-of-onset was significantly influenced by the nature of the 
mutation (p<0.0001): 15.8 years in patients with large deletions, 28.6 years for 
missense, 35.6 years for frameshift, 38.6 years for nonsense mutations, and 
42.7 years for patients with alternative splicing mutations; 70% of mutations 
were located in the AAA spastin domain, and these patients had a trend to an 
earlier disease onset (p=0.02). 
 
Severity and disease progression 
On average motor severity score was not significantly different among 
genotypic groups: 3.8 for SPG3; 3.4 for SPG4; and 3.7 for patients without 
identified mutation. Even in older patients (>40 y) we found no differences in 
this score between the genotypes. 
In SPG3, SPG4 and patients without mutation we found no significant 
association of the rate of disease progression with gender, generation, age-at-
onset of the affected parent, and with the type of mutation.We found, however, 
an association of the disease progression within the family (p=0.001). 
Excluding patients with less than five years of disease duration, an association 
between a late disease onset and a faster progression was found in SPG4 
patients (figure 2, p<0.0001), but not in SPG3 and in patients without identified 
mutations.  
 
Progression of disease in SPG3 and SPG4 patients 
The average rate of disease progression was 4.5%/year in SPG4 patients and 
4.3%/year in those without identified mutations, faster than in SPG3 patients 
with 1.7%/year (p<0.001). As showed, SPG4 patients with an earlier disease 
onset had a slower progression than patients with a later onset. Comparing only 
patients with early disease onset (<20 years), the disease progression of SPG4 
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(n=24) patients was 2.7%, not significantly different (p=0.54) from the 
progression rate of SPG3 (n=13) patients, 1.7%. As in this aspect, the SPG4 
patients resemble SPG3, the slower average progression of these SPG4 
patients could be attributable their younger disease onset. 
 
COMMENT 
 
AD-HSP prevalence is 2.4/100,000. Prevalence in other studies ranges from 0.5 
to 5.5/100,000 12, 13, 29-36 but only three studies have a solid population base 12, 
13, 36. In Portugal the prevalence is higher than in Ireland (1.27/100,000) 36 and, 
in spite of an active search for patients 21, is lower than in Norway 
(5.5/100,000)12.  
 
Isolate patients are almost inexistent. Included in the majority of the series, 
these patients have uncertain clinical significance37. Their inexistence was 
probably due to the personal observation of most families, at their health 
centres or at home, facilitating the recording of a detailed family history. 
Frequently, persons unaware of the medical condition of other relatives were 
picked and registered in the same large family tree. 
 
SPG3 (5.6%) and SPG4 (33.3%) frequency is similar to what was described in 
other countries 7, 12, 13 but the percentage of SPG4 deletions (7%) is far below 
the other studies. One study found 20% of SPG4 deletions admitting that the 
agreed 40% of SPG4 mutations were due to this high number of deletions7. 
Different percentages (2.5% to 23.5%) in non-population-based studies were 
found by others14, 38-40. SPG31 is rare in our population (~1%). In French 
patients, a frequency of 4.5% was recently reported15. 
 
This study was soundly based in a population survey. Therefore, the 
epidemiological results and gene frequencies are probably accurate for the 
Portuguese population, and should represent some of the most reliable 
estimates published in this area. Nevertheless, several of the clinical variables 
employed could have some reserves. The age-at-onset is always difficult to 
94 
 
assess in HSP. We use uniform criteria; however there is still a considerably of 
subjectivity involved. The severity scale evaluates only motor impairment, and 
do not reflect cognitive decline. In spite of this, we think that it still captures most 
of the patient’s disability, because cognitive impairment was found to be rare. 
The analysis of disease progression may be affected by are errors in evaluation 
of disease onset and severity. 
 
After 20 years of disease, only 12% of patients could not walk. Moderate 
corticospinal signs above lower limbs, although signalising a higher 
corticospinal lesion, does not indicate a poor prognosis. Complex forms have a 
worst course than pure forms only when associated with dementia. These 
patients form a clinically distinct sub-group needing further investigation. Their 
rate of progression accelerates after several years of disease. With the 
exception of this small group we have no sufficient longitudinal data to evaluate 
if disease progression is or not linear over time. 
 
Age-at-onset and progression of the disease are associated with each family. In 
spite of variation among and within families, there is a significant trend for an 
intra-familial aggregation of age-at-onset, and of the rate of disease 
progression. 
 
Association of mutational class of each gene with any phenotypic trait has never 
been possible3, 4, 40, 42-44, with exception of the suggestion for an earlier onset in 
SPG4 missense mutations39. Patients with large SPG4 deletions had the 
earliest age-at-onset, followed by missense, frameshift and nonsense 
mutations, with patients with alternative splicing mutations having the latest 
onset. The early age-at-onset of the missense mutations group may be due to a 
very early onset in two particular mutations (p.Leu380Pro and p.Ser445Asn), 
one novel and the other previously described, both located in the AAA-cassette. 
SPG4 mutations were not associated with a different rate of disease 
progression.  
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Even before the genes identification, it was suggested that when onset was 
after age 35 years the disease progresses more rapidly3, 24, 45. Patients with 
SPG4 and with unidentified mutations had a faster progression, than those with 
SPG3. When making a multivariate analysis, however, there is no difference in 
the rate of progression with genotype, but instead an association with age-at-
onset. The SPG4 and SPG3 patients could have a quite similar progression of 
disease if the onset be at the same age. The differences in progression rates 
could be caused by the confounding factor of age-at-onset. 
 
CONCLUSIONS 
 
SPG3 has been considered the most frequent cause of AD-HSP with onset 
during the first decade8. However, the probability of finding SPG4 mutation is 
higher than for SPG3 even when the disease begins before age 10 years. As a 
rule, we should start the genetic study by searching for SPG4 mutations. Some 
authors suggested that rare late-onset forms legitimate the study of SPG3 
mutations in all the SPG4 negative families41. This has little justification 
according to our experience. The SPG31 gene can hardly be regarded as the 
third most frequent in AD-HSP, since there are still 63% families that remain 
without a molecular diagnosis. This large number of families reinforces the high 
genetic heterogeneity of HSP. The low inter-familial variability does not allow for 
the organization of distinct phenotypic groups making the identification of novel 
genes a challenging task. 
 
There is no significant difference in disease progression with genotype, but an 
association with the age-at-onset. In SPG4 an earlier onset pointed to a slower 
progression, and a later onset to a faster progression. 
 
We identified seven new SPG4 mutations, we found for the first time that the 
nature of the SPG4 mutations predicts the age-at-onset, and we verified a trend 
to an earlier disease onset when mutations are located in the AAA-spastin 
domain. 
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Table 1. General phenotypic features  
 All 
Patients 
(n=239) 
SPG3 
(n=16) 
SPG4 
(n=97) 
SPG31 
(n=1) 
No mutation 
identified 
(n=111) 
Gender, men/women (%) 54.4/45.6 62.5/47.5 60.8/49.2  47.3/52.7 
Age of onset, years (95% 
CI) 
29.9 (26-31.7) 5.6 (0-12) 31.7 (27.8-
35.6) 
 30.4 (25.9-34.9) 
Duration, years (95% CI) 23.3 (20.9-
25.8) 
 36.6 (25.1- 
48.1) 
22.6 (19.1-
26.2)  
 21.7 (18.2-25.2) 
Severity sore, 0-7 (95% CI) 
1
 3.5 (3.3-3.7) 3.8 (2.9-4.6) 3.4 (3.1-3.7)  3.7 (3.3-4.1) 
Rate of progression, %/year 
(95% CI) 
2
 
4.1 (3.3-4.9) 1.7 (1.3-2.1) 4.5 (3.1-5.8)  4.3 (3.2-5.4) 
Upper limb strength, 0 to 5 
3
 4.8 4.5 5  4.7 
Lower limb strength, 0 to 5 
3
 4 4.3 4.4  3.8 
Lower limb spasticity 
(Ashword Modified Scale, 0 
to 4) 
4
 
2.2 2.4 1.9  2.2 
 
1
 Severity scale: 0 = normal; 1 = no functional handicap but signs at examination; 2 = mild, able to run, walking 
unlimited; 3 = moderate, unable to run, limited walking without aid; 4 = severe, walking with one stick; 5 = walking with 
two sticks; 6 = unable to walk, requiring wheelchair; 7 = confined to bed. 
 
2
 Annual rate of progression was calculated dividing a percent scale of the severity score by disease duration, and was 
expressed as a percentage per year. 
 
3
 Muscle strength: 0 = no contraction, 1 = contraction no movement, 2 = movement but unable to overcome the gravity 
force, 3 = movement possible against gravity force but not against resistance; 4 = moderate weakness, possibly against 
some resistance, 5 = normal strength. 
 
4
 Modified Ashword Scale: 0 = no increase in tone; 1= slight increase in muscle tone, manifested by a catch and release 
or minimal resistance at the end of the range of movement (ROM) when the affected parts are moved in flexion or 
extension; 1
+
 = slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the 
remainder (less than half) of the ROM; 2 = more marked increase in muscle tone through most of the ROM, but affected 
parts easily moved; 3 = considerable increase in muscle tone, passive movement difficult; 4 = affected parts rigid in 
flexion or extension. 
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Table 2. Mutations found in AD-HSP patients  
 
SPG4 Family 
code   
Age-at-
onset 
(average) 
Progression 
rate 
(average) 
Location 
Exon/ 
Intron 
AAA 
cassette 
Nucleotide 
change 
Predict protein 
change 
Mutation type and 
Reference 
S1  36.5 15.74 E15 yes c.1634_16
55del 
p.Ser545TrpfsX13 Frameshift
3
 
S3 43.5 20 E5 no c.748A>T p.Lys250X Nonsense
3
 
S4 46.5 50 E15 yes c.1667C>
T 
p.Ala556Val Missense
3
 
S5 54.5 19.81 E10 yes c.1291C>
T 
p.Arg431X Nonsense
3
 
S6 39 12.82 E8 no c.1108G>
A 
p.Gly370Arg Missense
3
 
S7 35 28.33 E8 no c.1108G>
A 
p.Gly370Arg Missense
3
 
S9 56 40 E11 yes c.1413dup p.Val472CysfsX7 Frameshift
46
 
S14 3 17.86 E12 yes c.1417C>
T 
p.Gln473X Nonsense
46
 
S16 20 42.86 E7 no c.1055A>
C 
p.Gln352Pro Missense
46
 
S23 36 15,52 E5 no c.727_727
del 
p.Ser243AlafsX19 Frameshift
3
 
S28  29 20.36 E12 yes c.1466C>
T 
p.Pro489Leu Missense
47
 
S30 25 16.5 E11 yes c.1408G>
T 
p.Asp470Tyr Missense/this study 
S33 37 46.15 E14 yes c.1573C>
T 
p.Gln525X Nonsense
46
 
S34 34.5 38.89 E9 yes c.1223C>
T 
p.Ala408Val Missense/this study 
S36 6 8.06 E2-9;E16-
17 
yes c. 415-
_1245+?d
el–c.1687-
?_1851+?
del 
p.? Large deletion/ 
this study 
S38 46.5 13.66 I6 no c.1004+5
G>C 
? Splicing
46
 
S45 18.5 13.66 E10-12 yes c.1246-
?_1493+?
del 
? Large deletion/ 
this study 
S49 11 9.41 E8 yes c.1139T>
C 
p.Leu380Pro Missense/this study 
S53 30 21.09 E11 yes c.1379del p.Arg460ProfsX2 Frameshift
46
 
S54 6.5 4.59 E8 yes c.1160_11
70del 
p.Gly387AlafsX3 Frameshift
46
 
S60 12 11.76 E11 yes c.1334G>
A 
p. Ser445Asn Missense
48
 
S65 40 37.5 E5 no c.807C>G p. Tyr269X Nonsense
3
 
S67 11 10.2 E11 yes c.1356del p.Glu454SerfsX8 Frameshift
46
 
S69 20 n.a. E8 yes c.1172T>
A 
p.Leu391Gln Missense/this study 
S70 28 n.a. E14 yes c.1555A>
T 
p.Lys519X Nonsense
46
 
S71 n.a. n.a. E8 Yes c.1157A>
G 
p.Asn386Ser Missense
49
 
S80 40 16,22 I10 no c.1321+1
G>T 
? Splicing/this study 
SPG3 S25 2 6.52 E12  c.1504dup p.Glu502GlyfsX21 Frameshift
46
 
S39  9 15.38 E12  c.1483C>
T 
p.Arg495Trp Missense
6
 
S48  2 11.97 E10  c.1006T>
C 
p.Tyr336His Missense
42
 
S50  1 13.33 E10  c.1006T>
C 
p.Tyr336His Missense
42
 
S78  1 6.25 E7  c.715C>T p.Arg239Cys Missense
18
 
SPG31 S43 n.a. n.a. E5  c.337C>T p.Arg113X Nonsense
50
 
Novel variants (not present in dbSNP131, the 1,000 genomes database or in our in-house dataset) pathological 
significance was assessed by web-based programs, such as Polyphen2, Mutation Taster or SIFT. 
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Figure 1. Age-at-onset in patients with SPG3 mutations (n=16), SPG4 (n=97) 
and in patients without identified mutations (n=111) 
Bimodal distribution: the left mode represents SPG3 patients, early onset SPG4 
patients and early onset patients without identified mutations; these last two 
subgroups also had a bimodal distribution. 
 
 
 
 
Figure 2. Correlation between age-at-onset and progression rate in SPG4 
(n=97) patients. 
 
 
99 
 
Funding/Support: This study was supported by research grants POCI/SAU-
ESP/59114/2004 and PIC/IC/83232/2007, FCT (Fundação para a Ciência e 
Tecnologia), co-funded by FEDER (Fundo Europeu de Desenvolvimento 
Regional) and COMPETE (Programa Operacional Factores de 
Competitividade) and by Financiamento Plurianual de Unidades de 
Investigação (FCT). IA is funded by Programa Ciência, POPH – QREN - 
Tipologia 4.2 - Promoção do Emprego Científico, co-funded by ESF and 
national funds by the MCTES (Ministério da Ciência e Ensino Superior).  
Acknowledgments: We would like to thank all patients and their families who 
accepted to participate in this study. We also thank to all the colleages that 
contributed for this study, Carolina Silva, José Barros, Assunção Tuna, Paula 
Ribeiro, Clara Barbot, João Guimarães, Cristina Alves, Esmeralda Lourenço, 
Rui Chorão, Christel Depienne, Sylvie Forlani, Eduardo Cruz, Carlos Pinheiro, 
José Neves, Pedro Serrano, Mário Rui Silva, Ana Morgadinho, Cláudia Guarda, 
Assunção V Pato, Augusto Ferreira, Cristina Correia.  
 
100 
 
REFERENCES 
 
1. Hazan J, Fontaine B, Bruyn RP, et al. Linkage of a new locus for 
autosomal dominant familial spastic paraplegia to chromosome 2p. Hum 
Mol Genet. Sep 1994;3(9):1569-1573. 
2.  Reid E, Dearlove AM, Rhodes M, Rubinsztein DC, et al. A new locus for 
autosomal dominant "pure" hereditary spastic paraplegia mapping to 
chromosome 12q13, and evidence for further genetic heterogeneity. Am 
J Hum Genet. 1999;65:757-763. 
3. Fonknechten N, Mavel D, Byrne P, et al. Spectrum of SPG4 mutations in 
autosomal dominant spastic paraplegia. Hum Mol Genet. Mar 1 
2000;9(4):637-644. 
4. Lindsey JC, Lusher ME, McDermott CJ, et al. Mutation analysis of the 
spastin gene (SPG4) in patients with hereditary spastic paraparesis. J 
Med Genet. Oct 2000;37(10):759-765. 
5. Sauter S, Miterski B, Klimpe S, et al. Mutation analysis of the spastin 
gene (SPG4) in patients in Germany with autosomal dominant hereditary 
spastic paraplegia. Hum Mutat. Aug 2002;20(2):127-132. 
6. Durr A, Camuzat A, Colin E, et al. Atlastin1 mutations are frequent in 
young-onset autosomal dominant spastic paraplegia. Arch Neurol. Dec 
2004;61(12):1867-1872. 
7. Depienne C, Fedirko E, Forlani S, et al. Exon deletions of SPG4 are a 
frequent cause of hereditary spastic paraplegia. J Med Genet. Apr 
2007;44(4):281-284. 
8. Namekawa M, Ribai P, Nelson I, et al. SPG3A is the most frequent 
cause of hereditary spastic paraplegia with onset before age 10 years. 
Neurology. Jan 10 2006;66(1):112-114. 
9. Zuchner S, Wang G, Tran-Viet KN, et al. Mutations in the novel 
mitochondrial protein REEP1 cause hereditary spastic paraplegia type 
31. Am J Hum Genet. Aug 2006;79(2):365-369. 
10. Schlang KJ, Arning L, Epplen JT, Stemmler S. Autosomal dominant 
hereditary spastic paraplegia: novel mutations in the REEP1 gene 
(SPG31). BMC Med Genet. 2008;9:71. 
101 
 
11. Beetz C, Schule R, Deconinck T, et al. REEP1 mutation spectrum and 
genotype/phenotype correlation in hereditary spastic paraplegia type 31. 
Brain. Apr 2008;131(Pt 4):1078-1086. 
12. Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM. 
Prevalence of hereditary ataxia and spastic paraplegia in southeast 
Norway: a population-based study. Brain. Jun 2009;132(Pt 6):1577-1588. 
13. Braschinsky M, Luus SM, Gross-Paju K, Haldre S. The prevalence of 
hereditary spastic paraplegia and the occurrence of SPG4 mutations in 
Estonia. Neuroepidemiology. 2009;32(2):89-93. 
14. Alvarez V, Sanchez-Ferrero E, Beetz C, et al. Mutational spectrum of the 
SPG4 (SPAST) and SPG3A (ATL1) genes in Spanish patients with 
hereditary spastic paraplegia. BMC Neurol. 2010;10:89. 
15. Goizet C, Depienne C, Benard G, et al. REEP1 mutations in SPG31: 
frequency, mutational spectrum, and potential association with 
mitochondrial morpho-functional dysfunction. Hum Mutat. Oct 
2011;32(10):1118-1127. 
16. Errico A, Ballabio A, Rugarli EI. Spastin, the protein mutated in 
autosomal dominant hereditary spastic paraplegia, is involved in 
microtubule dynamics. Hum Mol Genet. Jan 15 2002;11(2):153-163. 
17. Hazan J, Lamy C, Melki J, Munnich A, de Recondo J, Weissenbach J. 
Autosomal dominant familial spastic paraplegia is genetically 
heterogeneous and one locus maps to chromosome 14q. Nat Genet. Oct 
1993;5(2):163-167. 
18. Zhao X, Alvarado D, Rainier S, et al. Mutations in a newly identified 
GTPase gene cause autosomal dominant hereditary spastic paraplegia. 
Nat Genet. Nov 2001;29(3):326-331. 
19. Evans K, Keller C, Pavur K, Glasgow K, Conn B, Lauring B. Interaction of 
two hereditary spastic paraplegia gene products, spastin and atlastin, 
suggests a common pathway for axonal maintenance. Proc Natl Acad 
Sci U S A. Jul 11 2006;103(28):10666-10671. 
20. Saito H, Kubota M, Roberts RW, Chi Q, Matsunami H. RTP family 
members induce functional expression of mammalian odorant receptors. 
Cell. Nov 24 2004;119(5):679-691. 
102 
 
21. Silva MC, Coutinho P, Pinheiro CD, Neves JM, Serrano P. Hereditary 
ataxias and spastic paraplegias: methodological aspects of a prevalence 
study in Portugal. J Clin Epidemiol. Dec 1997;50(12):1377-1384. 
22. Harding AE. Classification of the hereditary ataxias and paraplegias. 
Lancet. May 21 1983;1(8334):1151-1155. 
23. Gasser T, Finsterer J, Baets J, et al. EFNS guidelines on the molecular 
diagnosis of ataxias and spastic paraplegias. Eur J Neurol. Feb 
2010;17(2):179-188. 
24. Durr A, Davoine CS, Paternotte C, et al. Phenotype of autosomal 
dominant spastic paraplegia linked to chromosome 2. Brain. Oct 
1996;119 ( Pt 5):1487-1496. 
25. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth 
scale of muscle spasticity. Phys Ther. Feb 1987;67(2):206-207. 
26. Compston A. Aids to the investigation of peripheral nerve injuries. 
Medical Research Council: Nerve Injuries Research Committee. His 
Majesty's Stationery Office: 1942; pp. 48 (iii) and 74 figures and 7 
diagrams; with aids to the examination of the peripheral nervous system. 
By Michael O'Brien for the Guarantors of Brain. Saunders Elsevier: 2010; 
pp. [8] 64 and 94 Figures. Brain. Oct 2010;133(10):2838-2844. 
27. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for 
extracting DNA from human nucleated cells. Nucleic Acids Res. Feb 11 
1988;16(3):1215. 
28. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals 
G. Relative quantification of 40 nucleic acid sequences by multiplex 
ligation-dependent probe amplification. Nucleic Acids Res. Jun 15 
2002;30(12):e57. 
29. Polo JM, Calleja J, Combarros O, Berciano J. Hereditary ataxias and 
paraplegias in Cantabria, Spain. An epidemiological and clinical study. 
Brain. Apr 1991;114 ( Pt 2):855-866. 
30. Brignolio F, Leone M, Tribolo A, Rosso MG, Meineri P, Schiffer D. 
Prevalence of hereditary ataxias and paraplegias in the province of 
Torino, Italy. Ital J Neurol Sci. Aug 1986;7(4):431-435. 
103 
 
31. Sridharan R, Radhakrishnan K, Ashok PP, Mousa ME. Prevalence and 
pattern of spinocerebellar degenerations in northeastern Libya. Brain. 
Dec 1985;108 ( Pt 4):831-843. 
32. Hirayama K, Takayanagi T, Nakamura R, et al. Spinocerebellar 
degenerations in Japan: a nationwide epidemiological and clinical study. 
Acta Neurol Scand Suppl. 1994;153:1-22. 
33. Filla A, De Michele G, Marconi R, et al. Prevalence of hereditary ataxias 
and spastic paraplegias in Molise, a region of Italy. J Neurol. Jul 
1992;239(6):351-353. 
34. Leone M, Bottacchi E, D'Alessandro G, Kustermann S. Hereditary 
ataxias and paraplegias in Valle d'Aosta, Italy: a study of prevalence and 
disability. Acta Neurol Scand. Mar 1995;91(3):183-187. 
35. Mori M, Adachi Y, Kusumi M, Nakashima K. A genetic epidemiological 
study of spinocerebellar ataxias in Tottori prefecture, Japan. 
Neuroepidemiology. May 2001;20(2):144-149. 
36. McMonagle P, Webb S, Hutchinson M. The prevalence of "pure" 
autosomal dominant hereditary spastic paraparesis in the island of 
Ireland. J Neurol Neurosurg Psychiatry. Jan 2002;72(1):43-46. 
37. Brugman F, Veldink JH, Franssen H, et al. Differentiation of hereditary 
spastic paraparesis from primary lateral sclerosis in sporadic adult-onset 
upper motor neuron syndromes. Arch Neurol. Apr 2009;66(4):509-514. 
38. Beetz C, Nygren AO, Schickel J, et al. High frequency of partial SPAST 
deletions in autosomal dominant hereditary spastic paraplegia. 
Neurology. Dec 12 2006;67(11):1926-1930. 
39. Shoukier M, Neesen J, Sauter SM, et al. Expansion of mutation 
spectrum, determination of mutation cluster regions and predictive 
structural classification of SPAST mutations in hereditary spastic 
paraplegia. Eur J Hum Genet. Feb 2009;17(2):187-194. 
40. Svenson IK, Ashley-Koch AE, Gaskell PC, et al. Identification and 
expression analysis of spastin gene mutations in hereditary spastic 
paraplegia. Am J Hum Genet. May 2001;68(5):1077-1085. 
41. Smith BN, Bevan S, Vance C, et al. Four novel SPG3A/atlastin mutations 
identified in autosomal dominant hereditary spastic paraplegia kindreds 
104 
 
with intra-familial variability in age of onset and complex phenotype. Clin 
Genet. May 2009;75(5):485-489. 
42. Ivanova N, Lofgren A, Tournev I, et al. Spastin gene mutations in 
Bulgarian patients with hereditary spastic paraplegia. Clin Genet. Dec 
2006;70(6):490-495. 
43. Hentati A, Deng HX, Zhai H, et al. Novel mutations in spastin gene and 
absence of correlation with age at onset of symptoms. Neurology. Nov 
14 2000;55(9):1388-1390. 
44. Yip AG, Durr A, Marchuk DA, et al. Meta-analysis of age at onset in 
spastin-associated hereditary spastic paraplegia provides no evidence 
for a correlation with mutational class. J Med Genet. Sep 
2003;40(9):e106. 
45. Harding AE. Hereditary "pure" spastic paraplegia: a clinical and genetic 
study of 22 families. J Neurol Neurosurg Psychiatry. Oct 
1981;44(10):871-883. 
46. Loureiro JL, Miller-Fleming L, Thieleke-Matos C, et al. Novel SPG3A and 
SPG4 mutations in dominant spastic paraplegia families. Acta Neurol 
Scand. Feb 2009;119(2):113-118. 
47. Meijer IA, Hand CK, Cossette P, Figlewicz DA, Rouleau GA. Spectrum of 
SPG4 mutations in a large collection of North American families with 
hereditary spastic paraplegia. Arch Neurol. Feb 2002;59(2):281-286. 
48. de Bot ST, van den Elzen RT, Mensenkamp AR, et al. Hereditary spastic 
paraplegia due to SPAST mutations in 151 Dutch patients: new clinical 
aspects and 27 novel mutations. J Neurol Neurosurg Psychiatry. Oct 
2010;81(10):1073-1078. 
49. Orlacchio A, Kawarai T, Totaro A, et al. Hereditary spastic paraplegia: 
clinical genetic study of 15 families. Arch Neurol. Jun 2004;61(6):849-
855. 
50. Hewamadduma C, McDermott C, Kirby J, et al. New pedigrees and novel 
mutation expand the phenotype of REEP1-associated hereditary spastic 
paraplegia (HSP). Neurogenetics. Apr 2009;10(2):105-110. 
105 
 
 
 
 
 
Article 3. 
 
 
Novel SPG3A and SPG4 mutations in dominant spastic paraplegia families 
Loureiro JL, Miller-Fleming L, Thieleke-Matos C, Magalhães P, Cruz VT, Coutinho P, 
Sequeiros J, Silveira I 
Acta Neurol Scand 2009; 119: 113-118  
 
 
 
 
 
 
  
107 
 
 
 
 
108 
 
 
 
 
109 
 
 
 
 
110 
 
 
 
 
111 
 
 
 
 
112 
 
 
 
 
113 
 
3. Autosomal recessive hereditary spastic paraplegia 
 
The course of the study, as well as the results obtained on the AR-HSP, were different 
from those on the AD-HSP. After a review of clinical data from all families ascertained 
during the survey, these were divided according to phenotypic groups.  
 
One group of families with the thin corpus callosum syndrome, was selected due to 
their particular characteristics. This was the only group that was systematically studied 
(Articles 4 and 5).  
 
There were still 73% of the families without molecular diagnosis, whose general 
characteristics are summarized and commented on Chapter IV, and provide matter for 
further studies. 
 
As in the autosomal dominant families, the recessive ones were also studied according 
to homogeneous criteria, and by the same team of neurologists. Differences in clinical 
perspective will certainly have been small. 
 
In the families with the thin corpus callosum syndrome, 87% of the patients were 
personally observed at least twice (from a minimum of 3 to a maximum of 20 years of 
follow-up). This group was characterized in detail, both clinically and imagiologically. 
Their phenotype was already well-known and our study did not bring any essential 
novelty in that regard; however, we drew several conclusions, among which we 
highlight two: first, the process of neurono-axonal degeneration ends up covering a 
greater extension of brain areas than previously thought, both in the cerebral cortex, 
and the white matter; secondly, a rigorous definition of the phenotype was an important 
guide for the molecular genetics studies (Article 4).  
 
In addition, during the work that ked to this dissertation, some Portuguese families 
contributed to the discovery of two novel genes (SPG11 and SPG15) and one new 
locus (SPG32, gene still unknown). 
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The syndrome of hereditary spastic paraplegia with 
corpus callosum atrophy 
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ABSTRACT 
Background 
Autosomal recessive hereditary spastic paraplegia (AR-HSP) with thin corpus 
callosum (AR-HSP-TCC) in addition to TCC, and besides spastic paraplegia, 
includes: mental deterioration, spinal neuronopathy, peripheral neuropathy, and 
other less frequent features. TCC families are a heterogeneous clinical and 
genetic group, whose most frequent causal genes are SPG11 and SPG15, 
present in variable percentages. 
Objective 
To describe the clinical and genetic characteristics of TCC families identified 
through a Portuguese population-based survey on hereditary ataxias and 
spastic paraplegia. 
Methods 
Review all the AR-HSP families searching for TCC phenotype and mutations 
screening of SPG11, SPG15 and SPG21 genes. 
Results 
We identified 31 families with a complete or almost complete TCC syndrome 
(52 patients). The patients with a complete TCC syndrome (86% of TCC 
families) all had mutations in SPG11 or in SPG15 genes. The patients that have 
an almost complete TCC syndrome (14% of TCC families) are clinically and 
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genetically more heterogeneous, and do not have mutations in SPG11 or in 
SPG15 genes. 
Conclusions 
 
The TCC phenotype represents: 30% of all AR-HSP families. The SPG11 is 
present in 17.4% of AR-HSP, and the SPG15 in 3.8%. One SPG11 mutation is 
novel. No SPG21 mutations were found. 
There is not an initial mental retardation, but a mental deterioration starting 
early, and this is the mode of the disease onset.  The thin corpus callosum is 
not hypoplasic but progressively atrophic. 
The patients with a complete TCC syndrome all had mutations in SPG11 or in 
SPG15 genes. The TCC syndrome associated with SPG11 and SPG15 patients 
seem to be a relatively well defined entity. The patients that have an almost 
complete TCC syndrome are clinically and genetically more heterogeneous, 
and do not have mutations in SPG11 or in SPG15 genes. 
 
Corresponding author : 
José Leal de Loureiro 
Serviço de Neurologia, Centro Hospitalar entre Douro e Vouga. 
Rua Dr. Cândido de Pinho 4520-211 Santa Maria da Feira. 
Tel. +351 256 379 700, Fax. +315 256 37 3867. 
leal.loureiro@chedv.min-saude.pt 
 
Running title: Hereditary spastic paraplegia with corpus callosum atrophy 
 
Keywords: recessive spastic paraplegia; thin corpus callosum; TCC, early 
cognitive decline; frontal cognitive deterioration, 
 
Abbreviations: ALS: amyotrophic lateral sclerosis; CC: corpus callosum; EMG: 
electromyography; FTD: front-temporal dementias; FDG-PET: (FDG) [18F]-2-
fluoro-2-deoxy-D-glucose - (PET) positron emission tomography; HSP: 
hereditary spastic paraplegia; MRI: magnetic resonance image; WAIS: 
Wechsler adult intelligence scale; WM: white matter; IQ: intelligence coefficient; 
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SPATAX: European and Mediterranean spastic paraplegia and ataxia network; 
SPG: spastic paraplegia gene; TCC: thin corpus callosum. 
 
INTRODUCTION 
Autosomal recessive hereditary spastic paraplegia (AR-HSP) with thin corpus 
callosum (TCC) is one of the most common forms of recessive spastic 
paraplegia. In addition to TCC, besides spastic paraplegia, includes: mental 
deterioration, spinal neuronopathy, peripheral neuropathy, and other less 
frequent features. TCC families are a heterogeneous clinical and genetic group, 
whose most frequent causal genes are SPG11 and SPG15, representing 
variable percentages of these families 1-3  
 
OBJECTIVE 
To describe the clinical and genetic characteristics of 31 Portuguese TCC 
families identified through a Portuguese population-based survey on hereditary 
ataxias and spastic paraplegia. 
 
MATERIAL AND METHODS 
 
Patients’ ascertainment  
From 1994 to 2004, a population-based survey on hereditary ataxias and 
spastic paraplegias was conducted in Portugal. Its methodology was discussed 
elsewhere4. Looking for the clinical and imagiological criteria for the diagnosis of 
AR-HSP-TCC we assessed all the families with AR-HSP, and recessive spastic 
ataxias, ascertained during that survey, as well as some identified after.  
 
Clinical screening criteria 
Data of all families with complex AR-HSP were reviewed, independently of age 
at onset, and the following symptoms or signs were assessed: TCC, cognitive 
impairment, muscle atrophy suggestive of anterior medullar horns lesion 
(neuronopathy), peripheral neuropathy, ataxia, extrapiramidal signs (tremor, 
akinesia or distonia) or suspicion of any of these signs in siblings. Some details, 
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such as epilepsy, ocular signs (cataracts, retinopathy or optic atrophy) and skin 
alterations were also very briefly reviewed in all recessive families with or 
without the features above mentioned. 
 
Clinical inclusion criteria 
After the first screen, we include in this study families with: (1) at least one 
patient by family with image of thin CC whatever the clinical symptoms or signs, 
and (2) not yet available cerebral MRI, in the presence of any type and any 
grade of mental impairment, with particular focus on cognitive and behavior 
deterioration, or limb muscle atrophies or peripheral neuropathy. 
 
Clinical studies 
Patients examination was done by neurologists, mostly by the same team and 
blood samples were collected after written consent. Telephone interviews to 
families and physicians were recently performed to know how many patients 
were currently alive and where they lived. 
Mental retardation was graded from 0 to 3 (0 = absent; 1 = mild, literate; 2 = 
moderate, literacy inability; 3 = severe, rudimentary speech or no language). 
Although carefully performed, in many patients this was done retrospective. The 
correspondence of WAIS III scores with the simplified scale were: grade 1 = 
border-line or slight debility (IQ 50-79); grade 2 = moderate debility (IQ 35-49); 
grade 3 = severe debility (IQ<35). Whenever possible patients were evaluated 
in more detail (52%). 
Mental deterioration was graded from 0 to 3 (0 = absent; 1 = slight, reasonable 
activities of daily life (ADL), behaviour changed; 2 = moderate, compromised 
ADL, apathetic or hardly supportable behaviour; 3 = severe, total dependence, 
mutism, lodging). 
Disartria was graded from 0 to 4 (0 = absent; 1 =slight, causing doubt if it exists; 
2 = moderate, perceptible speech; 3 = severe, almost imperceptible speech; 4 = 
anarthria). Disphagia was graded from 0 to 4 (0 = absent; 1 = slight, occasional 
for liquids; 2 = moderate, frequent for liquids; 3 = frequent for liquids and solids; 
4 = nasogastric tube or PEG).  
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The motor severity of disease was classified according to the SPATAX disability 
scale from 0 to 7 (0 = normal; 1 = no functional handicap but signs at 
examination; 2 = mild, able to run, walking unlimited; 3 = moderate, unable to 
run, limited walking without aid; 4 = severe, walking with one stick; 5 = walking 
with two sticks; 6 = unable to walk, requiring wheelchair; 7 = confined to bed) 5. 
Muscle strength was graded from 0 to 5, using the Medical Research Council 
Scale for Muscle Strength (ref)  (0 = no contraction, 1 = contraction no 
movement, 2 = movement but unable to overcome the gravity force, 3 = 
movement possible against gravity force but not against resistance; 4 = 
moderate weakness, possibly against some resistance, 5 = normal strength) 6. 
Spasticity was quantified from 0 to 4, according to the Modified Ashword Scale 
(ref) (0 = no increase in tone; 1= slight increase in muscle tone, manifested by a 
catch and release or minimal resistance at the end of the range of movement 
(ROM) when the affected parts are moved in flexion or extension; 1+ = slight 
increase in muscle tone, manifested by a catch, followed by minimal resistance 
throughout the remainder (less than half) of the ROM; 2 = more marked 
increase in muscle tone through most of the ROM, but affected parts easily 
moved; 3 = considerable increase in muscle tone, passive movement difficult; 4 
= affected parts rigid in flexion or extension) 7. 
Tendinous reflexes were graded from 0 to 3 (0 = abolish; 1 = decreased; 2 = 
normal; 3 = brisk; 4 = very brisk, polikinetic). 
Muscle atrophies, not caused by disuse, was assessed on a scale from 0 to 3 
(0= absent; 1 = mild; 2 = moderate, and 3 = severe). 
Sphincters function was graded from 0 to 3 (0 = no symptoms, occasional 
urinary tract infections; 1 = difficulty in beginning urination; 2 = incontinence by 
over-flow; 3 = indwelling catheters). 
Diseases mimicking HSP were excluded by radiological and biochemical 
investigations at least in one patient in each family (in 87% of families cerebral 
MRI was performed  in all affected siblings). We accessed data of 94% to 100% 
of patients. The exceptions are indicated in the respective sections. Families 
were designated by the initials SR followed by a number.  
 
Mutation screening 
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Genomic DNA was extracted from blood, according to standard procedures. 
Mutation detection was performed by direct sequencing of SPG11, SPG15 and 
SPG21 coding sequences and exon-intron boundaries. Each fragment was 
amplified by PCR with HotStarTaq Master Mix (Qiagen, Hilden, Germany), 
directly sequenced with the Big Dye Terminator Kit v1.1 (Applied Biosystems, 
Carlsbad, CA, USA) and loaded on an ABI 3130xl Genetic Analyzer (Applied 
Biosystems, Carlsbad, CA, USA).  In patients in whom only one or no mutation 
in SPG11was found, we performed Multiplex Ligation-dependent Probe 
Amplification to detect large deletions or duplications8. 
 
Statistical analysis  
Univariate analysis of variance (One-way ANOVA) was used to assess the 
effect of different clinical parameters namely motor severity of the disease, the 
degree of cognitive delay and cognitive deterioration on the onset of motor 
symptoms, the spastic paraplegia duration, and patients' age at the last clinical 
observation. The significance level used for statistical analysis was P≤0.05. The 
analysis was performed using the PASW Statistics 18 software (for Windows). 
 
RESULTS 
Families reviewed and excluded 
We reviewed the clinical features of 209 patients, belonging to 123 families: 103 
with autosomal recessive spastic paraplegia (175 patients), and also 20 families 
(34 patients) with recessive spastic ataxias, due to the frequent report of ataxia 
on TCC syndrome. 
 
Families selected 
We selected 31 with a complete or almost complete TCC syndrome (52 
patients) that were studied for mutations on SPG11, SPG15 and SPG21.The 
mutation screening was also done in more 7 families (14 patients) that had 
some, but very uncompleted,  clinical elements of the TCC syndrome. 
 
Frequency of TCC syndrome among AR-HSP families 
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TCC phenotype represents: 30% of AR-HSP families; 41% of AR-HSP complex 
forms; 56% of complex forms with cognitive impairment, and virtually 80 to 
100% of the families in which this impairment included a progressive mental 
deterioration. 
The gender distribution was similar (52% female, 48% male), and 55% of 
families were consanguineous. The age at last observation was on average 34 
years (SD 8.17; range 51-14). Since 1994, when the survey started, 30% of 
patients died on average at 40 years of age (SD 8.76; range 54 -24). 
 
Geographic distribution 
The 31 families were distributed by 12 of the 20 Portuguese districts in a rather 
asymmetric manner, 84% originated from six districts of the north of the country.  
                           
Figure 1: Geographic distribution of families (legend: SPG11 ●, SPG15 ○, 
others □) 
 
The gender distribution was similar (52% female, 48% male), and 55% of 
families were consanguineous. The age at the time of the last observation was 
on average 34 years (SD 8.17; range 51-14). Since 1994, when the survey 
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started, 30% of patients died on average at 40 years of age (SD 8.76; range 54 
-24). 
 
Mode and age of onset  
The spontaneous description of parents tends to define the first symptoms of 
disease as coincident with the beginning of gait difficulty, that is, with arrival of 
puberty. However, after a detailed anamnesis, in almost all patients the disease 
is manifested by a slight retardation in mental development detected in 82% of 
patients, on average at 3 years of age. In four of these families there was even 
a congenital global psychomotor delay, severe in two of them (SR9, SR45) and 
mild in the other two (SR49, SR100), but in general a delay of language, a lower 
vivacity or a more childish behavior attracted the attention of relatives and 
patients’ teachers. In some patients (18%) this delay, difficult to detect, only 
became clear at school age (6-7 years) due to learning difficulties. In the clinical 
history of diverse patients, slow learning at school early marks, not the 
expression of a previous mental retardation, but the initial stage of a continuous 
mental deterioration. 
 
Age of onset of gait difficulties 
The onset was on average at 12 years of age (SD 6.82; maximum: 30, 
minimum: first months of life). The average duration of gait difficulty was 21 
years (SD 9.99; range 42-2). 
Motor difficulties began by spastic walking (spastic and paretic later) in all 
patients, except one who also had concomitant ataxia (SR102). 
 
Severity of motor difficulties  
The majority of patients had severe motor difficulty, the SPATAX  Disability 
Scale (0-7) was on average 5.5 (grade 1: 2%; grade 2: 2%; grade 3: 12%; 
grade 4: 4%; grade 5: 12%; grade 6: 41%, and grade 7: 27%). The disability 
score was associated with the patient’s age (p<0.001), and also with the 
duration of motor difficulties (p=0.002). The severity had no significant 
association with the age of onset of motor difficulties. 
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Graphic1. Distribution of severity of motor difficulties (from 0 to 7) 
 
Mental development delay 
Patients had a mild to moderate mental delay that on a scale of 0 to 3 was 1.5 
on average (grade 0: 0%; grade 1: 67%; grade 2: 16%, and grade 3: 16%). 
The grade of mental delay attributed was not correlated with the age of onset of 
motor difficulties, although grade 2 of mental debility was associated with a 
greater duration of motor difficulties and then grade 1 (p=0.03) which means 
that there is a “delay” in progress.  
 
 
Graphic 2. Distribution of the grade of mental debility (from 0 to 3) 
 
Cognitive and behavioral deterioration 
Although patients may reach a severe stage, the deterioration was usually 
moderate, on a scale of 0 to 3 the average was 1.6 (grade 0: 16%; grade 1: 
28.5%; grade 2: 27%, and grade 3: 14%). 
Cognitive deterioration was not associated with the age of onset of motor 
difficulties; it was associated with the duration of motor difficulties (p=0.003 
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between grades 0 and 3; p=0.01 between grades 1 and 3), and also with the 
age of patients (p=0.02 between grades 0 and 3; p=0.02 between grades 1 and 
3).  
 
 
Graphic 3. Distribution of cognitive deterioration (from 0 to 3) 
 
Neuropsychological profile 
The apparent delay, in reality the early stage of a mental deterioration, had a 
frontal profile. Patients had deficits in attention and in executive functions. They 
frequently had an impulsive, uninhibited and childish behaviour. 
Except in two TCC families with two different severe congenital 
encephalopathies (SR9, SR45), the patients with more severe cognitive 
impairment were over 20 years of age, and in addition to attention and 
executive dysfunction, they also had relevant memory and language defects. 
Some (12%) also had praxis defects. 
The more severe affected patients were mentally slow, had a facial bradykinetic 
and verbal expression. In their slowness, they show that they understand more 
than what they express. 
In short, the early mental difficulties are progressive and have frontal features. 
With time this frontal profile increases and then it becomes more evident that a 
mental deterioration is underway. The eldest patients evolve to a front-temporal 
or to a o fronto-temporo-parietal neuropsychological profile. 
 
Cranial nerves 
A brisk jaw reflex was present in 35% of patients. A spastic disartria existed in 
most patients, and in all the more advanced cases, with an average degree of 
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1.4 (grade 0: 17%; grade 1: 38%; grade 2: 19%; grade 3: 15% and grade 4: 11 
%). Dysphagia existed in fewer patients, and on average was 0.5 degree (grade 
0: 73%; grade 1: 16%; grade 2: 5%; grade 3: 3% and grade 4: 3%). 
 
Upper limbs 
Upper limb weakness was present in 80% of patients, mostly of grade 4, except 
in bedridden patients that had an extreme weakness. With the exception of two 
patients, already confined to a wheelchair, patients whose upper limbs strength 
was still normal, all had a less severe disease, whether in respect to 
paraparesia or to cognitive impairment; they had a slightly shorter duration of 
the disease and also an age somewhat inferior to the average. Generalized 
upper limbs hiperreflexia was present in 63% of patients; 21% had proximal 
hiperrreflexia and distal hyporeflexia, and 16% were arreflexic. 
 
Lower limbs 
All patients had marked weakness, with an average grade of 2.6, and high 
spasticity, on average 3.6, with proximal predominance. Patients with degrees 6 
or 7 of motor severity (SPATAX disability scale, 0 to 7) and more than 25 years 
of age, tended to lose spasticity by overlapping of the hypotonia inherent to a 
progressive motor neuronopathy. 
 
Amyotrophies 
Muscle atrophies were present in 82% of patients, always more distal than 
proximal (10% only in the upper limbs; 10% only in the lower, and 62% in both). 
Globally, comparing the upper with the lower limbs (using a 0 to 3 grade scale) 
the severity of atrophy was similar (upper limbs: average 1:47; lower limbs: 
1.41). The age of onset of this neuronopathy was not possible to determine 
accurately. Fasciculations were present in two patients. 
 
Sensory changes 
The ankle vibration sense was decreased or absent in 24% of patients, normal 
in 30%. Postural sense was normal in 52%, abolished in 6%, and not 
assessable in 42% of patients.  
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Sphincter alterations 
Suggestive symptoms of a spastic bladder, generally moderate, appeared in 
52% of patients, 23% had no change, and in 25% we could not obtain reliable 
data. 
 
Magnetic resonance image (MRI) 
With the exception of three families, MRI was performed on the remaining 
patients with an average age of 29 (range 15-49). In five families (6 patients) it 
was possible to compare images taken at different ages, with intervals of 3 to 
10 years. 
MRI brain scans of 31 families (34 patients) demonstrated thinning of the 
corpus callosum. 
 
Figure 2. Left: normal CC. Middle: anterior predominance of CC atrophy: Right: 
CC atrophy in a more affected patient 
 
a) In 24 families there was the same pattern at the time of the first MRI, which 
had a similar evolution. This pattern was characterized in the following way: (1) 
a thin CC through all its extension; (2) a reduction of thickness predominantly in 
the anterior portion: rostrum, knee and anterior half of the body, and this 
anterior predominance was more marked in younger patients; (3) with aging the 
CC was reduced to a thin blade. 
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Figure 3. Family SR24, the same patient at 18, 21 and 27 years of age 
 
b)  As early as callosal atrophy it was possible to demonstrate, at least from the 
age 15, hyperintensities in the white matter (WM), predominantly in the anterior 
and periventricular regions and, with the course of time, extending diffusely to 
the brain periphery, sparing the regions just below the cortex, and the U fibers. 
 
 
Figure 4. Patient of family SR51, with 23 years of age 
 
c) At least from 20 years of age, there were progressive signals of brain volume 
loss with cortical predominance; this atrophy apparently occurring later than that 
of CC, had from the beginning a slight anterior predominance, and tends to 
affect the whole brain. After the second decade (before or around 30 years of 
age) the cerebral atrophy had a much clearer bilateral frontotemporal 
predominance. On the RMI of the older patient (49 years) this atrophy also 
included the meso-temporal structures, together with very extensive WM 
hyperintensities. 
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Figure 5. Patient of family SR8 with 49 years of age 
 
All this description corresponded to the majority (24/28 families) and to the 
standard MR image within the clinical TCC syndrome. In 4/28 families, different 
patterns were found, as described below. 
 
Clinical and imaging correlations 
 
1. Patients from the 24 families, who showed the pattern described above, 
clinically had: an early onset progressive cognitive impairment developing into a 
frontotemporal cognitive deterioration, a spastic paraplegia starting at early 
adolescence, and later more or less generalized amyotrophies. 
This is what we think the complete (clinical and imagiological) TCC syndrome 
is. In other words, the core of the syndrome of hereditary spastic paraplegia 
with corpus callosum atrophy. 
In five of these patients a cerebral FGD-PET was performed (at average age of 
32 years). There was a reduction of glucose metabolism in the thalamus and 
cerebral cortex. In the cortex there were variations, with reduction in frontal 
regions, including the anterior cingulus, a constant reduction in the temporal 
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lobes, particularly the left, including the insular cortex, and the parietal cortex in 
one patient. 
 
2. The patient of one family (SR49, 47 years of age) came out of that standard 
imaging majority because the CC was only slightly and homogeneously thin, 
and for the patient’s age (29 years old at time of MRI) it should be very thin. 
Clinically, there were no signs of neuronopathy. So, he neither had a standard 
image, nor a complete clinical TCC syndrome, although all the other clinical 
elements he had were highly suggestive. 
 
3. Another family (SR45, 5 brothers, RM at the age of 41, available in one 
patient) the CC was less thin than expected, the atrophy predominate in the 
posterior half of the CC body, including the splenium, showed  a diffuse 
reduction in the brain volume without WM changes. This patient, similarly to her 
brothers, had a moderate microcephaly. Compared with the brain volume in a 
visual exam (without volumetric quantification) the mid-sagittal CC area was 
found to be less reduced than in the majority of patients.  
This patient had a clinical TCC syndrome and her four siblings, had a congenital 
encephalopathy with a marked psychomotor retardation, evidence of early 
mental deterioration, evolving to a long standing tetraplegic stage, with huge 
muscular atrophies in the four limbs. In this family the clinical heterogeneity, 
deviating from the standard clinical syndrome, was also associated with a 
nonstandard image. 
   
Figure 6. Patient of family SR45 with 41 years of age 
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4. In another family (SR2, two patients, MRI at the ages 33 and 41) the CC was 
irregular in thickness and thin across all its length, a little more in the posterior 
half. There was also: a very mild cerebral cortical atrophy, slight cerebellar 
atrophy predominantly in the vermis; discreet peri-ventricular WM 
hyperintensity, and a bulbo-protuberance hypoplasia, with a ventral notch. 
Clinically, they had: a slight mental retardation (IQ 58 and 54), a less 
progressive spastic paraplegia (gait possible with bilateral aid); a dubious 
cognitive deterioration in the younger patient but obvious in the older patient 
and absence of clinical or electromyography lesion of the anterior horns spinal 
cord cells (neuronopathy). In this family, a different MRI image also 
corresponded to a slight different clinical pattern. 
 
   
Figure 7. Patient of family SR2 with 33 years of age 
 
5. Finally, in another family (SR59, one patient, MRI at the ages of 18 and 28) 
the CC thickness was only slightly reduced, and there was only a slight cortical 
atrophy, without WM changes, and without any modification in ten years. 
This pattern also differs from that of the majority, and also corresponded to a 
somewhat different clinical pattern: the patient was 30 years old, had a mild 
cognitive delay (IQ = 65); a mild frontal deterioration (only with attention and 
executive defects); a much less progressive spastic paraplegia (walking still 
possible unaided); an axial and gait ataxia, slightly more progressive than the 
spastic paraplegia; a marked cervical dystonia, and absence of clinical and 
electromyography signs of peripheral neuropathy or neuronopathy. The patient 
also had cataracts. 
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Cerebral FDG-PET shows a slight reduction of uptake in the frontal poles, 
hypothalamus and brainstem. 
 
    
 Figure 8. Left: SR59 family, patient with 28 years of age. Right: normal control 
 
Electromyography (EMG) 
Electromyography and neurographic data were available only in 45% of the 
patients. Two patients had normal EMG, two were 18-20 years old, and one 30 
(SR59). The others showed signs of neurogenic atrophy, without significant 
decrease in conduction velocities. EMG was mostly suggestive of anterior horns 
spinal cells lesion, and sometimes suggestive of a motor axonal neuropathy. 
Only in two patients a decrease in sensory conduction velocities, suggestive of 
an axonal sensory-motor polyneuropathy, was recorded. In one patient, in a 
neuro-muscular biopsy, besides neurogenic atrophy, signs of axonal 
degeneration and segmental demyelization were found. 
 
Genetic study 
1. In the 31 families with TCC syndrome, 26 (84%) had molecular diagnosis: 20 
had the SPG11 gene, 4 SPG15 mutations. One family (SR59) was linked to 
SPG46 locus (Stevenin G, submitted), and another (SR2) was previously linked 
to SPG32 9. No SPG21 mutation was found. 
2. The five TCC families without molecular diagnosis were: two already 
described (SR45, SR49); three with missing data [unavailable DNA and IRM in 
one family (SR18), unavailable DNA in other with thin CC (SR83), and in the 
last (SR9) RMI was unavailable and a linkage to two loci on chromosomes 2 
and 4 was found, still under investigation]. 
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3. Besides the 31 families, genetic study was also carried out in 7 more families 
with much uncompleted clinical elements of the TCC syndrome, and no 
mutations were found. 
The molecular analysis of this cohort allowed the identification of 20 families 
with SPG11 mutations (Table 1). Our results show that two mutations are found 
in ~50% of the alleles (c.529_533del and c.733_734del). Additionally, large 
gene rearrangements account for 18% of the mutated alleles, which reinforces 
the need for gene dosage analysis in SPG11 diagnosis. In fact, large gene 
rearrangements probably account for a higher percentage of SPG11 alleles 
than previously thought. Together with the two most common mutations they 
represent 65% of the alleles in our population. 
More interesting conclusions can be reached from a worldwide perspective. 
From a total of 119 different mutations and 294 SPG11 alleles we can find only 
3 mutations accounting for 22% of all alleles (c.529_533del – 5%, c.733_734del 
– 10% and c.6100C>T – 7%). While two of these mutations strongly support a 
founder effect in the Portuguese (c.529_533del) and North African border 
(c.6100C>T) populations10, the c.733_734del is found in families from 3 
different continents, with very distinct ancestries, which is much more 
compatible with a mutational hotspot.  
Similarly to previous reports, SPG15 is much less frequent than SPG11, as only 
four families and two mutations have been identified (c.6296dup and 
c.4914_4917del). Of interest, three of the families carried the same mutation 
(c.6296dup), until now exclusively found in the Portuguese population, probably 
due to a founder effect.          
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Table 1. Genetic study of  31 families with TCC syndrome 
 
 
Family 
code 
Consanguinity 
Number of 
patients 
Geographi
cal origin 
Location 
Exon/ 
Intron 
Nucleotide change Predicted protein change 
Mutation 
type and 
Reference 
SPG11 
33 patients 
 
SR8 yes 4 Vila Real E3 [c.529_533del]+ [c.529_533del] [p.I177SfsX2]+ [p.I177SfsX2] 
Stevanin 
2007 
SR10 yes 2 Vila Real E6 [c.1235C>G]+ [c.1235C>G] [p.S412X]+ [p.S412X] 
Stevanin 
2008 
SR11 yes 3 Vila Real E3 [c.529_533del]+ [c.529_533del] [p.I177SfsX2]+ [p.I177SfsX2] 
Stevanin 
2007 
SR24 no 2 Porto I13/E29 [c.2444+1G>C]+[c.4907-?_5121+?del] [p.?]+[p.?] This study 
SR25 yes 1 Bragança E3 [c.529_533del]+ [c.529_533del] [p.I177SfsX2]+ [p.I177SfsX2] Pereira 2012 
SR43 yes 2 Aveiro E37 [c.6832_6833del]+ [c.6832_6833del] 
[p.S2278LfsX61]+ 
[p.S2278LfsX61] 
Stevanin 
2008 
SR51 yes 1 Vila Real E3 [c.529_533del]+[c.733_734del] [p.I177SfsX2]+[p.M245VfsX2] Pereira 2012 
SR57 no 1 Aveiro E29 
[c.4907-524_5121-317del]+ [c.4907-524_5121-
317del] 
[p.G1636DfsX11]+ 
[p.G1636DfsX11] 
Pereira 2012 
SR64 yes 2 Coimbra E4/E33 [c.733_734del]+ [c.6206-160_6344-833del] [p.M245VfsX2]+[p.?] Pereira 2012 
SR74 no 1 Aveiro E3/E34 [c.592C>T]+[ c.6477+4A>G] [p.Q198X]+[p.?] This study 
SR77 no 2 Lisboa E4 [c.733_734del]+ [c.733_734del] [p.M245VfsX2]+ [p.M245VfsX2] Pereira 2012 
SR85 yes 1 Vila Real E4/E29 [c.733_734del]+[c.5075del] [p.M245VfsX2]+[p.V1692EfsX4] This study 
SR78 no 2 Lisboa E22 [c.3809T>A]+ [c.3809T>A] [p.V1270D]+ [p.V1270D] Pereira 2012 
SR90 yes 1 Beja E3 [c.529_533del]+ [c.529_533del] [p.I177SfsX2]+ [p.I177SfsX2] Pereira 2012 
SR94 yes 1 Lisboa E3 [c.529_533del]+ [c.529_533del] [p.I177SfsX2]+ [p.I177SfsX2] 
Stevanin 
2008 
SR95 yes 1 Leiria E6/I34 [c.1282A>T]+[c.6477+4A>G] [p.K428X]+[p.?] 
Stevanin 
2008 
SR96 no 3 Setúbal E3 [c.529_533del]+ [c.529_533del] [p.I177SfsX2]+ [p.I177SfsX2] Pereira 2012 
SR101 yes 1 Leiria E31 [c.5989_5992del]+ [c.5989_5992del] 
[p.L1997MfsX60]+ 
[p.L1997MfsX60] 
Pereira 2012 
SR102 no 1 Lisboa 
E31-
E34/E37 
[c.5867-3237_6478-450del]+[c.6832_6833del] [p.T1956SfsX17]+p.S2278LfsX61] Pereira 2012 
SR103 yes 1 Vila Real E29 
[c.4907-524_5121-317del]+ [c.4907-524_5121-
317del] 
[p.G1636DfsX11]+ 
[p.G1636DfsX11] 
Pereira 2012 
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Table 1. Genetic study of  31 families with TCC syndrome (cont.) 
 
 
Family 
code 
Consanguinity 
Number of 
patients 
Geographi
cal origin 
Location 
Exon/ 
Intron 
Nucleotide change Predicted protein change 
Mutation 
type and 
Reference 
SPG15 
6 patients 
SR42 yes 2 Bragança E34 [c.6296dup]+ [c.6296dup] 
[p.N2100EfsX12]+ 
[p.N2100EfsX12] 
Goizet 2009 
SR82 no 1 Viseu E34 [c.6296dup]+ [c.6296dup] 
[p.N2100EfsX12]+ 
[p.N2100EfsX12] 
This study 
SR93 yes 2 Bragança E25 [c.4914_4917del]+ [c.4914_4917del] [p.F1638LfsX4 This study 
SR100  no 1 Setúbal E34 [c.6296dup]+ [c.6296dup] 
[p.N2100EfsX12]+ 
[p.N2100EfsX12] 
This study 
SPG32 SR2 yes 3 Viseu    
Stevanin 
2007 
SPG46 SR59 yes 1 Aveiro    
Stevanin, 
submited 
Note: to simplify as different mutations and different alleles were identified by several authors, we choose to refer who studied the 
families rather than the author of identification of alleles and mutations. 
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Table 2. Genetic frequency in AR-HSP phenotypic groups 
 
Phenotypic groups SPG11 SPG15 
AR-HSP  19.4% 3.9% 
Complex forms (73% of AR-HSP) 26.7% 5.3% 
Cognitive impairment (73% of complex forms) 36.3% 7.3% 
Completed or almost TCC syndrome (31 families) 64.5% 12.9% 
Complete TCC syndrome (24 families) 83.3% 16.6% 
 
Phenotype and genotype correlation 
 
The patients with a complete TCC syndrome (24/28 families) were similar, having 
a complete or standard clinical and imaging pattern, and all had mutations in 
SPG11 or in SPG15. Out of this group no mutation in these genes was found. 
 
In the others patients (4/28 families) having an almost complete TCC syndrome, 
with slight different clinical and imaging patterns (no one being exactly identical to 
the other) no gene was identified in two families (SR49, SR45), one (SR2) was 
linked to the SPG32 locus, and the remainder (SR59) to the SPG46. 
 
    
Figure 9. Cerebral FDG-PET. Left: SPG46 patient (SR59) with 30 years of age: 
slight reduction of uptake in the frontal poles, hypothalamus and brainstem. Right: 
SPG11 patient (SR24) with 35 years of age: widespread and marked reduction in 
the cerebral cortex, and slight thalamic reduction. 
 
 As with other common characteristics, the SPG11 phenotype (one family, SR43) 
included a pigmented maculopathy, a characteristic described in the Kjelling 
syndrome. 
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Although families with SPG11/SPG15 syndrome are quite similar, there was some 
clinical heterogeneity, even within the same mutation, without allelic variation. In 
one family (SR24) with two brothers, 35 and 29 years old, starting their spastic 
paraplegia at the same age (6 years), the older one had tremendous spasticity, 
and  the younger one had generalized amyotrophies similar to an ALS syndrome; 
the older brother had the apathetic variant of his mental deterioration, with marked 
reduction in verbal fluency and vocabulary, and the younger one had a very 
impulsive and uninhibited deterioration. 
In many other families there was also less prominent sibling variation. 
 
    
Figure 10. Family SR24, the older brother (left), and the younger one (right) 
 
COMMENTS 
 
1. In spite of some clinical and genetic diversity, the complete syndrome of CC 
atrophy is exceptionally homogeneous among the usual AR-HSP heterogeneity. 
The few TCC families that come out of this SPG11/SPG15 atrophic CC syndrome 
draw our attention because discrete but significant clinical differences, which can 
easily go unnoticed, allow us some genotypic prediction.  
 
2. Although it was suggested that the anterior part of CC may participate in 
procedural learning 11, it is not possible to simply assign the CC atrophy as the 
cause of the cognitive and behavioral disorders. However, from very early phases 
of the disease, a frontal dysfunction certainly exists, and probably involves the 
prefrontal and the premotor cortex because the atrophic anterior portion of the CC 
contains projections of these regions. We verified that, with time, progressing form 
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front to back, the marker of the disease (the atrophic CC) gradually indicates the 
extent of disease to larger and more posterior brain areas. In reality, the disease 
progressively involves multiple nervous structures: of the brain (talamus, frontal 
cortex, including the anterior cingulus, temporal cortex, including the insular 
cortex, even the parietal cortex, and the white matter); of the spinal cord 
(corticospinal tracts, second motor neuron, and posterior columns), and of the 
peripheral nerve, although this rather less. 
 
3. Being SPG11 and SPG15 patients clinically indistinguishable. This raises the 
hypothesis of a similar or complementary pathogenic mechanism, and it has 
already been shown, using zebrafish orthologues of the SPG11 and SPG15, that 
they probably act in a common pathway 12.  
 
4. The syndrome of hereditary spastic paraplegia with CC atrophy, linked to 
SPG11 and SPG15, seems to be a relatively well-defined entity. 
If carefully observed, almost all forms in which a thin CC was described are 
different. The exceptions may be the SPG21 and SPG46. The SPG21 has some 
affinity but its phenotype has not been updated for a long time 13, 14, and regarding 
the SPG46 phenotype it is necessary to accumulate more experience 15.  The 
SPG1 is different, it is an X-linked CC hipolasia or agenesis 16. From a clinical and 
imaging perspective the SPG20 17, SPG32 9 and SPG47 18 are also different. The 
changes described in SPG3 19 SPG 4 20, 21, SPG7 22 and SPG18  are rare 
curiosities 23. 
This entity is a cerebral and spinal neurono-axonopathy damaging the cerebral 
cortex, the CC and the WM peripheral to the CC, a probably dying-back cortical-
spinal axonopathy, and the same pathological process in the second motor 
neuron. In spinal anterior horn motor neurons this process may also be dying-
back, since clinically the amyotrophies walk in a distal-proximal sequence. 
In summary, the succession of three overlapping clinical phases is the expression 
of a progressive axonal degeneration that involves, in this chronological order, the 
cortico-cortical projections, the corticospinal tracts, and the second motor neurons. 
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5. The patient linked to SPG46 had some clinical and imaging differences 
compared with SPG11/SPG15 patients, as shown, and also compared with a 
small group of other SPG46 patients already known. In these patients the CC is 
more atrophic, there seems to be greater brain atrophy, and they do not have gait 
ataxia but upper limbs dysmetria 15.  
 
CONCLUSIONS 
 
1. The TCC phenotype represents: 30% of all AR-HSP families; 41% of the 
complex forms; 56% of complex forms with cognitive impairment, and virtually 80 
to 100% of families with a progressive mental deterioration.  
 
2. The SPG11 is present in 66% of families with TCC phenotype, and the SPG15 
in 13%.  
3. The SPG11 is present in 19.4% of AR-HSP, and the SPG15 in 3.8%. One 
SPG11    mutation is novel. No SPG21 mutations were found. 
 
4. SPG11 plus SPG15 genes represent 23% of the AR-HSP families, 32 % of AR-
HSP complex forms, 44% of complex forms including cognitive impairment, and 
77% of families with TCC syndrome. 
 
5. All or almost all of these patients were always “different children”. The patient’s 
initial learning difficulty is not a mental retardation, but a mental deterioration 
starting at an early age, and this is the mode of the disease onset.  
 
6. The motor and cognitive severity of the disease worsens significantly with age, 
independently of the age of onset of motor difficulties. Despite the severity, the 
patients survived nearly four decades. 
 
7. The thin corpus callosum is not hypoplasic but progressively atrophic. In 
addition to the WM impairment expressed as CC atrophy, the WM is progressively 
affected towards the periphery.  
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8. The patients with a complete TCC syndrome (86% of TCC families genetically 
tested) all had mutations in SPG11 or in SPG15 genes. The SPG11 and SPG15 
patients are clinically indistinguishable. 
 
The patients that have an almost complete TCC syndrome (14% of TCC families 
tested) are clinically and genetically more heterogeneous, and do not have 
mutations in SPG11 or in SPG15 genes. 
 
9. Both clinically and imagiologically, the disease progresses from front to back. 
The mental deterioration begins with a frontal and anterior limbic predominance, 
ending in a more diffuse (frontotemporal) profile. The brain atrophy also 
predominates in the frontal and temporal cortex. FDG-PET images showed a more 
extensive impairment than cortical atrophy demonstrated by MRI. The cortical 
hipometabolism is diffuse, not always with a frontotemporal predominance, and 
includes the thalami.  
 
10. Resembling some leukodystrophies, this cortical and subcortical 
encephalopathy consists of a succession of three overlapping clinical phases. 
First: cognitive deterioration with childhood onset, evolving as a slowly progressive 
frontal dysfunction and progressing to a peculiar frontotemporal dementia. 
Second: onset at early adolescence of a severe spastic paraparesis, causing loss 
of gait at the end of the second decade of life. Third: involvement of the second 
motor neuron, in the form of progressive muscle atrophies, configuring the clinical 
setting of an ALS syndrome, with more pseudo-bulbar than bulbar involvement, 
and with rare fasciculations. 
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Discussion 
 
HSP in Portugal 
In spite of the possibility of some false negatives, it is likely that ascertainment was 
nearly complete, given the systematic character of the survey and the way it was 
planned, the use of multiple sources of information and active demand by patients. 
Clinical epidemiology 
Comparison with other studies 
The prevalence of HSP in Portugal was 4.1/100,000, being 2.4/100,000 for AD-
HSP and 1.5/100,000 for AR-HSP. The HSP prevalence ranges, according to 
other series published over the last decades, varied from 0.5 to 7.4/100,0005, 58, 
104-109. This disparity may be due, at least in part, to different methodologies, but 
also to geographic clustering. Only three studies were population based (in 
Estonia, Ireland and Norway). In Estonia110, the prevalence was similar to ours 
(4.4/100,000). In Ireland111, only pure autosomal dominant forms were considered, 
and, possibly as a consequence, overall prevalence (1.27/100,000) was lower 
than in Portugal. In Norway112, the global prevalence was higher (globally: 
7.4/100,000; AD-HSP: 5.5; AR-HSP: 1.3; and 0.6 for isolated cases), due to a 
much higher occurrence of dominant forms.  
In these three studies, using multiple sources of information, the methodology 
looked similar to ours, but was not exactly the same. The Portuguese study had a 
more solid systematic approach and population basis, with a larger participation of 
the primary care structures of the National Health System, and a more proactive 
ascertainment of patients. 
Isolated forms are almost non-existent in Portuguese AD-HSP, probably due to the 
personal observation of most families at Health Centres or at home, and the 
follow-up of many patients, facilitating the recording of detailed and extended 
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family histories. Quite frequently, persons who were unaware of the same medical 
condition in other relatives proved to belong to the same large kindred. 
 
Geographic distribution of HSP in Portugal 
For all forms, there is a predominance of HSP in the north. We could question that 
this was due to the proximity of these families to the neurologists involved, though 
the survey was systematic, district by district. But, in fact, there were clear 
asymmetries also in the distribution of the autosomal dominant hereditary ataxias 
(included in the survey), which had different foci all over the country. Moreover, the 
AR-HSP with thin corpus callosum had also a definite greater prevalence in the 
northern districts; analysis of the allele frequency of the two main genes mutated 
(SPG11 and SPG15) was very suggestive of founder effects that may explain the 
asymmetry founded. 
 
AD-HSP (89 families)  AR-HSP (103 families) 
 
 
Figure 3. HSP are distributed all over the country, although not proportionately to 
population density. 
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Genetic epidemiology of AD-HSP 
Genotypes frequency in the 89 families with AD-HSP Portuguese was 30.3% for 
SPG4; 5.6% for SPG3; and 1.2% for SPG31. No other known mutated genes were 
found in the Portuguese population so far. A large number of these families still 
remain without molecular diagnosis (63%).  
These values were similar to what has been described in other countries6, 110, 113, 
except for SPG31, which was rare in our population. Also, another difference was 
that a previous study reported 20% of deletions in SPG4, what was considered as 
being responsible for the high frequency (40%) of that form113. In our series, 
however, only 7% of SPG4 were due to deletions.  
Nine other loci are related to pure forms: SPG633, 114, SPG834, SPG1035, 36, 
SPG1237, SPG1338,39, SPG1940, SPG3341, SPG3742, and SPG4243. Other seven 
loci are associated with complex forms: SPG944, SPG1712, SPG2945, SPG3646, 
SPG3847, SPG4148 and SPG44115. All these 16 loci are rare, having been 
described in a few or even in just one family. 
Three studies tried to analyze the frequency of some of these genotypes, but none 
was population-based. One study, investigating 80 index patients, extrapolated for 
the European population a frequency of 3% of SPG10 50. Another study51, 
including 60 HSP families and 15 isolated patients, found no mutations in SPG6, 
SPG10, and SPG13. In another study, 223 European index patients were 
screened for SPG42 mutations, and none was found, concluding that the gene 
linked to SPG42 was extremely rare52. 
In Table 4, a summary of the main studies on the frequency of the most prevalent 
genes in AD-HSP is shown. 
Even now, a systematic screening of all known loci and genes has not yet been 
possible in a representative sample of families. Additionally, the low inter-familial 
variability that characterizes ours and other series of AD-HSP families makes 
difficult the identification of novel genes, or modifier genes. 
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Genetic epidemiology of AR-HSP 
The genotypes frequency among the 103 AR-HSP Portuguese families was 17.4% 
for SPG11 and 3.9% for SPG15. No cases of SPG21 have been identified so far. 
SPG11 and SPG15 together (Table 2, Article 4) represented 23% of all AR-HSP 
families, 32% of the AR-HSP complex forms, 44% of these complex forms that 
included cognitive impairment, and 77.5% of families with TCC syndrome. 
SPG11 is the second most frequent among all HSP forms, dominant or recessive. 
Overall, SPG11 is less frequent than SPG4, but more frequent than SPG3. In this 
perspective, SPG15 may be the fourth more frequent HSP form. SPG15 has 
already been considered the second most frequent cause of TCC116. 
Like in other population-based studies, X-linked forms were not found, which 
shows their rarity. 
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Table 4. Studies of frequency of the most prevalent genetic forms in AD-HSP 
Author 
(year) 
Geographic 
origin 
Study source 
 
Families or patients 
included 
Results 
 
Molecular 
techniques 
Hazan (1999) France Laboratorial 14 families, 14 patients SPG4: 50% Sequencing 
Reid (1999) 
United 
Kingdom 
Clinical genetics 
departments 
28 families, 144 patients 
(only pure forms) 
Linked to 
chromosome 2 
(SPG4) 25% 
Linkage 
analysis 
Fonknechten 
(2000) 
Mostly 
European 
Laboratorial 
 
87 families SPG4: 37% 
Linkage and 
sequencing 
McMonagle 
(2011) 
Ireland Populational 
19 families, 82 patients 
pure AD-HSP 
SPG4: 26% 
Linkage 
analysis 
Lindsey (2000) 
United 
Kingdom 
Laboratorial 
 
32 families and 
????patients 
 
SPG4: 43.8% 
SSCP and 
Sequencing 
Sauter (2002) German Laboratorial 63 families, 161 patients 
SPG4: 
Families: 38%  
Sporadic: 8.5% 
SSCP and 
Sequencing 
Meijer (2002) North America Laboratorial 76 index patients SPG4: 10% 
SSCP and 
Sequencing 
Proukakis 
(2003) 
United 
Kingdom, 
Austria 
Laboratorial 
41 patients (30 families 
and 11 sporadic) 
SPG4: 
Families 33.3% 
Sporadic: 0% 
SSCP and 
Sequencing 
Dürr (2004) European Laboratorial 
13 families (SPG4 
excluded) 
SPG3: 39% Sequencing 
Brugman 
(2005) 
Netherlands 
Neurology 
departments 
99 sporadic upper motor 
neuron syndrome (47 
restricted to legs) 
SPG4: 13% 
(restricted to leg 
spasticity) 
Sequencing 
Depienne 
(2006) 
European 
mostly French 
Laboratorial 146 isolated patients SPG4: 12% 
DHPLC and 
Sequencing 
Depienne 
(2006) 
France Laboratorial 
121 negative probands for 
point mutations 
SPG4: 40% (20% 
by MLPA) 
MLPA 
Crippa (2006) Italy Laboratorial 
60 pure and complex 
forms (15 isolated) 
SPG4:  
Families 22%; 
Isolated: 0% 
(SPG3, 6, 10, 13: 
0%) 
Sequencing 
Magariello 
(2006) 
Italy 
Neurological 
departments 
38 patients (24 families 
and 14 isolated patients) 
SPG4: 36.8% 
(families 45.8%; 
sporadic 21.4%) 
DHPLC, 
Sequencing 
and MLPA 
Namekawa 
(2006) 
European 
mostly French 
Neurogenetic 
department and 
SPATAX 
network 
106 families 
Age-of-onset 
<10years 
SPG3: 31.8% 
SPG4: 13.6% 
DHPLC and  
Sequencing 
Loureiro (2008) Portugal 
Laboratorial and 
populational 
80 patients (61 families 
and 19 isolated patients) 
SPG4: families 
28%, isolated 
patients: 0% 
DHPLC and 
Sequencing 
Erichsen (2007) Norway 
Neurology 
departments 
59 index patients, from 35 
families, and 24 isolated 
 
SPG4: 28.8% 
(families: 39%, 
isolated patients 
5.5%) 
Sequencing 
and 
MLPA 
Smith (2009) 
United  
Kingdom 
Three neurology 
departments 
100 index patients (70 
families and 30 with 
uncertain inherence) 
SPG3: 9% Sequencing 
Erichen (2009) Norway 
Population- 
based 
194 patients (65 families, 
and 19% of isolated 
patients) 
Families:  
SPG4: 40% 
SPG3: 11% 
SPG31: 4% 
Sequencing, 
and 
MLPA 
Shoukier (2009) Netherlands 
Neurological and 
genetic 
departments 
1386 unselected patients 
with suspected HSP 
SPG4: 11% 
Sequencing 
and MLPA 
Braschinsky 
(2009) 
Estonia 
Population- 
based 
59 patients SPG4: 21.6% DHPLC 
Alvarez (2010) Spain 
Several 
neurology 
departments 
370 patients: 141 (38%) 
familial and 229 (62%) 
isolated 
SPG4: 14.6% 
(families 31% 
isolated: 38%) 
SPG3: 3% 
Sequencing 
and MLPA 
Loureiro (in 
press) 
Portugal 
Population- 
based 
89 families 
(239 patients) 
 
SPG4: 33.3% 
SPG3: 5.6% 
SPG31: 0.4% 
Sequencing 
and MLPA 
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Autosomal dominant HSP 
After many years of disease duration (mean of 20 years) many patients (88%) are 
still able to walk, although with some difficulty. Moderate corticospinal signs above 
lower limbs were present in half of the patients. Even though representing a higher 
corticospinal lesion, they do not indicate a poor prognosis. 
The mean age-at-onset for all patients was 30 years, and its distribution had a 
bimodal shape.  Variation in age-at-onset is not simply the result of different causal 
genes, as it exists even with the same gene. SPG4 patients and those without 
identified mutation also had a bimodal distribution of age-at-onset. 
In the studies published so far, there was no association between age-at-onset 
and disease progression within families28, 96. In spite of intrafamilial variation, it 
was interesting to verify that association existed in our AD-HSP families. As 
patients often claimed, there was a trend for an aggregation of age-at-onset and 
disease progression in each family.  
This is also coherent with one of the most interesting aspects found in the 
Portuguese AD-HSP study – the demonstration of some genotype-phenotype 
correlation. Age-at-onset varied with certain types of mutations. A putatively 
greater deleterious effect of a mutation corresponded to a lower age-at-onset, as 
is frequent in other genetic diseases.  
Though important and new, this involves some contradiction and new questions 
the study itself raised. First, why is the rate of disease progression also not 
associated with the mutational class, but only the age-at-onset? Second, and 
contrarily to what one would expect, why an earlier age-at-onset did not imply a 
worse prognosis, as is more usual with hereditary diseases, but precisely the 
opposite? 
Along this line of thought, we demonstrated that the slower progression in patients 
with SPG3 is only apparent, as SPG4 patients showed the same rate of 
progression when they had the same age-at-onset (which is almost always under 
age 10 years in SPG3).  
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Unlike most hereditary diseases that show more severe symptoms and 
progression the earlier they start, HSP seemed to progress more rapidly when 
started later. Even before gene identification, Anita Harding and others suggested 
that when onset was after 35 years of age, the disease progressed more rapidly28, 
117, 118. We found that, overall, age-at-onset had no clear correlation with disease 
severity, but also that there was an association between later onset and higher 
progression index, at least in SPG4 (p<0.001).  
When the disease starts later, does it really progress faster? Or is this due just to 
normal ageing functional decline? There could be a bias introduced here: older 
patients may not have a faster progression, but longer subliminal disease duration 
or a less precise memory of its onset. On the other hand, we found that, in spite of 
a lower age-at-onset in younger generations, the rate of disease progression was 
not significantly different in these and in older generations. We also did not find 
any clear trend towards an increase of the index of progression between 
successive generations of the same family.  
 
Investigation of an AD-HSP subgroup with dementia  
In two interesting and unrelated families (six patients), an autosomal dominant 
spastic paraplegia was associated to a severe frontotemporal dementia (Article 2). 
These families add a fourth type to the known evolutional profiles of cognitive 
impairment in HSP (Introduction, clinical manifestations). They had a very unusual 
late-onset dementia, after an apparently usual late-onset spastic paraplegia. 
The paraplegia began in the sixth decade of life, at the mean age of 57 years 
(range, 42 to 65). It preceded the onset of dementia in four patients (average, 8 
years earlier) and came after dementia in two of them. The evolution of paraplegia 
was not linear; it accelerated with time and evolved to a very spastic tetraplegia. 
Dementia had a more severe outcome than in Alzheimer's disease. 
MRI showed moderate cerebral atrophy, in contrast with SPECT and FDG-PET, 
which showed a marked frontotemporal cortical hypometabolism. Biomarkers in 
cerebrospinal fluid were normal (beta-amyloid, total TAU and phosphorylated 
TAU). No mutations were found for SPG4 and SPG31, neither in the PSEN1 
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(presenilin 1), PSEN2 (presenilin 2), APP (amyloid beta A4 presusor protein), 
MAPT (microtubule-associated protein TAU), nor GRN (progranulin). Other genes 
recently related with frontotemporal dementia or with ALS (CHMP2B, VCP, 
TARDBP, FUS and C9orf72) have not yet been tested. Study of NIPA1 (SPG6) 
mutations is also needed. 
 
Anticipation of age-at-onset in AD-HSP, fact or fiction? 
In our AD-HSP families, we found an apparent anticipation of age-at-onset in 
successive generations. Others have also noticed this fact117, 119, 120, some 
concluding it resulted probably from ascertainment biases117. 
Globally considered, age-of-onset decreased with younger generations: mean of 
42 years, for the first generation of patients; mean of 34 years, for the second 
generation; and a mean of 19 years for the third one. This is worth investigating 
further, after excluding possible ascertainment biases. 
 
Analysing by genotypes 
 
In SPG4, the mean age-at-onset was 42.0 years in the first generation (n=11), 
35.3 years in the second (n=55), and 20.1 years in the third (n=26). This trend had 
statistical significance (p<0.001). Anticipation was also seen in SPG3 families 
(17.0, 3.2 and 3.0, on average, in successive generations), though with no 
statistical significance (p=0.15), possibly due to the small sample size. In patients 
without an identified mutation, age-at-onset was 41.4 (n=7), 32.6 (n=70) and 16.4 
years (n=18), in successive generations (p<0.001). 
In a multivariate ANOVA, after adjusting for genotype, family and gender, 
anticipation was still significant in SPG4 (p<0.0001) and in patients without 
identified mutation (p<0.0001).  
 
Analyzing family by family and looking at families with more than one generation 
 
Of the 89 families, 38 (42.7%) had age-at-onset available for more than one 
generation (17 SPG4; 4 SPG3; and 17 without known mutation). Of these families, 
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age-at-onset was the same between generations in six (16%), there was 
anticipation in 30 (79%), and onset was later in the second generation in two (5%) 
of them. In the 17 SPG4 families, there was anticipation in 16 families, and in one 
age-at-onset was similar in the two generations (three years). In three of these 
families, there was data from three generations, and anticipation was observed 
between the first and second generation, but also between the second and third. 
In the four SPG3 families, age-at-onset was the same between generations of two 
families; there was anticipation in one and a later age-of-onset was observed in 
the second generation of another one. This phenomenon was not confined to pairs 
of parent-child, but was also evident in nephew-cousin pairs. 
In summary, when analysing family by family (looking at families in which more 
than one generation was available), anticipation was observed in 79%, there was 
no variation in 16%, and onset was later in the second generation in 5% of them.  
Some authors attributed the observation of anticipation to a shorter follow-up in 
younger generations, causing the distribution in age-of-onset to be partially 
censored, with preferential ascertainment of patients with earlier onset. To explore 
this, we looked at the median chronological age of the third generation of our 
families. We found that the third generation is now considerably old. In SPG4, 
median age of the third generation was 41 years (25th and 75th percentiles of 50 
and 37 years). Therefore, we would expect patients with later onset, if existing, to 
have been also identified in our families. 
Additionally, in SPG4, the mean of age-of-onset for each generation was quite 
similar through generations (1st, 57 years; 2nd, 65 years; 3rd, 47 years); the same 
happened for patients with no mutation (59; 69; and 44). This points to a shift in 
the distribution to a lower age-at-onset, more than to a shorter follow-up. Similarly, 
the distribution of age-at-onset in the 3rd generation, in SPG4 patients and patients 
without identified mutation, did not seem to be censored by the higher age 
spectrum.  
In conclusion, anticipation observed in our families does not seem to result from a 
bias produced by a shorter follow-up. An yet unknown genetic or environmental 
factor could play a role. However, it cannot be discarded that older generations 
had onset earlier that they recalled, or that increased surveillance and anxiety 
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about the disease in younger generations lead to greater awareness and earlier 
identification of symptoms. 
 
Figure 4. Association of age at onset and generations in AD-HSP patients 
 
 
Autosomal recessive HSP 
In 1999, Paula Coutinho et al.8 defined five major familial phenotypes among AR-
HSP, based on the analysis of 106 patients, belonging to 46 Portuguese and 
Algerian kindreds: (1) pure early-onset; (2) pure adult-onset; (3) complex forms 
with mental retardation; (4) complex forms with mental retardation and peripheral 
neuropathy; and (5) complex forms with cerebellar ataxia. This subdivision, which 
still makes sense clinically, was adjusted by the continuous advancement of 
genetic studies and the discovery of new loci and genes, in an attempt of 
establishing a genotype-phenotype correlation. 
On average, the main general features were: mean age-at-onset of paraplegia 
was at 12.8 years (range, 0 to 47); patients age was 34.8 years (range, 3 to 69); 
the motor difficulties lasted for 23.0 years (range, 2 to 51); the severity was 4.7 
(range, 1 to 7), and the annual progression of the disease was 3.7 (range, 1.0 to 
14.3). 
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Table 5. Summary of clinical forms in 103 AR-HSP families (175 patients) 
Complex forms 
75 families 
 
73% of AR-HSP 
Cognitive alterations 
55 families 
 
53% of AR-HSP 
73% of complex forms 
 
TCC phenotype 
31 families 
 
30% of AR-HSP 
41% of complex 
56% of families with cognitive 
alterations 
  Mental retardation 
24 families 
44% of families with cognitive 
alterations 
 Others alterations 
20 families 
20% of AR-HSP 
27% of complex forms 
Pure forms 
28 families 
 
27% of AR-HSP 
Early-onset 
21 families 
 
75% of pure forms 
Late-onset 
7 families 
 
25% of pure forms 
 
Unlike AD-HSP, complex forms represent 73% of AR-HSP families, whereas pure 
forms are 27%. In recessive complex forms, 73% had cognitive impairment; and 
half of these (56%) had the TCC syndrome. 
The majority of AR-HSP had early-onset. In complex forms, 86% were early-onset 
and 14% had late-onset. In pure forms, 75% had early-onset and 25% had late-
onset. 
Table 6. Comparing complex and pure forms, mean (range) 
 Age-at- 
onset of 
motor 
difficulties 
Age-at-last 
observation 
Disease 
duration 
Severity Disease 
progression  
Complex 
forms 
(75 families) 
11.7 
(0-36 
years) 
36.6 
(4-69 years) 
23.1 
(2-51 
years) 
5.0 
(1 to 7) 
3.8 
(1-14) 
Pure 
Forms 
(28 families) 
16.3 
(1-47 
years) 
39.3 
(3-64 years) 
22.5 
(2-40 
years) 
3.3 
(1 to 7) 
3.0 
(1-12) 
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Table 7. Early and late-onset pure forms, mean (range) 
 Age-at- 
onset of 
motor 
difficulties 
Age-at-last 
observation 
Disease 
duration 
Severity Disease 
progression  
Early-onset 
(21 families) 
10.3 
(1-24 
years) 
35.0 
(3-64 years) 
24.6  
(2-40 
years) 
3.4 
(2-6) 
2.7 
(1-14) 
 
Late-onset 
(7 families) 
35.0 
(23-47 
years) 
51.1 
(40-63 years) 
16.6 
(3-40 
years) 
3.0 
(2-5) 
4.3 
(1-10) 
 
Table 8. Complex forms with and without mental retardation (MR), excluding those 
with TCC syndrome, mean (range) 
  Age-at- 
onset of 
motor 
difficulties 
Age-at -last 
observation 
Disease 
duration 
Severity Disease 
progression  
Without MR 
(20 families) 
12.9 
(1-34 
years) 
33.7 
(4-69 years) 
23.8  
(3-
41years) 
5.2 
(3-7) 
3.4 
(1-8.6) 
 
With MR  
(24 families) 
9.2 
(1-36 
years) 
34.8 
(13-60 
years) 
27.5 
(5-51 
years) 
4.6 
(3-7) 
3.2 
(0.9-14.3)  
 
In this study, we tried to define phenotypic groups, as homogeneous as possible. 
However, there was not much difference among families regarding age-at-onset, 
disease duration, severity and disease progression, in these AR-HSP clinical 
subgroups. So, we selected families with cognitive changes and associated 
neuropathy, and focused on those corresponding to the TCC syndrome.  
Autosomal recessive spastic paraplegia with thin corpus callosum  
We identified 38 families (66 patients) with confirmed or suspected clinical 
elements of the TCC syndrome. These were studied for mutations in the genes 
SPG11, SPG15 and SPG21: 31 had a complete or almost complete TCC 
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syndrome (52 patients); and 7 families (14 patients) had an incomplete TCC 
syndrome (none of which with mutations in the three genes studied). 
One of these families excluded (SR5, healthy non-consanguine parents, six 
children, three of whom affected) had only one mutated allele in the gene for 
SPG11, showing a very early spastic paraplegia, with severe mental impairment 
and epilepsy. We put the hypothesis that there was a further mutation, in the 
regions not covered by the genetic analysis. However, the fact that one of the 
affected sisters did not carrier the SPG11 allele, transmitted by the mother, led us 
to look other way. More probably, there is another causal yet unknown gene; 
however, the existence of a rare mutated allele in an affected patient is, 
nonetheless, curious and should be kept in mind.  
Among the 31 families with a complete or almost complete clinical TCC syndrome, 
MRI was available in 28: a typical CC atrophy was observed in 24 of them, all with 
mutations in the genes for SPG11 (20 families) or SPG15 (4 families). None of the 
4 remaining families (with an incomplete TCC syndrome) had mutations in these 
genes.  
The TCC phenotype represented 30% of all our AR-HSP families, and 80% of 
those families with progressive mental deterioration (4 families excluded from the 
TCC group had cognitive impairment, but MRI was not available, and no mutation 
was found); the percentage, thus, reached 100%, when these families were 
excluded.  
In other published series, not all patients with atrophy of the corpus callosum had 
mutations in SPG11. The percentage varied: 41% in one series9, 63% in 
another121, and 33% in still another122. These differences are probably due to the 
genetic heterogeneity among different populations, but may also be related to the 
mode of selection of patients. In a northern European population-based study, 
SPG11 mutations were detected in 20% (2/10) of families6. In our population-
based study, SPG11 represented 19.4% of the AR-HSP families and SPG15 was 
present in 3.9%.  
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SPG11 plus SPG15 represent 77.5% of families with TCC syndrome, though they 
were present in 100% of families if we considered only those with the (complete 
and typical) syndrome of HSP with TCC, as defined; however, this is not always 
easy to conclude when we observe patients at an early stage of evolution.  
SPG21 mutations were studied in patients excluded for mutations in the two most 
frequent genes. The fact that no mutation has been found reinforces the idea that 
SPG21 (the Mast syndrome) is very rare; it remains limited to the Amish 
population68. 
Thus, we can say that the syndrome of HSP with TCC, linked to SPG11 or 
SPG15, is a relatively well-defined clinical and genetic entity. 
An isolated impaired corpus callosum is, however, a nonspecific change. It may 
appear in several neurological diseases in which white matter impairment is 
considerable, such as multiple sclerosis, metachromatic leukodystrophy, vascular 
encephalopathies, and other degenerative and metabolic diseases, as well as 
other HSP genotypes. In HSP, it has been described in SPG1, SPG2, SPG3, 
SPG4, SPG7, SPG11, SPG15, SPG18, SPG20, SPG21, SPG32, SPG46 and 
SPG47; however, though often referred, this is just a list of genotypes with a 
common trait, and not exactly genotypes that correspond to a defined syndrome. 
With the exception of the uncommon SPG21, and of the recent SPG46, all other 
forms correspond to clinically and imagiologicaly different phenotypes. SPG21 
may have some affinity, but its phenotype has not been reviewed for a long time67, 
68 Regarding SPG46, more experience is needed70. It is nonetheless important to 
note that, without knowing the locus, we consider our unique SPG46 patient to be 
clinically different from the others, and increasingly so as her disease progresses. 
The inclusion of all other genotypes in the TCC syndrome should be viewed with 
great reservation. In SPG1, there is not a CC atrophy but an X-linked agenesis80. 
In SPG2, the CC is thin, but in the context of a genetic hipomielinization disease 
(Pealizaeus-Merzbacher leucodistrophy)82. In SPG3, in which complex forms are 
infrequent, the CC impairment is extremely rare123. In SPG4, an occasional large 
CC dysplasia was described in two families, which may or may not be part of HSP 
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phenotype124, 125. In SPG7, CC alterations described are very rare and not 
clinically relevant, as they were only slight MRI changes in the white matter of two 
heterozygous daughters of one patient126. In SPG18, atrophy of the corpus 
callosum was found in just one patient, but the other two members of the same 
family had only epilepsy72, 127. SPG2064, SPG3269 and SPG4771 are also different 
from a clinical and imaging point of view from the complete (clinical and 
imagiological) TCC syndrome.  
The present study provides some strong and simple positive arguments that the 
TCC syndrome has a genetic background in which the probability of finding one of 
two genes mutated is very high; these genes probably act in the same pathway128. 
This syndrome also has clinical and imaging congruent features, the absence of 
which seems to be able to predict the exclusion of mutations in the genes for 
SPG11 and SPG15. 
Neuropathological studies are missing in patients with genetic confirmation. A 
postmortem study in a patient with AR-HSP and "hypoplastic corpus callosum" 
showed neuronal loss in corticospinal tracts, thalami, lateral geniculate bodies, 
dentate nuclei, posterior columns, and a clear reduction of pigmented neurons in 
the substantia nigra129. It should be noted that, although the corpus callosum was 
severely reduced, it had well preserved myelination. This is consistent with our 
clinical observation and conclusions.  
More interestingly, Kuru el al. reported a patient with a typical TCC syndrome, but 
without molecular characterization130. The autopsy revealed a severely atrophic 
brain, with extreme thinning of the whole corpus callosum, degeneration in the 
corticospinal tract, thalamus, cerebral white matter, substantia nigra, as well as in 
the anterior horns and posterior columns of the spinal cord. The remaining 
neurons contained large amounts of lipofuscin and eosinophilic granules. The 
authors concluded that the predominant feature was degeneration, rather than 
hypoplasia, which is clinically consistent. 
A combination of axonal loss and demyelinating sensory-motor neuropathy was 
referred for a long time131; however, in the series published by Giovani Stevanin et 
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al.132, the EMG detected lower-motor neuron involvement in 13/16 (81%) patients, 
after a mean disease duration of 14 years. In two patients, there was clear 
involvement of the anterior horns, while the others had an axonal neuropathy.  
Our study did not fully clarify the question of whether the patients have a 
neuropathy (predominantly motor and axonal) or a neuronopathy (anterior horn 
involvement), or both. EMG was done at different age in various patients, and their 
reports are sometimes short and difficult to compare.  
Clinically, there are scarce sensitive changes, sometimes only more marked than 
in pure forms, in which moderate changes in vibration sense are admitted. The 
EMG shows little reduction in conduction velocities. In some patients there were 
no changes in conduction velocity, in the presence of generalized limb 
amyotrophies. These findings favor the fact that the existence of a neuronopathy, 
though not exclusive, is the most clinically relevant aspect. 
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Study limitations 
Limitations in identification and characterization of families 
The main epidemiological limitation is the inevitable and invisible presence of false 
negatives that this type of study always carries, and we could not quantify. Some 
families, scattered through the country had little data available. Particularly in 
complex AR-HSP patients, the disease may be underestimated, because in its 
early phase they may not show the entire phenotypic spectrum, but only the 
starting point of a long history.  
Although uniform criteria have been used, several variables like severity should be 
analyzed with some reservation, because clinical data represent transversal 
sections made at different moments in the more or less long evolution of a 
heterogeneous disease.  
Clinical subjectivity and other difficulties 
Definition of age-at-onset  
Subjectivity of physicians, patients and relatives must always be considered. Age-
at-onset is a variable that is not easy to define and assess in many diseases, 
particularly those with insidious onset and slow progression, and mode of onset 
with unspecific symptoms and signs. Consequently, analyses of disease 
progression may be affected by errors in evaluation of disease onset and duration. 
Sometimes, as is the case in many chronic diseases, onset is reported as 
coinciding with an independent significant life-event (as a fall, accident, surgery, 
psychological trauma, or childbirth, among others). Often, patients focus more on 
the age at which they get worse, than on the actual onset. When motor difficulties 
have started in adolescence or early adulthood, parents or other relatives 
sometimes admit, after being questioned, that patients had always walked in a 
strange way, meaning an earlier beginning of spasticity.  
Particularly in AR-HSP families, in which complex forms predominate, age-at-
onset depends on what is considered to be the mode of onset, and this depends 
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on the observer, the perspective varying from parents to teachers and physicians. 
Parents tend to regard the first difficulties of gait as the onset of the disease, even 
if there were other (motor or non motor) previous disease signs.  
The description of the disease also depends on memory of who reports, on their 
relationship and proximity to patients, on how many years have passed since the 
beginning of the first syptoms, on the type of disease and its duration, and on the 
symptoms at onset (less obvious if a more insidious onset). 
Evaluation and evolution of mental status  
When asked about mental development, the tendency is to consider it to be good 
until the beginning of the difficulties in walking or until the child enters school age. 
Also, mental retardation is often overshadowed by social and cultural conditions, if 
implying a decrease of learning opportunities, as well as by the emergence of 
other symptoms and signs apparently more serious than the delay itself, as 
paraplegia.  
Later on, the degree of mental impairment in some patients may be misleading, 
due to apathy, weakness of voice or slowness of speech. Many of these patients 
would need better-adapted protocols and scales of neuropsychological evaluation. 
Evaluation and evolution of motor difficulties 
The scale of severity used (SPATAX disability score)101 evaluates only motor 
impairment, but does not reflect other clinical variables. For this reason other 
scales were also employed, many of them (as a rule graded from 0 to 3) having 
the advantage of being very simple, though subjective and still not validated. 
The presence of neurogenic muscle atrophy may be difficult to distinguish from 
atrophy by disuse. In the lower limbs, swelling and deformities make them even 
more difficult to detect. 
Strangely enough, it is not always easy to date loss of gait (of patient becoming 
wheel-chair bound or bedridden), given the chronic evolution. 
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Limitations of the complementary exams used 
MRI, which was especially used to identify and study patients with corpus 
callosum changes and other features, was available only in 45% of the 103 AR-
HSP families. With the exception of families with a clinical TCC phenotype, no 
others were found to have similar imagiological changes. Conversely, none of the 
patients without MRI had clinical similarities with the TCC syndrome. 
Nevertheless, the possibility exists that a small number of patients with TCC may 
have not been identified. 
It would be interesting to have MRI images taken before and after the beginning of 
spastic paraplegia, or images performed in a defined temporal sequence, 
according to the clinical subgroups’ profile, which was not possible to perform. 
The fact that a TCC functioned as a marker in some cases may have influenced 
the overall frequency of the AR-HSP-TCC. Although it is our conviction that all 
patients with SPG11 or SPG15 have an atrophic CC, we cannot fully guarantee 
this, as a longer observational time and larger sample are needed. Moreover, 
cerebral FDG-PET data on cortical and thalamic glucose metabolic reduction 
needs to be compared with age-matched healthy controls. 
Finally, ophthalmological studies were very incomplete, as were other data, such 
as those from EMG. 
 
 
 
 
 
 
  
 
 179 
 
2. Conclusions 
2.1. Epidemiology 
Prevalence of HSP, in Portugal, was 4.1/100,000 inhabitants (2.4/100,000 for AD-
HSP, and 1.5/100,000 for AR-HSP). The frequency of the main AD-HSP 
genotypes (SPG4 and SPG3) was similar to other studies, except for SPG31 that 
is rare in our population. SPG11 was the second most frequent genotype in HSP 
(dominant or recessive); SPG11 and SPG15 together represented almost one-
quarter of all our AR-HSP forms. 
2.2. Autosomal dominant HSP 
In spite of their motor difficulties, the vast majority of patients were still able to walk 
after two decades or more of disease. Pure forms predominated (88% of patients). 
Average age-at-onset, for all these patients, was 30 years. 
SPG3 has been considered the most frequent cause of AD-HSP, with onset during 
the first decade. However, the probability of finding SPG4 mutations was higher 
than for SPG3, even when the disease began in the first decade. As a rule, we 
should start the genetic studies of AD-HSP by searching for SPG4 mutations. 
 
There was no significant difference in disease progression with genotype, but an 
association with age-at-onset. In SPG4, unlike other hereditary diseases, an 
earlier onset pointed to a slower progression, while later onset leads to a faster 
progression. 
There was a significant trend for intra-familial aggregation of age-at-onset and of 
the rate of disease progression. 
We identified 17 novel mutations: 16 new ones in SPG4, and one in SPG3. 
We demonstrated, for the first time, that the type of SPG4 mutations is associated 
with age-at-onset, and found a trend toward an earlier disease onset when 
mutations are located in the functionally important AAA-spastin domain. 
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More than a half of all AD-HSP families still remain without a molecular diagnosis. 
The small inter-familial variability greatly difficults the organization of distinct 
phenotypic groups, making the identification of novel genes a greater challenge. 
2.3. Autosomal recessive HSP  
In AR-HSP, 73% of forms were complex, and onset of motor difficulties was 
predominantly early. Mean age-at-onset of paraplegia was 12.8 years, overall. 
Cognitive impairment was present in 73% of complex forms.  
The TCC syndrome represented 30% of AR-HSP families; 41% of complex forms; 
56% of complex forms with cognitive impairment; and 80-100% of the families 
studied with progressive mental deterioration.  
In the TCC syndrome group, 24 mutations were identified: 20 in the SPG11 and 
four in the SPG15 genes. SPG11 represented 19.4% of all AR-HSP, while SPG15 
was 3.8%. No SPG21 mutations were found.  
SPG11 and SPG15 explain, together, 77.5 % of the families with a TCC 
syndrome. These patients do not have mental retardation, rather an early 
progressive mental deterioration, which is the mode of onset; and the corpus 
callosum is not hypoplasic, but progressively atrophic. Any absence of this typical 
features seems to be able to predict the exclusion of mutations in the genes for 
SPG11 and SPG15. 
The complete TCC syndrome (coincident with SPG11 or SPG15 forms) seems to 
be a relatively well-defined entity. The disease progresses front-to-back, beginning 
with a frontal syndrome and ending in a more diffuse neuropsychological deficit. 
Brain atrophy predominates in frontal and temporal cortex. FDG-PET images 
showed a much more extensive impairment than the cortical atrophy shown at 
MRI. 
In the TCC syndrome, there was a progressive neuroaxonal degeneration 
involving, in this order, the cortico-cortical projections, the corticospinal tracts and 
the second motor neurons. 
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Among the SPG11 mutations found, one was novel. Founder effects were found 
for mutations c.529_533del, in SPG11, and c.6296dup, in SPG15 (this one, so far, 
exclusive of the Portuguese population).  
In AR-HSP almost three quarters of families are still without molecular diagnosis. 
This large number of families reinforces the high genetic heterogeneity of HSP and 
the need for additional genetic studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 182 
 
3. Repercussions 
This thesis, though without a direct impact on the quality of the patient’s life, can 
serve to improve somewhat the management of patients and families in Portugal. 
Much clinical data was confirmed and many other data was clarified. 
The overall prevalence and relative frequency of each form, including more 
important genotypes became known.  
The need to reach conclusions increased the ability to serve as an incentive for 
the assembly of further molecular analysis techniques. 
Three undergraduate theses in Biology and Biochemistry were accomplished by 
Carolina Lemos, Leonor Fleming and Maria Conceicao Pereira. A Master's thesis 
(Genetic characterization of Portuguese families with Spastic Paraplegia 
dominantly inherited) was also achieved by Ana Filipa Brandão. These theses 
integrated the activities of UnIGENe (Unidade de Investigação Genética e 
Epidemiógica em Doenças Neurológicas) and CGPP (Centro de Genética 
Preditiva e Preventiva) belonging to the Institute for Molecular and Cell Biology 
(Porto). 
The work involved in this thesis could contribute to a better preventive approach of 
genetic counseling in clinical and genetic well identified groups. It may also serve 
as a basis for further studies. 
 
 
 
 
 
 
 183 
 
4. Future studies 
Two facts are quite clear, the need to find new genes, although there are already 
dozens because most families do not yet have molecular diagnosis. Moreover, 
further studies are needed to better understand the pathogenesis. The treatment 
of these diseases is still a dream, but there are dreams that are worth pursuing. 
We hope it will be able to identify novel genes using next generation sequencing 
(NGS) in a series of families available, to screen additional families for mutations 
in the new identified genes, and to functionally characterize the identified 
mutations and genes. 
Clinically, in AD-HSP, three families must be better studied: one family with mental 
retardation and a large SPG4 deletion and two families with HSP and dementia. In 
AR-HSP, there should be a second effort of systematic review and study of the 
clinical subgroups out of the TCC syndrome.  
Despite the cultural difficulties, the geographic dispersion of patients and little 
tradition of neuropathological studies in Portugal, it would be worth making an 
effort in this sense. 
In order to improve health care in life; a multidisciplinary national  reference center 
for all our patients and families should be created in Portugal.  
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